




















This work is protected by copyright and other intellectual property rights and 
duplication or sale of all or part is not permitted, except that material may be 
duplicated by you for research, private study, criticism/review or educational 
purposes. Electronic or print copies are for your own personal, non-
commercial use and shall not be passed to any other individual. No quotation 
may be published without proper acknowledgement. For any other use, or to 
quote extensively from the work, permission must be obtained from the 
copyright holder/s. 
 
The association between osteoarthritis 
and invasive management strategies 
and clinical outcomes following acute 
myocardial infarction in electronic 


























This thesis was undertaken as part of an intercalated degree between the fourth and fifth year 
of an undergraduate medical degree (MBChB) at Keele University. 
The initial idea for this thesis was conceived by Professor Mamas Mamas and Dr. Ross Wilkie. 
I was responsible for deriving the search strategy for the included systematic searches with 
guidance from Dr. Ross Wilkie. 
The statistical analyses presented in this thesis were planned with support from Dr. Mohamed 
Mohamed, Dr. Ross Wilkie, and Professor Mamas Mamas. I was responsible for conducting the 
















I started studying medicine at Keele University in 2015 after completing a BSc in mathematics 
and chemistry at the University of British Columbia in Vancouver, Canada. I have developed a 
passion for both cardiology and epidemiology during my time studying medicine. I have been 
awarded a Young investigator Award by the Osteoarthritis Research Society International 
(OARSI) for my contributions to a project that used mediation analysis within a Cox-
proportional hazards model to elucidate pathways through which OA can lead to mortality. I 
have also been awarded the Wolfson Intercalated Award for academic excellence which has 
helped fund my intercalated degree. After medical school I will apply for the academic 

















The association between osteoarthritis (OA) and acute myocardial infarction (AMI) is unclear, 
as are the outcomes of people with OA diagnosed with AMI. This study aimed to describe the 
annual prevalence of OA among AMI patients and describe the association between OA and 
invasive management strategies and adverse outcomes in AMI patients presenting to 
secondary care. 
Methods 
The National Inpatient Sample (NIS) was searched for all AMI hospitalisations between 2004 
and 2015. The prevalence of OA among the AMI group was calculated. The proportion of 
patients receiving invasive management strategies (coronary angiography (CA), percutaneous 
coronary intervention (PCI), and coronary artery bypass grafting (CABG)) and experiencing 
adverse clinical outcomes (in-hospital mortality, major acute cardiovascular and cardiovascular 
events, all-cause bleeding, and stroke or TIA) was compared by OA status. Adjusted binary 
logistic regression determined the association between OA and each invasive management 
strategy and adverse clinical outcome. 
Results 
Of 6,561,940 hospitalizations for AMI between 2004 and 2015, 414,072 (6.3%) had a 
concurrent OA diagnosis. OA patients were older (mean: 75.3 versus 67.1 years, p<0.001) and 
more likely to be female (55.7% vs. 38.6%, p<0.001). OA was associated with a decreased odds 
of receiving CA (adjusted odds ratio 0.909; 95% confidence interval 0.903, 0.916), PCI (0.873; 
0.866, 0.879), and CABG (0.983; 0.971, 0.996). OA was also associated with a decreased odds 
of adverse clinical outcomes (in-hospital mortality: 0.680; 0.670, 0.691; MACCE: 0.709; 0.699, 




A systematic differential misclassification bias, where unwell patients with OA were less likely 
to receive an OA code because codes for serious illness took precedence, is likely to explain the 
unexpected result of OA being associated with better outcomes following AMI. This bias 
should be considered when using electronic health record data to study the effects of 
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1 Chapter 1: Introduction 
1.1 Introduction: OA and AMI 
Osteoarthritis (OA) is the most common joint condition and a leading cause of disability 
globally (Y. Zhang & Jordan, 2010). The global prevalence of symptomatic OA in adults is 
approximately 10-12% (Hunter et al., 2014) and is expected to rise due to the ageing 
population and increasing obesity rates (both are risk factors for OA) (Murray et al., 2012). The 
burden of OA can be measured by disability adjusted life years (DALYs), which was introduced 
by the Global Burden of Disease study in 1990 and is the sum of the years of life lost and the 
years lived with disability caused by a particular disease (for example, a person living in good 
health to their full life expectancy would have 0 DALYs) (Murray et al., 2012). In 2010, OA was 
responsible for 10% of musculoskeletal DALYs globally (which accounted for 6.8% of all DALYs 
in 2010), increasing by 64% from 1990 to make it the condition with the second fastest 
increasing burden (after diabetes) (Murray et al., 2012). The lack of effective disease-modifying 
OA drugs (DMOADS) and the progressive nature of the condition means that many people with 
OA will eventually experience joint failure and require surgical interventions such as total joint 
replacement. In the US, UK, Canada, and France, it is estimated that the total cost of OA is 1-
2.5% of these countries gross domestic product (GDP), with joint replacement surgery 
accounting for 85% of this cost (Hunter et al., 2014). While OA was once thought to be a “wear 
and tear” disease caused by biomechanical factors such as overuse, excessive loading, and 
malalignment, there is a growing body of evidence that suggests there to be an inflammatory 
component to the pathophysiology of OA (Kapoor et al., 2011). This combined with the sharing 
of risk factors with cardiovascular disease (for example age, obesity, and metabolic syndrome) 
may suggest a shared pathophysiology between the two conditions.  
Cardiovascular disease (CVD), including myocardial infarction (MI), heart failure (HF), stroke, 
and peripheral vascular disease accounts for up to 40% of all deaths globally, more than any 
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other cause (Santulli, 2013). Advancements in the identification, management, and primary 
and secondary prevention of CVD and AMI have led to better patient outcomes in developed 
countries; however, developing countries still face increasing rates of CVD and AMI incidence 
and mortality (J. L. Anderson & Morrow, 2017; Sanchis-Gomar et al., 2016). Traditional 
cardiovascular risk factors include advanced age, obesity, hypertension, smoking, 
dyslipidaemia, and diabetes mellitus (DM) (Boersma et al., 2003). Similar to OA, there is 
evidence that systemic inflammation is a risk factor for atherosclerosis and CVD. Autoimmune 
diseases such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis are 
associated with an increased risk of both fatal and non-fatal CVD when compared to people 
without these conditions, even after adjustment for traditional CVD risk factors (Symmons & 
Gabriel, 2011). There is now further research hypothesising that low-grade inflammation from 
obesity and normal ageing (called “inflammageing”) may also increase the risk of CVD 
(Gustafson, 2010; Rocha & Libby, 2009). Similar hypotheses have been made between low-
grade inflammation and the development of OA, as two of the most potent risk factors for OA 
are increased age and obesity (Mobasheri & Batt, 2016; Sowers & Karvonen-Gutierrez, 2010). 
This suggests a shared pathophysiology between OA and CVD, where both conditions may be 
caused or perpetuated by low-grade inflammation from inflammageing and obesity/metabolic 
syndrome. 
Previous studies have reported an association between OA and overall CVD, however the 
relationship between OA and specific cardiovascular diseases are less clear (Hall et al., 2016). 
Ong and colleagues (2013) reported an increased prevalence of MI (8.2% versus 3.7%), heart 
failure (5.9% versus 2.1%), angina (8.8% versus 2.5%), and stroke (6.8% versus 2.6%) in 
patients with OA compared to those that did not have OA (Ong et al., 2013). Cross-sectional 
analysis of patients in Canada also reported an association between OA and any heart disease 
in crude models (odds ratio (OR) 1.54 95% CI 1.45 to 1.64) and models adjusted for 
demographic and socioeconomic factors,  chronic obstructive pulmonary disease (COPD), 
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hypertension, and diabetes (adjusted OR 1.45 95% CI 1.36-1.54) (Rahman, Kopec, Cibere, et al., 
2013). However, the same study found that OA was only associated with MI in women 
(adjusted OR 1.49, 95% CI 1.28 to 1.75) and not in men (adjusted OR 1.08, 95% CI 0.91 to 1.28). 
Because the adjusted and unadjusted odds ratios were similar throughout the analysis, the 
authors suggest that covariates not included in the analysis, such as inflammation and muscle 
weakness, may be responsible for the association between OA and CVD and warrant further 
research. Similarly, a systematic review and meta-analysis in 2016 examining OA and various 
types of CVD found that OA was associated with heart failure (relative risk (RR) 2.80, 95% CI 
2.25 to 3.49) and ischemic heart disease (RR 1.78, 95% CI 1.18 to 2.69), but not with AMI or 
stroke (Hall et al., 2016).  
The overall aim of the work in this thesis was to describe the prevalence of OA in AMI patients 
over time and to determine the association between OA and invasive management strategies 
and adverse clinical outcomes in patients presenting to secondary care with a diagnosis of 
AMI. This chapter will first introduce OA and AMI, followed by a discussion of the links 
between the two diseases. It will also include a systematic review that was designed to identify 
published peer-reviewed papers that used EHR to investigate the effect that OA has on 
patients diagnosed with AMI. The remaining chapters will describe a study which examines 
whether OA is associated with the management offered to patients diagnosed with AMI and 
their outcomes using the National Inpatient Sample (NIS), a large electronic record of 
secondary care visits from the United States.  
1.2 Osteoarthritis 
1.2.1 Overview of OA  
Osteoarthritis was traditionally thought to be non-inflammatory and the result of “wear and 
tear” of joints that have been damaged through biomechanical factors including overuse, 
excessive loading, and malalignment. These insults cause the pathognomonic feature of OA, 
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the progressive and irreversible degradation of articular cartilage. Unlike other tissues, 
cartilage has minimal reparative capabilities owing to its avascular nature (Mobasheri & Batt, 
2016). However, osteoarthritis is now recognised as a “wear and repair” disease, with 
osteophyte formation (bony protrusions), subchondral plate thickening, and synovial 
membrane inflammation characterising an aberrant reparative process (Martel-Pelletier, 
1999). As the articular cartilage is broken down, there is an accompanied loss of joint space 
and the presence of cysts and sclerotic tissue within the bone. These disease processes 
produce pain, stiffness, and a loss of normal joint function, which are the cardinal features of 
OA.  
1.2.2 Definition of OA 
The National Institute for Health and Care Excellence defines OA as activity related joint pain in 
adults over 45 years-old with either no morning stiffness or morning stiffness that lasts less 
than 30 minutes (National Institute for Health and Care Excellence, 2014). However, people 
with OA can present with various signs and symptoms in addition to joint pain including joint 
stiffness, joint deformity, and loss of joint function. Imaging techniques such as radiographs 
were widely used to diagnose OA, however, this is no longer routinely performed because of 
the poor correlation between the radiographic and clinical features of OA (Cibere, 2006). 
Additionally, some people with OA may have radiographic changes including loss of joint space 
and osteophyte formation and be completely asymptomatic. There is no single presentation or 
linear progression of OA, as people with OA may be asymptomatic or present with a wide 
range of signs and symptoms. Additional complexity is added when considering whether a case 
definition of OA is self-reported or doctor diagnosed. For example, doctor diagnosed OA could 
mean either the identification of radiographic OA changes or the clinical syndrome of OA. 
Furthermore, the most widely used radiographic grading system, the Kellgren and Lawrence 
(K-L) grading system, is defined by relatively ambiguous wording that can further complicate 




1.2.3.1 Phenotypes of OA 
A phenotype is “the sum total of observable characteristics of an individual, regarded as the 
consequence of the interaction of the individual genotype and environment” (D. T. Felson, 
2010). It is useful to identify phenotypes within a disease because they may imply different 
causes or mechanisms of the disease and uncover a better understanding of the pathology and 
effective treatment methods (Dell’Isola et al., 2016). Consider the case where only a specific 
phenotype (amongst many disease phenotypes) responds well to a treatment. Because the 
other phenotypes see no response, the therapeutic effect of the new treatment will be 
diminished and potentially go unrecognised unless the patients are stratified by individual 
phenotype (D. T. Felson, 2010).  
It was once thought that OA was a single disease process resulting in a single phenotype, 
however, it is now recognised that OA is a heterogeneous disease with many phenotypes and 
joint failure is the common end-stage clinical presentation (Castañeda et al., 2014). Therefore, 
it is important to identify distinct phenotypes of OA in order to advance research and 
potentially find disease modifying OA drugs (DMOADs). 
OA phenotypes can be broadly categorised into a clinical syndrome or a radiographic 
syndrome (Vina & Kwoh, 2018). Distinguishing characteristics of the clinical syndrome include 
joint pain, joint malalignment, gait disturbances, and other comorbidities. Distinguishing 
characteristics of the radiographic syndrome include radiographic features of OA (loss of joint 
space, osteophytes, and subchondral cysts and sclerosis) and MRI-detected lesions. As 
previously mentioned, there is a relatively poor correlation between the clinical and 
radiographic syndromes of OA (Cibere, 2006). This implies the existence of many distinct 
phenotypes of OA which may each benefit from a specific and targeted management plan. 
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Bijlsma and colleagues (2011) proposed the differentiation of OA into four distinct clinical 
phenotypes: post-traumatic or repetitive, metabolic, ageing, and genetic (Bijlsma et al., 2011). 
Each proposed phenotype may potentially affect different age groups, different joints, and 
may have different treatments. For example, the post-traumatic or repetitive OA phenotype 
mostly affects the knee, thumb, ankle, or shoulder, while the metabolic OA phenotype is more 
likely to affect the hand or be generalised. Similarly, the post-traumatic or repetitive OA 
phenotype may benefit most from joint stabilisation and surgical techniques, while the 
metabolic OA phenotype may benefit most from weight loss and glycaemic and lipid control 
(Bijlsma et al., 2011).  
1.2.3.2 Identifying further phenotypes 
There are two main ways to identify phenotypes in OA (Berenbaum, 2019). The “top-down” 
approach involves grouping patients based on specific aetiological and risk factors. The idea is 
that different aetiologies may cause different pathologies and clinical presentations and 
provide a natural way of grouping patients. The second method is the clinical phenotyping 
approach, and relies only upon statistical models (cluster analysis) to find clusters of patients 
based on a set of patient characteristics (for example, the model can consider age, gender, and 
mobility) (Van der Esch et al., 2015).  
An editorial by Castaneda and colleagues used the “top-down” approach to suggest 
aetiological and pathogenic phenotypes for OA (Castañeda et al., 2014). They suggested 
reclassifying “primary OA” (idiopathic OA) into one of following three phenotypes (based on 
risk factors): genetically determined, oestrogen dependent, or age related. They also proposed 
metabolic and high bone mineral density as two additional phenotypes of OA. They also 
discuss pathogenic phenotypes, arguing that phenotypes of OA may be determined by the 
tissue type that is most damaged in the joint. For example, primarily subchondral bone injury 
may cause a phenotype characterised by pain and bone lesions on magnetic resonance 
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imaging (MRI), primarily synovium injury may cause an inflammatory phenotype, and primarily 
soft tissue injury may cause bursitis and tendonitis.  
van der Esch (2015) discussed how there was a lack of studies investigating clinical phenotypes 
of OA, and the few published works on the topic only consider single patient parameters (such 
as pain or alignment) and not a cluster of characteristics (Van der Esch et al., 2015). This 
motivated the authors to identify clusters of OA phenotypes in 551 patients based on 4 
characteristics (upper leg strength, body mass index (BMI), severity of radiographic OA, and 
depressive symptoms). Cluster analysis found 5 distinct phenotypes: minimal joint disease, 
strong muscle, severe radiographic, obese, and depressive symptoms. Promisingly, the same 
authors had previously performed the same analysis on a different cohort and found 5 similar 
clusters (Knoop et al., 2011).  
Both approaches have their advantages. A “top-down” approach has the benefit of being able 
to link risk factors with disease processes, helping to uncover disease pathology. Clinical 
phenotyping has the advantage of clustering patients by easily obtainable measurements and 
characteristics, thus allowing clinicians to easily identify and treat specific phenotypes. 
Regardless of how it is accomplished, the identification of evidence-based phenotypes of OA 
will help identify new treatment methods through randomised control trials (RCT), and 
hopefully propel OA research towards the development of effective DMOADs.  
1.2.4 Epidemiology 
1.2.4.1 Prevalence 
Osteoarthritis is the most common form of arthritis globally (O’Neill et al., 2018). The most 
common site of OA is the knee, affecting over 250 million people worldwide. The prevalence of 
OA  is expected to rise due to the ageing population and increasing obesity rates (both are risk 
factors for OA) (Murray et al., 2012). However, prevalence estimates of OA depend greatly on 
the definition being used. In the United States, symptomatic (clinical) OA is estimated to affect 
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10% of men and 13% of women over 60 years-old (Y. Zhang & Jordan, 2010). Similarly, in a 
cohort of the Framingham Study of participants aged 63 to 94 years-old, 9.5% had 
symptomatic knee OA (11.4% women and 6.8% men) (O’Neill et al., 2018). However, the 
prevalence of radiographic OA is generally higher than the prevalence of symptomatic OA. The 
same Framingham study reported the prevalence of radiographic OA (defined by at least 2 
radiographic changes) to be 33% (34% of women, 31% of men), much higher than their 
symptomatic OA prevalence estimate. Additionally, the true prevalence  of OA may be 
underestimated because  many studies rely on radiographic diagnoses that are insensitive to 
early disease (O’Neill et al., 2018). 
1.2.4.2 Incidence 
The overall incidence of OA was measured using the Framingham Cohort Study in 
Massachusetts. Using data from 20 to 89 year olds, the age and sex matched incidence of 
knee, hand and hip OA was 240/100,000, 100/100,000, and 88/100,000 person-years 
respectively (O’Neill et al., 2018). 
However, age and sex exert large effects on the incidence on OA. Using general practice 
registry data, the incidence of OA has been reported to increase rapidly starting from 50 years 
old, reach a maximum incidence at 75 years old, and progressively decline in adults over 75 
years old (Hunter & Bierma-Zeinstra, 2019) (Figure 1.1). Men and women under 55 years-old 
have a similar risk of developing OA, however, there is a substantially increased risk of incident 







Figure 1.1: The incidence of OA per 100,000 people by age, sex, and site (Hunter & Bierma-
Zeinstra, 2019). Reproduced with permission by Elsevier. 
 
1.2.4.3 Risk factors 
Risk factors for OA may be categorised as systemic or local. Systemic risk factors include 
advanced age, obesity, female gender, diet, high bone mineral density, genetic factors, and 
certain ethnicities. Local risk factors include joint injury, certain occupations, physical activity, 
muscle weakness, and joint malalignment (Johnson & Hunter, 2014). 
1.2.4.3.1 Systemic risk factors 
Age is one of the strongest and most well-known risk factors for the development of OA in all 
joints (Vina & Kwoh, 2018; Y. Zhang & Jordan, 2010). Using data from the National Health and 
Nutrition Examination Survey (NHANES), the prevalence of radiographic knee OA in males was 
27.4% in sexagenarians, 33.5% in septuagenarians, and 40.7% in octogenarians, with women 
experiencing a similar trend (35.2%, 44.6%, and 55.6% respectively) (Dillon et al., 2006). A 
comparison of the prevalence of OA between adults 55 to 64 and over 75 years old in the 
Johnston County Osteoarthritis Project found that the prevalence of radiographic knee OA 
increased from 26.2% to nearly 50%, respectively, and the prevalence of symptomatic knee OA 
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increased from 16.3% to 32.8%, respectively (S. Anderson & Loeser, 2010). Y. Zhang and 
colleagues (2010) proposed that older age is accompanied by cartilage thinning, reduced 
muscle strength, an accumulation of oxidative damage, and diminished proprioception which 
leads to increased joint susceptibility when exposed to stress and contributes to the 
development of OA (Y. Zhang & Jordan, 2010).  
Similar to advanced age, being overweight or obese is a strong and well documented risk 
factors for incident knee OA. A systematic review and meta-analysis of risk factors for OA 
reported that obesity was strongly associated with incident knee OA (pooled OR 2.63, 95% CI 
2.28 to 3.05) compared to non-obese individuals (Blagojevic et al., 2010). A more recent 
systematic review and meta-analysis similarly reported that compared to normal BMI, being 
obese (OR 2.66 95% CI 2.15-3.28) and being overweight (OR 1.98 95% CI 1.57-2.2) both 
increased the odds of experiencing knee pain (Silverwood et al., 2015). These findings may also 
suggest a dose response with BMI and knee pain and knee OA. Similarly, a 5% weight loss and 
exercise programmes were shown to reduce pain in established symptomatic knee OA and 
reduce the incidence of radiographic knee OA (David T. Felson et al., 1992; Messier et al., 
2004). The relationship between obesity and hip OA however is less consistent than that of 
knee OA, as there are conflicting reports of their association in the literature, ranging 
drastically from no effect all the way to obesity being associated with bilateral radiographic hip 
OA (O’Neill et al., 2018; Y. Zhang & Jordan, 2010). While the traditional aetiology of hip and 
knee OA in obese individuals is that increased joint loading causes articular cartilage 
degradation, a recent systematic review and meta-analysis on hand OA and BMI has found an 
association between increased BMI and radiographic or clinical OA of the hands (Jiang et al., 
2016). The fact that hands are non-weight bearing joints suggests that obesity may also 
increase the risk of OA through non-biomechanical pathways potentially mediated by low-
grade inflammation.   
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There are differences in the occurrence of OA phenotypes between men and women. A 2005 
systematic review and meta-analysis showed that compared to women, men had a lower 
prevalence of hand and knee OA and a lower incidence of knee and hip OA (Srikanth et al., 
2005). Additionally, women, particularly over 55 years-old, experienced more severe knee OA 
compared to men. This suggests that sex hormones may be responsible for these differences, 
however, research into the area has provided inconsistent results. Hormonal changes around 
the time of menopause may contribute to a triggering event that then predisposes post-
menopausal women to an increased risk of OA (Wluka et al., 2000). Previous studies have 
shown that oestrogen bound to oestrogen receptors on human chondrocytes induces pro-
inflammatory cytokines and cartilage metabolism (Wluka et al., 2000). However, endogenous 
hormone levels (measured by age of menarche and menopause and parity) were shown to 
have no effect on incident OA (Wluka et al., 2000). Studies looking at the effect of hormone 
replacement therapy (HRT) on OA in post-menopausal women have also demonstrated 
conflicting results. Wluka and colleagues described how HRT reduced the prevalence and 
severity of knee OA, however, a more recent RCT of post-menopausal women with heart 
disease found that there was no difference in knee pain among women taking oestrogen and 
progesterone HRT versus placebo (Nevitt et al., 2001; Wluka et al., 2000). This highlights the 
need for further research into explaining why older women are at an increased risk of OA. 
Observational studies have shown an association between deficiencies in vitamins D, C, K and 
selenium and the incidence and progression of OA (O’Neill et al., 2018; Y. Zhang & Jordan, 
2010). Vitamin D is of particular interest as it has a large role in bone and cartilage metabolism 
and homeostasis (Vina & Kwoh, 2018). Multiple observational studies have shown vitamin D 
deficiency to be associated with a faster rate of progression in established OA (O’Neill et al., 
2018; Y. Zhang & Jordan, 2010). This prompted the VIDEO study, a randomised, double blind 
placebo-controlled trial looking at whether vitamin D supplementation altered the progression 
of knee OA in people with established disease (Arden et al., 2016). This study concluded that 
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vitamin D supplementation made no difference in the rate of joint space narrowing nor OA 
symptoms over a 3-year period, providing evidence that there is no role for vitamin D in the 
management of OA. 
Both cross-sectional and longitudinal studies have shown the association between high bone 
mineral density (BMD) and OA incidence and prevalence (O’Neill et al., 2018). Additionally, 
high systemic BMD has been associated with OA of the hand and the formation of osteophytes 
in subclinical knee OA (Vina & Kwoh, 2018). The mechanism for this remains unclear. 
Evidence for a genetic component of OA comes from the fact that there is still a risk of 
developing OA even after adjusting for the other established risk factors. It is estimated that 
OA has a 30-65% genetic component (Vina & Kwoh, 2018). Twin studies have reported a 
heritable component of 40% for hand, 65% for knee, and 70% for both hip and spine OA 
(O’Neill et al., 2018). A recent review found 21 independent susceptibility loci for hip, knee, 
and hand OA (Warner & Valdes, 2017). However, this only accounts for approximately 25% of 
the inherited part of OA, and as such further research is necessary to further uncover genetic 
links (O’Neill et al., 2018). 
There are subtle variations of the phenotype of OA depending on ethnic origin. Data from the 
Johnston County Osteoarthritis Project showed that African American men and women were 
more likely to have joint space narrowing and osteophytes on knee radiographs compared to 
white Americans (Nelson et al., 2010). Radiographic hand OA was shown less common in 
African Americans compared to white Americans (O’Neill et al., 2018). Additionally, Chinese 
women experienced significantly more radiographic and symptomatic knee OA than white 
women (O’Neill et al., 2018). 
1.2.4.3.2 Local Risk Factors 
Overt joint injury, particularly of the knee, is one of the strongest risk factors for the 
development of OA (Y. Zhang & Jordan, 2010). Knee injury (most commonly damage to the 
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anterior cruciate ligament (ACL), medial cruciate ligament (MCL), meniscus, or a trans-articular 
fracture) accounts for 12% of all cases of knee OA in the United States (Brown et al., 2006). A 
sudden high impact event can lead to permanent tissue injury and chronic structural changes 
(O’Neill et al., 2018). From computer-simulated projections, knee injury before 25 years of age 
carries a 2.5 times increased risk of knee OA and 4 times increased risk of total knee 
replacement later in life (Suter et al., 2017). Interestingly, the more widespread use of MRI has 
led to the hypothesis that incidental or asymptomatic knee injury can possibly predispose to 
the development of OA or be part of the pathogenesis. Englund and colleagues examined knee 
MRIs from a subset of the Framingham cohort and discovered a higher prevalence of 
incidental meniscus damage in those with OA (82%) compared to those without (25%) 
(Englund et al., 2008). This provides evidence that the prevalence of secondary OA may be 
vastly underestimated and other more reliable phenotypes of OA should be used instead of 
the “primary versus secondary” classification (D. T. Felson, 2010). 
It is well documented that occupations that require repetitive loading of a joint will increase 
the likelihood of incident OA (O’Neill et al., 2018). This has been demonstrated in farmers who 
develop hip OA, labourers who use pincer grips who develop distal interphalangeal and 
proximal interphalangeal OA, and workers who kneel and squat such as electricians who 
develop knee OA (Y. Zhang & Jordan, 2010). Adjustments in technique and variations in 
repetitive motions can help prevent this increased risk. 
There is an interesting relationship between physical activity and OA. Extreme physical activity 
has been shown to be a risk factor for OA, as both long distance runners and elite soccer 
players are at an increased risk of knee OA (Y. Zhang & Jordan, 2010). However, these findings 
may be confounded by the additional risk of injury from their respective sport. Additionally, a 
subset of the Framingham cohort that self-reported heavy physical activity (strenuous sports, 
lifting carrying objects greater than five pounds, or gardening with heavy tools) for greater 
14 
 
than 4 hours per day had a greater odds of knee OA (OR 7.0, 95% CI 2.4-20) compared to those 
undertaking no daily heavy physical activity (McAlindon et al., 1999). Interestingly, moderate 
physical activity carried no additional risk of hip or knee OA (O’Neill et al., 2018). 
Muscle weakness has been long associated with OA. The previously proposed mechanism is 
that OA leads to less physical activity, which leads to weakness and atrophy of the muscles 
(O’Neill et al., 2018). Newer evidence however has shown that muscle weakness is present in 
early disease and can even predate symptomatic OA (O’Neill et al., 2018). Weak quadriceps 
muscles have been shown to increase the odds of incident symptomatic knee OA (OR 1.65, 
95% CI 1.23-2.21) (O’Neill et al., 2018). Muscle weakness has also been reported as a risk 
factor for progressing from asymptomatic radiographic OA to symptomatic OA (Y. Zhang & 
Jordan, 2010). Additionally, among participants with ACL injuries, higher ratios of muscle to fat 
in the thigh was protective against the development of incident knee OA (Vina & Kwoh, 2018). 
However, strong quadriceps muscles are not always protective. In the context of joint 
malalignment, stronger thigh muscles increase the risk of knee OA progression (Y. Zhang & 
Jordan, 2010).  
An uneven distribution of force across a joint, such as with varus (bow-legged) or valgus 
(knock-kneed) deformities, can cause damage to joints, particularly the knee. While 
malalignment has been shown to accelerate structural damage and the progression of 
prevalent knee OA, its effect on incident OA is less clear (Y. Zhang & Jordan, 2010). A study 
investigating such deformities found that after 30 months, varus deformities were associated 
with both the progression and incidence of medial (tibiofemoral) OA (OR 3.59, 95% CI 2.62-
4.93 and 1.49, 1.06-2.10 respectively), but valgus deformities were associated with lateral 
compartment OA progression (OR 4.85, 3.17-7.42) but not incidence (L. Sharma et al., 2010). 
Varus and valgus deformities may not be a risk factor for developing OA, but alternatively a 




1.2.5.1 Traditional pathophysiology 
Osteoarthritis was traditionally thought to be non-inflammatory, and the result of “wear and 
tear” of joints that have been damaged through biomechanical factors including overuse, 
excessive loading, and malalignment. These insults cause the pathognomonic feature of OA, 
the progressive and irreversible degradation of articular cartilage. Unlike other tissues, 
cartilage has minimal reparative capabilities owing to its avascular nature (Mobasheri & Batt, 
2016). However, osteoarthritis is now recognised as a “wear and repair” disease, with 
osteophyte formation (bony protrusions), subchondral plate thickening, and synovial 
membrane inflammation characterising an aberrant reparative process (Martel-Pelletier, 
1999). Synovial inflammation leads to the production of matrix metalloproteinases (MMPs), 
which further breakdown the articular cartilage. This results in loss of joint space, as well as 
the presence of cysts and sclerotic tissue within the bone due to the inflammatory state of the 
joint. These disease processes produce pain, stiffness, and a loss of normal joint function.  
1.2.5.2 The innate immune system 
While biomechanical factors play a major role in OA, the strongest risk factors for the 
incidence and progression of OA are advanced age and obesity/metabolic syndrome. This 
prompted researchers to re-evaluate the pathophysiology of OA, and led to the discovery that 
the innate immune system plays a major role in the development and progression of OA 
(Kapoor et al., 2011). The major drivers of these recently discovered pathways are the 
cytokines tumour necrosis factor alpha (TNFA) and interleukin one beta (IL1B), key mediators 
of the body’s inflammatory cascade. 
Studies have shown that compared to people without OA, those with OA have elevated levels 
of TNFA and IL1B and their corresponding receptors in their synovial fluid and membrane, 
articular cartilage, and subchondral bone (Kapoor et al., 2011). These cytokines activate 
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intracellular signalling pathways (such as nuclear factor kappa light chain enhancer of activated 
B cells (NFKB) and the Wingless integrated (WNT) pathways) in chondrocytes and other joint 
tissues (Kapoor et al., 2011). These pathways cause the release of MMPs, enzymes that 
potently degrade articular cartilage (Kapoor et al., 2011). In addition to MMPs these tissues 
also release pro-inflammatory cytokines (PICs) including TNFA, IL1B, and interleukin 6 (IL6). 
These cytokines go on to release more MMPs and PICs, creating a vicious cycle of PICs, MMPs, 
and progressive cartilage destruction (Kapoor et al., 2011).  
Another consequence of PICs in a joint is they can drive the conversion of normally senescent 
chondrocytes into chondrocytes exhibiting a senescence-associated secretory phenotype 
(SASP) (Mobasheri & Batt, 2016). All healthy cells eventually undergo replicative senescence, 
after which they cease to have replicative function. However, in the presence of inflammation, 
senescent chondrocytes can acquire SASP and secrete a high number of cytokines and MMPs 
which further accelerates cartilage degradation (Berenbaum, 2013).  
1.2.5.3 Sources of Inflammatory markers in people with OA 
Given the last sections discussion of how damaging an inflammatory state can be to joints, the 
natural next question is what causes a person to be in an inflammatory state? Mobasheri 
(2016) discussed the concept of “inflammaging” as a source of PICs that can initiate cartilage 
degradation. Normal ageing is associated with an underlying low level of PICs that are present 
in people’s bodies at all times (Mobasheri & Batt, 2016). These PICs may initiate the OA 
disease process by stimulating chondrocytes to release MMPs and more PICs (Mobasheri & 
Batt, 2016). This would explain why age is one of the strongest risk factors for developing OA. 
Similarly, inflammaging may also act as the trigger for other age-related diseases including 
atherosclerosis and cardiovascular disease. 
Another potential source of inflammation that may trigger the cascade of cartilage destruction 
in OA is from obesity and metabolic syndrome. Despite traditionally being thought of as an 
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inactive store of energy, adipose tissue plays a major role in paracrine and endocrine signalling 
(Sowers & Karvonen-Gutierrez, 2010). Adipose tissue consists of adipocytes, resident 
macrophages, and fibroblasts (Berg & Scherer, 2005). Adipocytes also release hormones called 
adipocytokines, which are leptin, resistin, and adiponectin (Sowers & Karvonen-Gutierrez, 
2010). Obesity alters the phenotype of adipocytes in three ways that may trigger the 
development of OA (Gustafson, 2010). An obese phenotype causes an attenuated release of 
adiponectin. Adiponectin normally has an anti-inflammatory role by decreasing the amount of 
TNFA that adipocytes release (Gustafson, 2010). The obese phenotype of adipocytes releases 
less adiponectin, and therefore promotes an inflammatory environment (Gustafson, 2010). An 
obese phenotype also causes the release of more leptin. Leptin, the satiety hormone, is often 
elevated in obese individuals because they become resistant to its effects (analogous to and 
often co-existing with insulin resistance) (Sowers & Karvonen-Gutierrez, 2010). Leptin 
receptors have been discovered on chondrocytes, therefore, high levels of leptin may 
stimulate chondrocytes to release MMPs and PICs into the synovium (Sowers & Karvonen-
Gutierrez, 2010), potentially causing cartilage destruction. Finally, obesity causes increased PIC 
release from adipocytes. Adipocytes have retained their evolutionary capability to release PICs 
(TNFA, IL1B) and acute phase reactants (such as C-reactive protein (CRP)) in certain conditions 
(Berg & Scherer, 2005). Studies have reported serum levels of CRP and other PICs to increase 
correspondingly with increasing BMI (Berg & Scherer, 2005). Additionally, weight loss has been 
shown to reduce previously high levels of such inflammatory markers, providing further 
evidence that obesity may be the source of systemic low-grade inflammation necessary to 
initiate OA (Berg & Scherer, 2005). 
Another potential mechanism for the generation of underlying inflammation is through the 
formation of advanced glycated end products (AGEs). AGEs are proteins created by a 
persistently hyperglycaemic environment and promote atherosclerosis and CVD (Sowers & 
Karvonen-Gutierrez, 2010) through the action of its membrane bound receptor (RAGE). 
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Interestingly, RAGEs have been discovered on the surface of chondrocytes and been shown to 
induce the release of PICs (Sowers & Karvonen-Gutierrez, 2010). These PICs can then 
potentially go on and initiate a cascade of events that can lead to OA. 
This discussion highlighted an updated pathophysiology of OA with consideration for an 
inflammatory component of the disease process. Next is a discussion of the clinical features of 
OA. 
1.2.6 Clinical Features 
Signs of OA include crepitus, restricted movement, bony enlargement, joint effusion, 
tenderness on palpation and pain on joint movement. Symptoms of OA include joint pain that 
increases with activity, joint stiffness, reduced function, joint locking, and the feeling of a joint 
“giving way”. These signs and symptoms tend to be clustered into distinct phenotypes and 
present differently to medical practitioners. These include but are not limited to an 
inflammatory phenotype (characterised by synovitis and joint effusion), a chronic pain 
phenotype, a metabolic phenotype (characterised by metabolic syndrome), and a potentially 
asymptomatic phenotype that may be characterised only by radiographic and MRI features of 
OA (Castañeda et al., 2014; D. T. Felson, 2010).  
In 2010, the European League against Rheumatism (EULAR) published an evidence-based 
recommendation for the diagnosis of knee osteoarthritis. They concluded that for knee OA, 
the three most diagnostic symptoms are persistent knee pain, limited morning stiffness and 
reduced function, and the three most diagnostic signs are crepitus, restricted movement and 
bony enlargement (W. Zhang et al., 2010).  
Joint pain is the most common symptom of OA, and accounts for a large proportion of 
disability associated with OA (Heidari, 2011). Joint pain is often the first symptom people with 
OA notice and is often the triggering factor that causes them to seek help from primary care 
(Bijlsma et al., 2011). Joint pain is worse during and immediately following exercise and better 
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following rest (Heidari, 2011). The type of the pain varies; people often experience a chronic 
dull ache, with superimposed flare-ups of sharp pain (Bijlsma et al., 2011). As discussed 
previously, chondrocytes are avascular and lack innervation. Therefore, it is hypothesised that 
joint pain in OA originates from the highly innervated subchondral bone (Glyn-Jones et al., 
2015). Because relatively mild disease may not yet reach the innervated bone, by the time a 
person present with pain they may already have advanced or irreversible OA (Glyn-Jones et al., 
2015). Alongside joint pain, joint stiffness is a common symptom of OA. The joint stiffness is 
caused by synovial inflammation and often follows periods of prolonged inactivity, such as 
sleeping (Sellam & Berenbaum, 2010). During assessment in clinical practice, a key 
differentiator between OA and inflammatory arthritis is that in OA, morning joint stiffness 
often lasts less than 30 minutes (Heidari, 2011). A third common symptom of OA is the loss of 
joint function causing disability and activity limitation. This can greatly impact the lives of 
people with OA and is another major reason for consultation (Bijlsma et al., 2011). Knee and 
hip OA can affect one’s ability to walk and climb stairs, and hand OA can make simple tasks 
such as household chores extremely difficult (Bijlsma et al., 2011). Additionally, symptomatic 
OA may also be associated with multimorbidity including cardiovascular disease, peptic ulcer 
disease, or psychological disorders (Swain et al., 2019; Vina & Kwoh, 2018). 
Crepitus is a common sign of an arthritic joint and is elicited by passively moving a joint and 
listening for crackles or a popping sound (W. Zhang et al., 2010). Knee crepitus has been 
associated with osteophytes and pathology to the meniscus and MCL and may be caused by 
osteophytes or osseous surfaces rubbing against soft tissue, cartilage, or bone (Crema et al., 
2011). Another common sign is restricted joint movement, often caused by synovial 
inflammation leading to joint stiffness (Sellam & Berenbaum, 2010). The inability for a joint to 
perform a full range of motion often leads to impaired function. Finally, joint deformity tends 
to worsen with OA severity, can affect any joint, and is part of a group of bone changes in OA 
including new bone formation at the joint margin (osteophytes), subchondral bone sclerosis, 
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and subchondral bone cysts (A. R. Sharma et al., 2013). Bony deformity is commonly seen in 
the distal (DIP) and proximal (PIP) interphalangeal joints and are called Heberden’s and 
Bouchard’s nodes, respectively. These deformities are linked to aberrant attempts to repair 
joint damage and may further impair a joints range of motion. 
1.2.7 Management 
1.2.7.1 Conservative Management 
The management of OA requires a biopsychosocial approach because OA is associated with 
many other extra-articular symptoms including poor sleep and depression. The treatment of 
articular symptoms is stepwise starting with conservative measures, followed by 
pharmacological and sometimes surgical interventions. A number of conservative measures 
have been proven efficacious for the management of OA symptoms. Clinicians should sign-post 
patients to sources of information, advice, and support, including the Arthritis Research UK 
and National Health Service (NHS) choices websites (National Institute for Health and Care 
Excellence, 2014). A 5% weight loss for overweight and obese people has been shown to 
improve pain and functional symptoms (McAlindon et al., 2014). Other conservative treatment 
options with little or no risk of adverse side effects include muscle strength training 
(particularly of the quadriceps for knee OA), low impact aerobic exercise, foot orthoses, and 
knee braces for instability (Mcalindon et al., 2014).  
1.2.7.2 Pharmacological management 
The National Institute for Health and Care excellence (NICE) advises the use of oral 
paracetamol and topical non-steroidal anti-inflammatory drugs (NSAIDs) as first line analgesics 
for people with OA. Regular paracetamol however has been associated with slightly increased 
risk of gastrointestinal events and multi-organ failure, and as such a person’s comorbidities 
must always be considered (McAlindon et al., 2014). If these measures are ineffective in 
treating pain, NICE recommends the addition of oral NSAIDs.  
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Oral NSAIDs are effective in pain relief, however they have potentially serious side effects 
including gastrointestinal tract ulcers, reductions in glomerular filtration rate, and 
cardiovascular risks including hypertension, myocardial infarctions, and strokes (Varga et al., 
2017). Regular NSAID use has been associated with an increased risk of cardiovascular disease 
in people with OA. A recent prospective cohort study used marginal structural modelling 
within a cox-proportional hazards model and determined that NSAID use mediated 41% of the 
total effect of OA on incident CVD (total effect adjusted hazard ratio: 1.23; 95% CI 1.17 to 1.28) 
(Atiquzzaman et al., 2019). The authors also found NSAID to mediate the relationship between 
OA and congestive heart failure (23%), ischemic heart disease (56%), and stroke (64%). 
To mitigate the gastrointestinal risks associated with NSAIDs, the OARSI guidelines for the 
management of OA suggest that NSAIDs be prescribed with a proton pump inhibitor if a 
patient has a moderate comorbidity risk profile (McAlindon et al., 2014). They advise against 
oral NSAIDs in patients with a high comorbidity risk profile.  
If oral NSAID therapy is ineffective, NICE recommends the use of oral codeine or topical 
capsaicin for pain relief. Transdermal opiates and intra-articular steroid injections are used for 
short-term relief of severe symptoms (National Institute for Health and Care Excellence, 2014). 
Pharmacological therapies with no proven effect as a DMOAD include glucosamine and 
chondroitin, while the effects of risedronate as a DMOAD are still uncertain (McAlindon et al., 
2014).  
1.2.7.3 Surgical Management 
The lack of effective DMOADs means that the failure of conservative and pharmacological 
management may lead to joint failure requiring surgical intervention. NICE recommends that 
people should be referred to an orthopaedic surgeon when the symptoms of OA are resistant 
to primary care management and significantly impact a person’s quality of life (National 
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Institute for Health and Care Excellence, 2014). There are three main categories of surgical 
procedures: arthroscopy, osteotomy, and total joint replacements.  
Since its inception in the 1980’s, arthroscopic debridement and lavage quickly became the 
standard treatment for symptomatic knee OA, despite the lack of peer-reviewed evidence in 
its favour (Katz et al., 2010). Arthroscopy is the insertion of a small camera into the joint, 
allowing surgeons to smooth the articular surface and shave osteophytes (debridement) and 
remove particulate matter such as of calcium deposits and fragments of cartilage (lavage) 
(Kirkley et al., 2008). The first RCT looking at the efficacy of knee arthroscopy found no 
difference in outcomes for 180 patients after 2 years when comparing each of debridement, 
lavage, and a sham procedure (Moseley et al., 2002). A subsequent RCTs compared 
arthroscopic debridement, lavage, physical therapy, and medical therapy with only physical 
and medical therapy and found that after 2 years arthroscopy provided no additional benefit 
(Kirkley et al., 2008). There are conflicting reports on the efficacy of arthroscopic partial 
meniscectomy (APM) in patients with knee OA and a meniscus tear, as some reports show 
APM to increase the rate of progression of OA, however this may be confounded by the direct 
effects of the tear itself (Katz et al., 2010). NICE recommend against the referral for 
arthroscopic debridement and lavage for the treatment of OA except for when there is a clear 
history of mechanical locking of the knee (National Institute for Health and Care Excellence, 
2014).  
Osteotomies can be performed in patients with unicompartmental knee OA (that often 
coexists with varus or valgus deformities) when other management strategies have failed 
(Brouwer et al., 2014). They are also performed in patients too young for a total knee 
replacement. The aim is to realign the knee in order to distribute force evenly across its 
surface. As discussed previously, malalignment is a strong risk factor for the progression and 
possibly incidence of OA. Osteotomies aim to prevent this progression of OA and relieve joint 
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pain (Katz et al., 2010). If a patient were to present with medial compartment knee OA and an 
associated genu varus deformity, a surgeon would shorten the lateral tibia (called a valgus 
osteotomy) in order to distribute more force onto the lateral compartment, thus reducing the 
force on the already damaged medial compartment and hopefully prevent further OA 
progression (Brouwer et al., 2014). Osteotomies have a lower success rate and carry a greater 
risk of revision surgery compared to replacement surgery (Katz et al., 2010). A meta-analysis 
found that 16% of patients who underwent a valgus high tibial osteotomy required knee 
arthroplasty within 12 years (Bennell et al., 2012). As such, the gold standard for advanced OA 
in older patients is a total joint replacement (Katz et al., 2010).  
For older patients with advanced OA characterised by pain, functional limitation, or reduced 
quality of life, joint arthroplasty is the recommended intervention (Bennell et al., 2012). Joint 
arthroplasty was once viewed as a last resort for advanced OA, however emerging evidence 
that post-operative function is dependent on pre-operative function highlights some of the 
benefits of earlier surgery (Katz et al., 2010). However, because implants can be worn down 
and revision arthroplasty is less successful than primary arthroplasty, patients under 60 are 
usually not offered replacement surgery (Bennell et al., 2012). Overall, the number of total 
joint replacements performed is on the rise. In the United States (US) in 2007, there were 
550,000 knee replacements, 250,000 hip replacements, and 23,000 shoulder replacement 
surgeries performed (Katz et al., 2010). This number is expected to rise, as it is estimated there 
will be 3 million joint replacements in the US by 2030 (Katz et al., 2010). Joint replacement of 
the ankle and wrist are relatively uncommon due to their relatively low incidence, and the 






1.2.8 Burden of OA 
1.2.8.1 Activity limitation and social participation 
Osteoarthritis exerts both an individual and a socioeconomic burden. A large individual burden 
is felt due to the chronic and progressive nature of OA (Hunter et al., 2014). This burden is 
often felt through activity limitation and participation restriction, which is defined by the 
World Health Organisations (WHO) International Classification of Functioning, Disability and 
Health (ICF) as difficulties in executing activities or problems in the involvement of life 
situations (World Health Organisation, 2007). Specific activities defined by the ICF that may be 
affected by OA include mobility, self-care, household tasks, work and employment, and 
recreation and leisure (World Health Organisation, 2007). Eighty percent of people with knee 
OA have some limitation, 25% cannot perform major activities of daily living, and 11% require 
personal care (Hunter et al., 2014). Additionally, OA is the most common reason for adults 
over 65 years-old to have difficulty walking or climbing stairs (Hunter et al., 2014).  
1.2.8.2 Quality of life 
People with OA also experience a greatly reduced quality of life (QOL), which is measured by 
alterations to one’s physical wellbeing, material wellbeing, social wellbeing, emotional 
wellbeing, development, and activity compared to people in the same social or cultural group 
(Felce & Perry, 1995). Quality adjusted life years (QALYs) are a measure of QOL and is the 
product of the length of life (in years) and the quality of life (ranging from death (0) to perfect 
health (1)) (Sassi, 2006). For example, 1 year of perfect QOL and 2 years lived at fifty percent 
QOL would both equal 1 QALY. Disability adjusted life years (DALYs), introduced by the Global 
Burden of Disease study in 1990, are a composite measurement of the burden of a disease 
(Murray et al., 2012). DALYs are the sum of the years of life lost and the years lived with 
disability caused by a particular disease (for example, a person living in good health to their full 
life expectancy would have 0 DALYs) (Murray et al., 2012). QALYs and DALYs are complements 
of each other. For the example of a person with an 80-year life expectancy:  
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# 𝑜𝑓 𝑄𝐴𝐿𝑌𝑠 + # 𝑜𝑓 𝐷𝐴𝐿𝑌𝑠 = 80 𝑦𝑒𝑎𝑟𝑠. 
In the United States, 15 million QALYs are lost annually due to OA, a similar number of QALYs 
lost due to cardiovascular disease and cancer (Hunter et al., 2014). Globally, musculoskeletal 
(MSK) disorders accounted for 6.8% of all DALYs in 2010, increasing from 4.7% in 1990 (Murray 
et al., 2012). OA in particular accounted for 10% of all MSK related DALYs in 2010 and had 
increased by 64% compared to estimates from 1990 (this was the 2nd fastest increasing 
burden, only next to diabetes) (Hunter et al., 2014).  
1.2.8.3 Association with comorbidity 
Osteoarthritis is associated with comorbidity. A recent systematic review and meta-analysis of 
42 studies examining the association of comorbidities with OA found that people with OA were 
more likely to have at least one comorbidity compared to people without OA (67% (95% CI 
57% to 74%) versus 56% (95% CI 44% to 68%)) (Swain et al., 2019). The same review also found 
that people with OA had an increased prevalence of stroke (prevalence ratio 2.6; 95% CI 2.1 to 
3.2), peptic ulcer disease (PR 2.4; 95% CI 1.7 to 3.3) and metabolic syndrome (PR 1.9; 95% CI 
1.2 to 3.1). People with OA were also significantly associated with psychological conditions (PR 
1.8; 95% CI 1.2 to 2.5) and any cardiovascular disease (PR 1.6; 95% CI 1.3 to 1.9). A recent 
meta-analysis found that OA was associated with cardiovascular disease and incident AMI 
(Schieir et al., 2017). Additionally, symptomatic knee OA has been associated with an 
increased all-cause and cardiovascular specific mortality (Kluzek et al., 2016).  
1.2.8.4 Socioeconomic burden 
OA also exerts a large direct and indirect socioeconomic burden. OA is the most common 
indication for total hip or knee replacements (Y. Zhang & Jordan, 2010), with 185,000 primary 
hip or knee replacements in the UK in 2016. In the US, United Kingdom (UK) Canada, and 
France, it is estimated that 1-2.5% of the GDP of these countries is spent on OA, with joint 
replacement surgery accounting for 85% of this cost (Hunter et al., 2014).  The average annual 
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direct cost of OA per person in Canada was USD $12,000 in 2002 (Hunter et al., 2014). Direct 
cost estimates in the US vary greatly (depending on whether healthcare resource categories 
were measured from claims data or survey data), ranging between $1,442 and $21,335 per 
person per year (Vina & Kwoh, 2018). Indirect costs are much greater than direct costs, and 
are comprised of sick days, early mortality, and early retirement. The cost of employees being 
absent from work due to OA is estimated at $10 billion per year, comparable to asthma ($5 
billion), migraines ($12 billion), and hypertension ($18 billion) (Hunter et al., 2014).  
1.3 Acute myocardial infarction 
1.3.1 Overview 
Cardiovascular disease (CVD) encompasses any disease that affects the heart or blood vessels 
(World Health Organisation, 2020). Common subtypes of CVD include coronary heart disease 
(CHD), strokes and transient ischemic attacks (TIAs), peripheral artery disease, aortic disease, 
heart failure and cardiomyopathy, and valvular disease. Globally, CVD accounts for up to 40% 
of all deaths, more than any other cause (Santulli, 2013). While advancements in the 
identification, management, and prevention of CVD has led to better patient outcomes in 
developed countries, developing countries still face increasing rates of CVD, including 
increasing AMI incidence and mortality (Sanchis-Gomar et al., 2016).  
1.3.2 Definitions 
1.3.2.1 Myocardial injury 
Myocardial injury is necessary but not sufficient for a diagnosis of myocardial infarction. 
Myocardial injury can be reliably detected by certain serum biomarkers such as cardiac 
troponin. The current definition of myocardial injury is a single cardiac troponin (cTn) level 
greater than the 99th percentile upper reference limit (J. L. Anderson & Morrow, 2017); acute 
injury is defined as a rise and fall of cTn as determined by serial measurements (Thygesen et 
al., 2019). Myocardial injury results in the release of cardiac enzymes (cardiac troponin I (cTn I) 
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and cardiac troponin T (cTn T)) into the serum (J. L. Anderson & Morrow, 2017). Cardiac 
troponins are part of the contractile apparatus in myocytes and are highly specific and 
sensitive to the heart (Thygesen et al., 2019). Elevated levels of these biomarkers can be 
detected via high sensitivity cTn assays. Creatine kinase myocardial band (CK-MB) is also 
specific to myocardial injury and used to be the preferred biomarker for myocardial injury, 
however, because of CK-MB’s relative lack of sensitivity (resulting in missed diagnoses) and the 
overall higher sensitivity and specificity of cardiac troponin, CK-MB has fallen out of favour in 
most healthcare services (Boersma et al., 2003). 
The many different causes of myocardial injury can be grouped into four main aetiologies 
(Thygesen et al., 2019). The first category of myocardial injury is due to decreased myocardial 
perfusion. Causes include coronary emboli, coronary vasospasm, shock, and severe anaemia. 
The second category of injury is due to increased myocardial oxygen demand, including 
sustained tachycardia and severe hypertension. The third category of injury is due to cardiac 
conditions such as cardiomyopathies, myocarditis, coronary procedures, and heart failure. The 
fourth and final category of myocardial injury is due to systemic conditions such as sepsis, 
chronic kidney disease, pulmonary embolisms, and stroke. It is the clinicians challenge and 
responsibility to distinguish these causes of myocardial injury from a myocardial infarction.  
1.3.2.2 Myocardial Infarction 
According to the fourth universal definition of myocardial infarction, an acute myocardial 
infarction (AMI) is defined as acute myocardial injury (a serum cardiac troponin level greater 
than the 99th percentile upper reference limit and a rise and fall of serial cTn measurements) 
and one associated clinical, pathological, or anatomical feature (Thygesen et al., 2019). 
Associated features include the signs and symptoms of an MI, new ischemic electrocardiogram 
(ECG) changes, pathological Q-waves, imaging showing the loss of viable myocardium in a 
pattern consistent with ischemia, or the identification of a coronary thrombus by angiography 
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or autopsy (Thygesen et al., 2019). Therefore, a detailed history, clinical examination, and 
investigations are required for a diagnosis of AMI. 
1.3.2.3 Sub-types of MI 
There are six sub-types of AMI, however all of them share the common endpoint of acute 
myocardial necrosis (J. L. Anderson & Morrow, 2017). Type 1 AMIs are the most common 
subtype and are caused by an acute atherothrombosis of an atherosclerotic plaque in a 
coronary artery. The atherosclerotic plaque undergoes rupture or erosion followed by 
immediate thrombus formation over the plaque. The resulting atherothrombosis causes 
coronary artery occlusion and downstream myocardial infarction (Thygesen et al., 2019). Type 
2 AMIs are not caused by an acute atherothrombotic event, but instead by situations where 
myocardial oxygen demand is greater than myocardial oxygen supply (Thygesen et al., 2019). 
Common causes of myocardial supply and demand imbalances include stable atherosclerotic 
plaques, coronary artery vasospasm (commonly from cocaine use), and anaemia from massive 
bleeds. Type 3 AMIs are infarctions causing sudden death without prior ECG or biomarker 
confirmation of AMI (J. L. Anderson & Morrow, 2017). Type 4a AMIs occur around the time of 
percutaneous coronary intervention (PCI), type 4b AMIs occurs due to thrombosis of a 
coronary stent, and type 5 AMIs are infarcts related to coronary artery bypass grafting (CABG) 
(J. L. Anderson & Morrow, 2017). In addition to these six subtypes, AMIs may also be classified 
by the presence or absence of ST-segment elevation on ECG; the importance of this 
classification with respect to management will be discussed further in section 1.3.6. 
1.3.3 Pathophysiology 
1.3.3.1 Atherosclerosis as the primary cause of AMI 
Atherosclerosis is the primary disease process of most cardiovascular diseases. Most AMIs are 
due to acute atherothrombotic events, where an atherosclerotic plaque is disrupted and an 
acute thrombus forms over the newly formed and highly thrombogenic surface (Boersma et 
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al., 2003). Atherosclerosis is a process initiated by endothelial activation and is characterised 
by a slow and progressive narrowing of large arteries and an accumulation of lipids and cellular 
debris in the sub-endothelium (Sakakura et al., 2013). Atherosclerosis can start to develop as 
early as childhood and adolescence. The initiating step in atherosclerosis is activation of the 
endothelium through a variety of insults, commonly hypertension, smoking, hyperglycemia, or 
hypercholesteremia (Santos-Gallego et al., 2014). Once activated, the endothelium displays 
different characteristics to a normal endothelium, particularly, an activated endothelium is 
more permeable to low density lipoproteins (LDL) and expresses an increased numbers of 
adhesion proteins that promote monocyte and lymphocyte extravasation (Santos-Gallego et 
al., 2014). LDL extravasates through the endothelium into the subendothelium where it 
becomes oxidised by resident macrophages. Oxidised LDL is highly inflammatory, stimulating 
the release of PICs from macrophages and smooth muscle cells (SMC) (Santos-Gallego et al., 
2014). PICs cause pathological thickening of the tunica intima and the proliferation of SMCs. 
This process does not initially reduce blood flow through the blood vessel, as coronary arteries 
can undergo outward remodelling to preserve cross sectional area. This produces a prolonged 
asymptomatic phase in coronary artery disease (Boersma et al., 2003). Over time, 
macrophages change phenotype to foam cells due to persistent LDL phagocytosis (Sakakura et 
al., 2013). These foam cells become the fatty streak, which is the earliest atherosclerotic 
lesion. Foam cells release further PICs that perpetuate the atherosclerotic process. This 
process causes the proliferation and migration of SMCs, which produce a fibrous cap to 
stabilise the atherosclerotic lesion (Ferrucci & Fabbri, 2018). Over time, intimal thickening and 
the accumulation of lipids and cellular debris eventually results in the narrowing of the blood 
vessel, which reduces blood flow beyond the plaque. The fibrous cap tends to become weaker 
and thinner over time, predisposing to disruption, thrombosis, and an acute myocardial 
infarction (Santos-Gallego et al., 2014). 
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1.3.3.2 Atherosclerosis associated with inflammatory diseases 
In addition to the previously mentioned risk factors for the development of atherosclerosis, 
there is a growing body of evidence that systemic inflammation plays a role in atherosclerotic 
development and progression. This is evident in chronic autoimmune conditions such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), seronegative 
spondyloarthropathies, and inflammatory bowel disease (IBD), all of which have been 
associated with an excess cardiovascular risk compared to people without these conditions 
(Steyers & Miller, 2014). People with RA and SLE have been most extensively studied and it has 
been shown that they have an increased incidence of both fatal and non-fatal CVD when 
compared to controls (Symmons & Gabriel, 2011). One study showed that over 50% of 
premature deaths among RA patients were attributed to CVD, and this excess risk is not 
accounted for by traditional cardiovascular disease risk factors (Symmons & Gabriel, 2011). 
Similarly, a 2001 cohort study compared the incidence of cardiovascular events in RA patients 
with those without RA and found an increased incidence rate ratio in the RA group (3.17, 1.33-
6.36) even after adjusting for traditional cardiovascular disease risk factors (Del Rincón et al., 
2001). 
Given this association between chronic inflammation and CVD, further research has looked 
into why this association exists. These works have suggested that inflammation induced 
endothelial activation may be a potential mediator of the relationship. A normal endothelium 
regulates vascular tone (constriction and dilation) and regulates cellular adhesion and 
thrombosis on the endothelium (via the expression of adhesion molecules and changing its 
permeability) (Steyers & Miller, 2014). Endothelial cells can be “activated” by a number of 
stimuli, including PICs from an inflammatory response (Steyers & Miller, 2014). Activated 
endothelium has a different phenotype that is characterised by increased cellular adhesion, 
increased permeability, and an increased risk of thrombosis (Steyers & Miller, 2014). One of 
the first papers describing endothelial activation as a mediator of CVD in patients with RA was 
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published in 2002. Bergholm and colleagues showed that newly diagnosed RA patients had an 
impaired vasodilatory response to acetylcholine, suggesting an impairment of the endothelial 
nitric oxide synthase pathway in RA patients (Bergholm et al., 2002). It is proposed that 
inflammatory mediators (particularly TNFA) cause endothelial activation by impairing 
vasodilation via the inhibition of nitric oxide release and by activating transcription factors 
such as NFKB which in turn increase endothelial permeability and increase the number of 
adhesion molecules on the surface (Steyers & Miller, 2014). The result of an activated 
endothelium is the promotion of atherosclerosis, and eventually cardiovascular disease. 
1.3.3.3 Atherosclerosis and low-grade inflammation from ageing and obesity 
Given the previously discussed association between autoimmune diseases, inflammation and 
CVD, there is interest in whether low levels of inflammation can stimulate or perpetuate the 
atherosclerotic process and predispose individuals to CVD. The previous section outlined how 
inflammation from both obesity and ageing (which are also potent risk factors for CVD) can 
predispose individuals to developing OA. Next is a discussion of how these two risk factors may 
promote atherosclerosis and CVD, followed by a proposed potentially shared pathophysiology 
between OA and CVD. 
As discussed previously, inflammageing is the accumulation of cytokines and inflammatory 
mediators with normal ageing. Age is a strong risk factor for CVD, but there is debate 
surrounding whether inflammageing causes CVD, or if the associated inflammation is simply a 
marker of CVD (Ferrucci & Fabbri, 2018). A randomised control trial promisingly showed that 
low dose (0.5 mg/day) colchicine (an anti-inflammatory) significantly reduced the incidence of 
acute coronary syndrome in people with stable coronary heart disease (CHD) (Nidorf et al., 
2013). There are proposed mechanisms for how low-grade inflammation can predispose to 
atherosclerosis and CVD. In an inflammatory environment, vascular SMCs are predisposed to 
undergo early replicative senescence (Ferrucci & Fabbri, 2018). This means that the normally 
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proliferating SMCs can no longer produce an extra-cellular matrix that supports the fibrous 
cap, thus predisposing to a weaker plaque that is more prone to rupture (Ferrucci & Fabbri, 
2018). Additionally, in a similar fashion to chondrocytes, PICs may induce the senescence-
associated secretory phenotype (SASP) from normally senescent SMCs (Ferrucci & Fabbri, 
2018). SMCs with SASP secrete MMPs which can further destabilise the fibrous cap of an 
atherosclerotic lesion and promote acute atherothrombotic events. 
The association between obesity and atherosclerosis has been known for decades, however, 
the mechanism linking them has changed drastically over recent years. Obesity and 
atherosclerosis were both once thought to be lipid storage disorders (Rocha & Libby, 2009), 
however, it is now well known that they both have substantial inflammatory components. The 
function of adipose tissue is no longer thought to be solely insulation and the storage of free 
fatty acids. It is now recognised to have an essential role in insulin sensitivity, hunger, 
inflammation, and the development of metabolic syndrome (Gustafson, 2010). Normal 
adipocytes secrete a number of cytokines. One of which is adiponectin, which plays an 
important role in attenuating inflammation (by decreasing adipocyte TNFA release), 
discouraging atherosclerosis (by inhibiting foam cell production and promoting nitric oxide 
release) and preventing intima media thickening (Gustafson, 2010). Normal adipocytes are 
capable of releasing IL-6, and resident macrophages in adipose tissue are capable of releasing 
TNFA. This normal phenotype of adipose tissue changes drastically with obesity. Firstly, obesity 
drives the enlargement of adipocytes (Gustafson, 2010). Enlarged adipocytes express markedly 
less adiponectin, thus promoting atherosclerosis. Enlarged adipocytes also release more PICs 
(including TNFA and IL-6) and release more free fatty acids than normal adipocytes, further 
promoting the development and progression of atherosclerosis.  
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1.3.3.4 AMI as caused by acute plaque disruption 
After the formation of an atherosclerotic plaque, there are three principle ways it may be 
disrupted, all of which lead to the exposure of a highly thrombogenic surface to the blood, 
resulting in thrombosis, coronary occlusion, impaired oxygen delivery to the myocardium, and 
potentially myocardial infarction. The most common plaque disruption is a plaque rupture (J. L. 
Anderson & Morrow, 2017), causing approximately 60% of atherothromboses (Sakakura et al., 
2013). This occurs when the thin fibrous cap of a plaque breaks, exposing its highly 
thrombogenic necrotic core composed of foam cells to the bloodstream. The next most 
common type of plaque disruption is an erosion, which causes approximately 30% of 
atherothromboses (Sakakura et al., 2013). Erosions have no evidence of plaque rupture; 
instead, the endothelium becomes eroded, leaving behind a thrombogenic surface of SMCs 
and collagen (Sakakura et al., 2013). The least common type of plaque disruption (2-7%) is a 
calcified nodule (Sakakura et al., 2013). Thrombosis occurs on a thrombogenic calcified nodule 
when it protrudes through a broken fibrous cap (Sakakura et al., 2013). Interestingly, the 
proportion of plaque ruptures causing AMIs are decreasing due to the widespread use of 
statins (J. L. Anderson & Morrow, 2017). This means that there is a growing proportion of 
plaque erosions and calcified nodules as the cause of acute atherothrombotic events (J. L. 
Anderson & Morrow, 2017).  
Regardless of the mechanism, a full occlusion of the coronary artery will generally cause full 
thickness ischemia/infarction of the myocardium and is characterised by ST segment elevation 
on an ECG (STEMI) (J. L. Anderson & Morrow, 2017). A partial occlusion or a full occlusion with 
sufficient collateral blood supply will result in partial thickness ischemia/infarction of the 
myocardium and result in a non-ST segment elevated MI (NSTEMI) or unstable angina (J. L. 
Anderson & Morrow, 2017). The reason AMIs can cause ECG changes is because infarcted 
myocardium loses its ability to propagate an electrical impulse. As a result, the waves of 
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depolarisation and repolarisation must take alternative paths to avoid the non-conductive 
myocardium, resulting in altered ECG waveforms. 
Impaired blood flow to the myocardium initially results in reversible ischemia (J. L. Anderson & 
Morrow, 2017). Generally, irreversible damage to the myocardium occurs after 30 minutes of 
occlusion, at which point the criteria for an MI is satisfied (Boersma et al., 2003). Following 
occlusion, the ischemic myocardium becomes necrotic, and complications such as left 
ventricular dysfunction, arrhythmias, and sudden cardiac death may occur (J. L. Anderson & 
Morrow, 2017). 
1.3.4 Epidemiology of CVD 
1.3.4.1 Prevalence and incidence 
Cardiovascular disease (CVD) is the leading cause of death worldwide and in the United States 
(Santulli, 2013). Globally, CVD accounts for 16.7 million deaths per year, and is expected to rise 
to 25 million deaths per year in 2025 (Dahlöf, 2010). This translates to 30% of all deaths 
worldwide (excluding stroke, which accounts for an additional 10% of all deaths) (Santulli, 
2013). Despite the large prevalence of disease, CVD death rates in developed countries are 
decreasing due to better preventative strategies and management of CVD (Dahlöf, 2010). This 
however means more people are living with CVD and as a result the burden of disease comes 
primarily from complications and morbidity and less so from mortality (Dahlöf, 2010). 
The epidemiology of coronary heart disease (CHD) shows a similar trend to that of overall CVD. 
The Global Burden of Disease study ranked ischemic heart disease as the top global cause of 
mortality (Murray et al., 2012). CHD causes one in three deaths globally in people over 35 
(Sanchis-Gomar et al., 2016). Better prevention and management of CVD has caused death 
rates from CHD continue to decrease in developed countries, however, in developing 
countries, the trend is reversed as death rates continue to rise (Boersma et al., 2003). 
Comparing the late 1960’s to the late 1990’s, CHD mortality in the US fell 63% for men and 
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60% for women (Sanchis-Gomar et al., 2016). Similarly, CHD mortality fell 32% for men and 
30% for women in the European Union (EU) over the same period (Sanchis-Gomar et al., 2016). 
Alternatively, in developing countries (including China, India, Sub-Saharan Africa, Latin 
America, and the Middle East), CHD mortality is expected to rise from 9 million in 1990 to 19 
million in 2020 (Sanchis-Gomar et al., 2016). This is thought to be caused by increased life 
expectancies, western diets, smoking, and social and economic changes (Sanchis-Gomar et al., 
2016).  
Similar to CHD, the incidence of AMI has decreased steadily in developed countries. The 
adjusted incidence rate of hospitalisation for AMI has dropped by 4% per year in the US every 
year since 1987 (J. L. Anderson & Morrow, 2017). Similarly, the age and sex adjusted incidence 
rates of AMIs in the US have decreased by 24% (274/100000 to 201/100000) between 1999 
and 2008 (J. L. Anderson & Morrow, 2017). Despite this, estimates state that every 42 seconds 
an American will have an AMI (Sanchis-Gomar et al., 2016), and AMI rates continue to rise in 
developing nations, as incident AMI rates are roughly inversely proportional to the nation’s 
total income (J. L. Anderson & Morrow, 2017). 
1.3.4.2 Risk Factors 
Many CVDs share the same aetiology and thus have similar risk factors (Dahlöf, 2010). Risk 
factors are classified into modifiable and non-modifiable. Modifiable risk factors include 
hypertension, smoking, abdominal obesity, abnormal lipids, hyperglycaemia, physical 
inactivity, stress, and a lack of dietary fruits and vegetables (Dahlöf, 2010). Non-modifiable risk 
factors include advanced age, male gender, genetic predisposition, and ethnicity (particularly 
high risk in South Asians) (Forouhi & Sattar, 2006). There is also an emerging body of evidence 
that inflammation is a risk factor for CVD, which was discussed previously in section 1.3.3.  
More than 90% of AMIs are attributed to modifiable risk factors, as demonstrated by the 
INTERHEART global case-control study (Dahlöf, 2010). Similarly, an RCT enlisting people with 
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stable CHD and myocardial ischemia showed that intensive pharmacological therapy and 
lifestyle intervention resulted in the same amount of adverse cardiovascular events as people 
receiving PCI (18.5% and 19% respectively) (Boden et al., 2007). This highlights the importance 
of overall lifestyle modification in the prevention of AMI and CVD. 
Risk factors for CVD tend to occur in clusters and not individually. Over 70% of those at risk of 
CVD have more than one risk factor (Dahlöf, 2010). These risk factors also act synergistically. 
People with no sub-optimal modifiable risk factors have a lifetime CHD risk is less than 5%, 
compared to a risk of 31-50% for those who have two or more suboptimal modifiable risk 
factors (J. L. Anderson & Morrow, 2017). Similarly, people with one risk factor are at a 4-fold 
increase of cardiovascular events, while people with five risk factors are at a staggering 60-fold 
increased risk (Dahlöf, 2010). Additionally, smaller optimisations of multiple risk factors result 
in a larger reduction in cardiovascular risk compared to larger reductions in a single risk factor 
(Dahlöf, 2010). For example, a modest 10% reduction in both systolic blood pressure and 
cholesterol translates into a 45% reduction in major CVD incidence (Dahlöf, 2010). Therefore, it 
is important to consider cardiovascular risk factors together and not in isolation of each other. 
This has prompted the development of global CVD risk scores, such as QRISK2. These scoring 
systems take into account multiple risk factors of CVD and produce a likelihood of having a 
cardiovascular event over a given time period. These scores are important because the 
majority of CVD events occur not in the high-risk population, but instead in those with low to 
moderate risk of disease (Dahlöf, 2010). Low to moderate risk individuals usually go unnoticed 
because many abnormal risk factors can be asymptomatic for many years, giving rise to the 
unfortunate scenario where the first manifestation of CVD may be death (Dahlöf, 2010).  
The increasing prevalence of certain risk factors means that the prevalence of CVD will 
continue to rise in the future. In 2008, The Health Survey for England estimated that one in 
four adults in the UK were obese (defined as BMI >30 kg/m2) (Agha & Agha, 2017). Similarly, in 
37 
 
2010, it was estimated that 33% of men and 28% of women were obese, and this is expected 
to increase to 60% of men and 50% of women by 2050 (Agha & Agha, 2017). Similar trends 
have been seen in the US, where obesity rates have increased from 12% to 21% from 1991 to 
2002 (Dahlöf, 2010). As obesity is a major risk factor for CVD, efforts in reducing CVD should 
start at interventions aimed at reducing BMI. Additionally, it is well known that 
hyperglycaemia and diabetes mellitus are strong risk factors for adverse coronary events. It 
was estimated by the American Heart Association in 2013 that 8.3% of adults in the US have 
diabetes mellitus and 38.2% of adults have prediabetes (Santulli, 2013). This represents a 
sharp increase from 1990 when there was an estimated 4.9% of adults with diabetes mellitus 
(Dahlöf, 2010), and may cause an increase in future CVD prevalence. Furthermore, 16.5% of all 
deaths in the world can be attributed to hypertension, as well as approximately half of all 
strokes and CHD related deaths (Santulli, 2013). Hypertension is the most important 
preventable cause of death worldwide, affecting 972 million in 2000, and estimated to rise to 
1.6 billion in 2025 (Dahlöf, 2010). Hypertension is a strong risk factor for MI, heart failure, and 
stroke, however only half of all people in the US with hypertension have it controlled to an 
optimal level (Santulli, 2013).  
1.3.5 Clinical Features 
The cardinal symptom of an AMI is chest pain or discomfort. However, it is important to realise 
that AMI is not the only cause of cardiac chest pain. It is also important to consider a wide list 
of non-cardiac conditions that also cause chest pain or discomfort. 
For any patient presenting with chest pain, the clinician must consider acute coronary 
syndrome (ACS) as a cause (Boersma et al., 2003). ACS encompasses three diseases, two of 
which are classified as myocardial infarctions (STEMI and NSTEMI), with the third being 
unstable angina. These three conditions can be distinguished from each other by ECG (only 
STEMIs have ST-segment elevation) and by measuring cardiac biomarkers such as cardiac 
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troponin (STEMIs and NSTEMIs have raised cardiac troponins, unstable angina does not) 
(Thygesen et al., 2019).  
While stable angina causes pain that is relieved by rest, the pain of ACS is persistent and often 
lasts longer than 10 minutes (J. L. Anderson & Morrow, 2017). The classic description of the 
pain is a heavy retrosternal burning or pressure, however, it is important to note that pain may 
be felt in the shoulder, arm, jaw, epigastrium, or the back (J. L. Anderson & Morrow, 2017). 
The pain is diffuse and not specific and is not changed by movement or position (Thygesen et 
al., 2019). Importantly, up to 20% of ACS are silent (painless) or atypical (no significant pain) (J. 
L. Anderson & Morrow, 2017). These presentations are especially common in the elderly and 
in diabetic patients. As such, one cannot rely on chest pain alone to identify ACS. It is 
important to be able to recognise the associated features of AMI, including dyspnoea, 
diaphoresis, nausea and vomiting, fatigue, or unexplained weakness (Thygesen et al., 2019).  
Clinical examination may reveal added heart sounds including S4 gallops or murmurs such as 
the one associated with mitral regurgitation. An anterior wall AMI may produce tachycardia or 
hypertension, while an inferior wall AMI may produce bradycardia or hypotension (J. L. 
Anderson & Morrow, 2017).  
1.3.6 Management 
1.3.6.1 General Care 
All patients with suspected ACS are to undergo an immediate 12-lead ECG, whether in the 
community by paramedics or in hospital. This will help rule ACS in or out and differentiate 
myocardial infarctions from unstable angina (Boersma et al., 2003). Serial cardiac troponins are 
also performed to help confirm a diagnosis of AMI. A combination of the patient’s history, 
clinical examination, ECG results, and cTn levels will determine whether the person has ACS, 
and if so, what management pathway will be employed (Boersma et al., 2003). General care 
for all patients with ACS include bed rest, Aspirin (75-325 mg), a second antiplatelet (often a 
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P2Y12 inhibitor), anticoagulation (often low molecular weight heparin), nitrates (for chest 
pain), oxygen (for hypoxemia), a high dose statin, morphine (for pain relief), a beta-blocker, 
and an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker 
(ARB) (J. L. Anderson & Morrow, 2017).  
Following general care, the patient is to undergo a specific management plan based on the 
presence or absence of a STEMI/NSTEMI and their immediate risk of adverse events, 
calculated by accredited risk scores such as GRACE (Global Registry of Acute Cardiac Events) or 
TIMI (thrombolysis in myocardial infarction).  
1.3.6.2 STEMI Management 
As described previously, a STEMI implies a full vessel blockage and full thickness myocardial 
ischemia and eventually infarction. Therefore, the patient should undergo coronary 
angiography (CA) and immediate coronary reperfusion through percutaneous coronary 
intervention (PCI) (J. L. Anderson & Morrow, 2017). This is the gold standard reperfusion 
strategy for hospitals capable of performing PCI within 90 minutes from medical contact and 
within 12 hours of first presentation (J. L. Anderson & Morrow, 2017). Patients in hospitals 
without the capacity to perform PCI and patients who cannot be transferred to a centre with 
PCI within 120 minutes from first medical contact should receive IV fibrinolytic therapy.  
Studies have shown the benefits of PCI compared to fibrinolytic therapy. A review of 23 
randomised trials in 2003 found that PCI was superior to intravenous thrombolytic therapy in 
reducing overall short-term mortality (27% reduction), stroke, non-fatal re-infarction, and a 
combined endpoint encompassing all three outcomes (Keeley et al., 2003). PCI also offers 
lower rates of intracranial haemorrhage (Boersma et al., 2003). While it used to be debated 
whether stenting or balloon angioplasty was preferred, it is now accepted that drug-eluting 
stents are the gold standard for PCI (J. L. Anderson & Morrow, 2017). Additionally, radial 
access (compared to femoral) has been shown to have a lower rate of access site bleeding, 
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major bleeding, and lower death rates, at the cost of a procedure time that is on average 2 
minutes longer (J. L. Anderson & Morrow, 2017).  
1.3.6.3 NSTEMI Management 
NSTEMIs are different from STEMIs in that there remains residual perfusion within the 
ischemic zone due to partial occlusion of the coronary artery (J. L. Anderson & Morrow, 2017). 
Fibrinolytics are contraindicated in NSTEMIs due to the lack of therapeutic effect found in 
previous studies and their potential to cause harm (Daga et al., 2011). Therefore, the patient 
must be triaged into either an invasive (PCI) or ischemia guided (conservative) management 
plan (J. L. Anderson & Morrow, 2017). This is decided based on the risk of recurrent ischemia 
(determined by GRACE or TIMI risk scores), the services available at the hospital, and by the 
preference of the patient and doctor (J. L. Anderson & Morrow, 2017). High-risk patients and 
those with rising troponins or complications (including heart failure) are treated invasively with 
PCI, while low-risk patients receive conservative management.  
1.3.6.4 Secondary prevention 
Secondary prevention plans include diet and lifestyle advice and pharmacological therapy 
including aspirin, beta-blockers, ACEI or ARB, statins, and anticoagulants. These medications 
are taken long term to lower the risk of having a recurrent cardiovascular event. 
1.4 AMI and OA 
The two previous sections have eluded to links between osteoarthritis and cardiovascular 
disease. These links stem from epidemiological studies showing associations between the two 
diseases and from research into a potentially shared pathophysiology. Links between OA and 
specifically AMI are unclear because of conflicting reports of associations. The following 




1.4.1 Associations between OA and AMI 
There is an apparent lack of consensus regarding the association between OA and AMI. A 2013 
cross-sectional study in Canada investigating the prevalence of CVD in people with OA found 
that OA was associated with AMI in women (OR 1.49, 95% CI 1.28 to 1.75) but not in men (OR 
1.08, 95% CI 0.91 to 1.28) (Rahman, Kopec, Cibere, et al., 2013). Interestingly, the same study 
found that OA was significantly associated any heart disease in both men and women (OR 1.45 
95% CI 1.36-1.54), even after adjustment for demographics and traditional CVD risk factors. A 
longitudinal study looking at the risk of CVD events in people with OA found that OA was 
associated with incident AMI in unadjusted models (OR 1.20, 1.09 to 1.32), however, the 
association became non-significant following adjustment for demographics and cardiovascular 
risk factors (AdjOR 1.02, 95% CI 0.92 to 1.12) (Rahman, Kopec, Anis, et al., 2013). The same 
study found that even after adjustment for demographics and traditional CVD risk factors, OA 
predicted CVD events (AdjOR 1.13, 95% CI 1.07 to 1.18). A systematic review and meta-analysis 
from 2017 looking at the association between AMI and various types of arthritis summarised 
that OA was associated with AMI after adjusting for age and sex (RR 1.31, 95% CI 1.01 to 1.71), 
however this effect became non-significant after traditional CVD risk factors were added as 
covariates to the model (Schieir et al., 2017). A prior systematic review and meta-analysis from 
2016 looking at OA with various types of CVD found that OA was associated with heart failure 
(RR 2.8, 95% CI 2.25 to 3.49) and ischemic heart disease (RR 1.78, 95% CI 1.18 to 2.69), but not 
with MI or stroke (Hall et al., 2016). This suggests that OA may be associated with overall CVD, 

















1.4.2 Shared Pathophysiology? 
There are striking similarities between the risk factors of both OA and CVD. Two of the 
strongest risk factors for both diseases are advanced age and obesity. As discussed previously, 
there is an emerging body of evidence that inflammation plays a crucial role in the 
pathogenesis of both diseases. Given the roles that both advanced age and obesity have in 
creating an inflammatory state (via inflammageing and adipocytokine dysregulation), Figure 
1.2 is a mechanism proposed by this author that could explain the link the pathophysiology of 
CVD and OA. 
As discussed previously, obesity leads to a change in adipocyte phenotype. The new 
phenotype has a propensity to release greater amounts of inflammatory markers (such as 
TNFA and IL6) and fewer anti-inflammatory mediators (such as adiponectin). Additionally, 
inflammageing results in an increased level of pro-inflammatory mediators in the body. Both of 
these processes result in a chronic state of low-grade inflammation. An inflammatory 
environment is conducive to cardiovascular disease as it promotes the activation of vascular 
endothelium, the development and of atherosclerotic plaques, and the destabilisation of 
fibrous caps through the induced senescence of smooth muscle cells (which normally stabilise 
the fibrous cap by releasing extra-cellular matrix). Similarly, an inflammatory environment may 
increase the risk of OA through chondrocyte activation, resulting in the release of MMPs into 



















1.5 Systematic search to identify peer-reviewed papers that examine for 
the association between OA and management strategies and 
outcomes following AMI. 
1.5.1 Introduction 
Further research into the role that inflammation plays in both OA and CVD is required to help 
elucidate associations and shared pathophysiological mechanisms between these two 
prevalent and important diseases. While there have been strong reports of an association 
between OA and overall CVD, there is a lack of consensus on the association between OA and 
AMI. It is also unclear if OA is associated with poorer outcomes following AMI. This section 
describes a systematic review that was designed with the aim of identifying papers and 
synthesising the information in the published literature to determine whether OA was 
associated with the treatments offered or the outcomes following AMI. The best way to 
examine this association is through secondary care electronic health record data (EHR). This is 
because AMI is an acute event that is not managed in primary care. Additionally, survey 
designs are less appropriate because of the serious nature of AMI. Therefore, routinely 
collected electronic health record data from secondary care visits is the most likely study 
design to answer the research question of whether OA is associated with the receipt of 
invasive management strategies (coronary angiography, percutaneous coronary intervention, 
and CABG) and clinical outcomes (in-hospital mortality, major acute cardiovascular or 
cerebrovascular events, all-cause bleeding, and stroke/TIA) following AMI.  
1.5.2 Systematic reviews 
The two main types of research are primary and secondary studies (Jalali & Wohlin, 2012). 
Primary studies are novel and try to answer a specific research question. Secondary studies 
involve reviewing previous literature to provide a summary or overall opinion. Narrative 
reviews and systematic reviews are the two main ways that one can summarise a body of 
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literature. Narrative reviews are descriptive and often focus on a select few studies, as chosen 
by the author (Uman, 2011).  Because there is no element of reproducibility or objectivity, 
narrative reviews may be subject to bias (Wright et al., 2007).  
Systematic reviews allow researchers to answer specific research questions in a rigorous and 
reproducible manner. The methodology directs the identification of a vast amount of 
information about a topic; distillation of this into a palatable amount of information can inform 
clinical practice or policy making (Uman, 2011). Systematic reviews follow explicit methods, 
which include the formation of a research question, creating a search strategy, applying the 
search strategy in a database, screening the search results for relevant articles, and finally 
appraising and synthesising the information. 
There are many benefits to systematic reviews. The synthesis of information from a number of 
studies, each with different settings, populations, and measurements of disease, means that 
conclusions are more generalisable than that of a single study (Rumona, 2014). Systematic 
reviews have explicit methods that help to limit bias and can be easily reproduced to validate 
findings. Articles can be arranged into a Forrest plot to provide a summary of the effect sizes of 
each study and to estimate the heterogeneity of the included studies. Systematic reviews also 
allow for meta-analysis, which is the pooling of data from individual studies into a larger 
sample that may be analysed as a whole. The increased sample size means an increased 
statistical power, which is important for rare events or when analysing small effect sizes 
(Biondi-Zoccai et al., 2011). Increased statistical power also narrows the range of confidence 
intervals allowing for more precise estimates. Perhaps most importantly, meta-analysis can 
uncover associations that may otherwise have been missed. A well-known example of this is a 
systematic review on the efficacy of corticosteroids in maturing the lungs of preterm infants, 
which identified 7 trials, of which only two demonstrated corticosteroids having a significant 
benefit (Roberts et al., 2017). However, by pooling the seven trials together and increasing the 
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sample size and power, it was discovered that corticosteroids did indeed have a statistically 
significant benefit to the lungs of premature babies. Important findings such as this may be 
missed without performing a meta-analysis.  
There are some considerations when undertaking a systematic review. Firstly, a search that is 
not broad enough may miss relevant studies, however, a search that is too broad may be 
extremely time consuming. The search terms are also vital in the accuracy of the search and 
experienced researchers are required to ensure that it is performed correctly (Rumona, 2014). 
Additionally, a systematic search is only as valid as the studies that it synthesises. Finally, 
publication bias, the withholding of negative results from publication, is not accounted for in 
systematic searches. 
1.5.3 The aims of this systematic review were: 
1) To identify studies that have examined if OA is associated with the receipt of invasive 
management strategies (coronary angiography, percutaneous coronary intervention, 
and coronary artery bypass grafting) or adverse clinical outcomes (mortality, all-cause 
bleeding, major acute cardiovascular or cerebrovascular events, and stroke/TIA) 
following AMI, using electronic health record (EHR) data. 
2) To synthesise data from relevant articles and establish if associations exist. 
1.5.4 Methods  
A systematic review protocol was first developed using the Arthritis Research UK Primary Care 
Centre Systematic Review Protocol & Support Template. This protocol included the proposed 
search terms and was approved by members of research staff before the search was 
performed. The search was executed using OVID Medline® (OVID Technologies Inc, 2019) to 
search the MEDLINE database from 1946 to the present (November 2019). To act as a 
sensitivity analysis for the first database search, a second search using EBSCOhost (EBSCO 
industries, 2020) was used to search all health databases, which included The Allied and 
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Complementary Medicine Database (AMED), MEDLINE, APA PsychInfo, APA PsychArticles the 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), AgeLine, and SPORTDiscuss. 
These databases encompass all of the health databases that relevant research would be 
published in.  
1.5.4.1 Search strategy 
A comprehensive search strategy was developed to search for key words in both search 
engines. Keywords included all synonyms for osteoarthritis (osteoarthr* or OA or arthrit* or 
“joint pain”), AMI ("myocardial infarct*" or "MI" or "AMI" or "STEMI" or "NSTEMI" or "heart 
attack*”), and EHR ("medical record*" or "health record*" or "CPRD" or "clinical practice 
research datalink" or "CIPCA" or “nationwide inpatient sample” or NIS or "Consultations in 
Primary Care Archive" or computerised health record* or computerized health record* or 
electronic health record* or electronic medical record* or EHR or "electronic record*"). 
Because MEDLINE is indexed with Medical Subject Heading (MeSH) terms, these terms were 
also used in the OVID search. The MeSH terms for OA were divided by the site of OA, which 
were unspecified OA (osteoarthritis/), hip OA (osteoarthritis, hip/), knee OA (osteoarthritis, 
knee/), and spine OA (osteoarthritis, spine/). MeSH terms were also used for AMI (myocardial 
infarction/ or anterior wall myocardial infarction/ or inferior wall myocardial infarction/ or 
non-st elevated myocardial infarction/ or st elevated myocardial infarction/) and EHR 
(electronic health records/ or medical record systems, computerized/). 
1.5.4.2 Eligibility criteria 
The research question was designed using the PICO (population, intervention/exposure, 
control, and outcomes) framework. The population of interest was all adults diagnosed with an 
acute myocardial infarction in secondary care. Primary care studies were excluded because 
AMI is unlikely to be diagnosed or managed in the primary care setting, and secondary care is 
the most likely setting to capture patients diagnosed with and treated for AMI. The exposure 
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was a concurrent diagnosis of OA, and controls were people without a concurrent diagnosis of 
OA. Primary outcomes included procedures offered (such as the proportion receiving CA, PCI, 
and CABG) and outcomes (such as in-hospital mortality, cardiovascular and cerebrovascular 
complications, bleeding, and stroke or TIA). These primary outcomes were chosen because 
they are the most commonly performed treatments for and complications of AMI (White & 
Chew, 2008). Additionally, previous studies have used the same primary outcomes to 
determine the association of a concurrent diagnosis of cancer or mental illness on outcomes 
following AMI (Bharadwaj et al., 2019; Mohamed et al., 2019).  
Inclusion criteria were a focus on the association between OA and outcomes following AMI, 
the use of electronic health record data, and the type of study design (cross-sectional, cohort 
studies, and systematic reviews). Studies were excluded if electronic health record data was 
not used, if patients were seen in primary care, or if patients were diagnosed with 
inflammatory arthritis. There were no exclusions for age of publication or language in which 
the paper was published.  
1.5.4.3 Screening 
The search results from both searches were imported into Mendeley where duplicate citations 
were removed. The results were title and abstract screened in Mendeley against the eligibility 
criteria by the author of this thesis. The articles that remained were screened by review of 
their full text. Remaining articles would be included for data extraction and synthesis. 
A template was designed for data extraction; this would extract data on lead author name, 
year of publication, country, study type, study population, number of participants, mean age, 
percent female, clinical outcome measures, case definition of OA, case definition of AMI, main 
findings, and confounding variables adjusted for.  
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1.5.4.4 Critical appraisal and narrative synthesis 
Articles that met the inclusion criteria would be critically appraised using validated tools from 
the Critical Appraisal Skills Programme (CASP) (Singh, 2013). These appraisal tools are designed 
to assess a studies internal validity, level of bias in the exposure and outcome variables, 
assessment of confounders, power, reproducibility, and external validity.  
Whether a narrative synthesis or meta-analysis, or both, would have been performed was 
dependent on the number of studies identified and similarities between studies. A narrative 
synthesis can summarise the results of the identified studies. The eligible studies will be 
displayed on a Forrest plot, and should there be little heterogeneity between the studies, 
meta-analysis will be conducted. Meta-analysis involves combining the estimates of each study 
into a pooled estimate to provide a summary statistic for all included studies. 
Alternatively, “vote-counting”, which compared the sums of the positively and negatively 
associated studies, may be used to establish the overall direction of the relationship (Stewart, 
2010).  
1.5.5 Results 
1.5.5.1 OVID Medline® Search 
The systematic search of OVID Medline® identified 46 peer-reviewed papers which were 
imported into Mendeley (Table 1.1). There were no duplicate articles. Title and abstract 
screening excluded all 46 articles from being included within this review. Many articles were 
excluded because they investigated associations between OA and incident AMI and did not 






Table 1.1: OVID Medline search results. 
Search Number Search Terms Number of Results 
1 osteoarthritis/ or osteoarthritis, hip/ or 
osteoarthritis, knee/ or osteoarthritis, spine/ 
60,611 
2 (osteoarthr* or OA or arthrit* or "joint 
pain").mp. 
273,888 




4 myocardial infarction/ or anterior wall 
myocardial infarction/ or inferior wall 
myocardial infarction/ or non-st elevated 
myocardial infarction/ or st elevation 
myocardial infarction/ 
166,565 
5 ("myocardial infarct*" or "MI" or "AMI" or 
"STEMI" or "NSTEMI" or "heart attack*").mp 
244,933 
6 4 or 5 244,933 
7 3 and 6 1421 
8 medical records systems, computerized/ or 




9 ("medical record*" or "CPRD" or "clinical 
practice research datalink" or "CIPCA" or 
"Consultations in Primary Care Archive" or 
"nationwide inpatient sample" or NIS or 
computerised health record* or 
computerized health record* or electronic 
health record* or electronic medical record* 
or EHR or "health record*" or "electronic 
record*").mp 
192,019 
10 8 or 9 192,019 
11 7 and 10 46 
 
1.5.5.2 EBSCOhost search 
The systematic search of EBSCOhost identified 386 articles (Table 1.2). Upon exporting the 
articles, 26 duplicate articles were removed by EBSCOhost. The remaining 360 articles were 
imported into Mendeley, where a further 95 duplicate articles were removed. All remaining 
265 articles were title and abstract screened in Mendeley. None met the inclusion criteria. 












Table 1.2: EBSCOhost search results. 
Search Number Search Terms Number of Results 
1 osteoarth* OR “OA” OR “arthrit*” OR "joint 
pain" 
505,689 
2 myocardial infarct* OR “MI” OR “AMI” OR 
“STEMI” OR “NSTEMI” OR "heart attack*" 
711,607 
3 "medical record*" OR CPRD OR "clinical 
practice research datalink" OR "CIPCA" OR 
"Consultations in Primary Care Archive" OR 
"nationwide inpatient sample" OR *NIS* OR 
"computerised health record*" OR 
"computerized health record*" OR "electronic 
health record*" OR "electronic medical 
record*" OR "EHR" OR "health record*" OR 
"electronic record*" 
577,223 



















































Records identified through 
database searching: 
 
OVID Medline search (n = 46) 
EBSCOhost search (n = 386) 
Total (n = 432) 
 
Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 277) 
Records screened 




Non-healthcare related   
(n = 112) 
Non-CVD and OA related 
(n = 145) 
Incidence of CVD (n = 16) 
Outcomes after AMI in 
RA patients (n = 2) 
Outcomes after AMI in 
PsA patients (n = 1) 
Treatments following 
AMI in RA patients (n = 1) 
 
Total (n = 277) 
Full-text articles assessed 
for eligibility 
(n = 0) 
Studies included in 
quantitative synthesis 




From the search of OVID databases, no articles were found that investigate the effect of OA on 
the management or outcomes following AMI. Acting as a sensitivity analysis, the second 
systematic search using EBSCOhost similarly found no relevant articles. As a result, there was 
no data available for extraction and a narrative synthesis and meta-analysis was not possible. 
Several articles were found to examine associations between OA or RA and incident CVD, 
however, no articles examined the prognostic effect of OA following AMI. One of the exclusion 
criteria of this review was studies set in primary care, however, none of the identified papers 
were excluded for this reason. Four articles met the inclusion criteria except for that they 
studied inflammatory arthritis. Two of these studies examined the effect of rheumatoid 
arthritis (RA) on mortality after AMI and found conflicting results (Francis et al., 2010; McCoy 
et al., 2013). The third study found that following PCI or CABG, RA patients experienced a 
lower mortality rate compared to people without RA (Varghese et al., 2010). The final study 
found that psoriatic arthritis had a protective effect on mortality following AMI (Jatwani et al., 
2020). Moreover, no studies were found to examine the effect of OA on outcomes following 
AMI. This is surprising because previous literature has shown that people with OA are 
associated with activity limitations, decreased quality of life, and various comorbidities 
including cardiovascular diseases, peptic ulcer disease, and psychological diseases (Hunter et 
al., 2014; Swain et al., 2019; Vina & Kwoh, 2018). Research into the effect of OA after 
cardiovascular disease events seems a natural next step. 
One strength of this search was the systematic approach used to identify relevant articles. 
Each search term was comprehensive and inclusive of all synonyms and was verified by an 
expert panel consisting of a senior lecturer in public health and epidemiology and a consultant 
cardiologist. Additionally, one can be confident that all major databases were searched. In 
particular, MEDLINE is a very comprehensive database that contains over 25 million references 
to journal articles in biomedicine and all of life sciences (MEDLINE®, 2019). MEDLINE records 
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are also indexed with Medical Subject Headings (MeSH), which help organise records to allow 
for a more efficient search (MEDLINE®, 2019). MEDLINE encompasses all key peer-reviewed 
cardiology and rheumatology journals. Therefore, one can be reasonably confident that this 
search was comprehensive.  
Relevant papers may have been missed because the search terms were not inclusive enough. It 
is possible that relevant papers exist but were excluded because of the narrowness of the EHR 
search term. Additionally, this search would become more robust by using additional search 
interfaces. Finally, the review was undertaken a single reviewer. A second reviewer would help 
to ensure there was no bias in the screening process and may help uncover relevant articles. 
1.5.7 Summary and further research 
As previously highlighted, there are a number of studies that have identified an association 
between OA and overall CVD occurrence following adjustment for confounder. However, the 
association between OA and incident AMI is less clear, as there are conflicting reports of their 
relationship. The association between OA and the treatments and outcomes following AMI is 
unknown, as a systematic search of peer-reviewed papers investigating this relationship 
identified no eligible results. This gap in the literature will form the basis of this thesis and may 
help identify strategies to enhance the management of patients with OA who are diagnosed 
with AMI. 
1.6 Thesis aims 
The study described in the remainder of this thesis examines for whether there is an 
association between OA and the management and outcomes of people diagnosed with AMI. 
This work will be performed using the National Inpatient Sample (NIS), the largest inpatient 
secondary care database in the United States. from 2004 to 2015. 
There were three aims for the study described in this thesis. Using NIS data, a sample 
representative to the entire US population, the first aim was to describe the prevalence of OA 
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in people with AMI for each year between 2004 and 2015. There have been no previous 
studies that have estimated the prevalence of OA in people diagnosed with AMI in a sample 
representative to the United States. It is hypothesised that the prevalence of OA in people with 
AMI will be higher than that of people without OA. It is also hypothesised that the prevalence 
of OA will increase over time due to better detection of OA and the increasing prevalence of its 
risk factors. 
The second aim was to determine the strength and direction of the association between OA 
and various invasive management strategies following a diagnosis of AMI. The management 
strategies investigated were coronary angiography (CA), percutaneous coronary intervention 
(PCI), and coronary artery bypass grafting (CABG). It was hypothesised that compared to 
people without a diagnosis of OA, people with OA were less likely to be offered invasive 
management strategies following AMI because of previous reports of comorbidity being 
associated with a decreased odds of coronary revascularisation (Haglund et al., 2004; Pathak & 
Strom, 2008). 
The third aim was to determine the strength and direction of the association between a 
concurrent OA diagnosis and adverse clinical outcomes following a diagnosis of AMI. The 
clinical outcomes to be investigated are in-hospital mortality, major acute cardiovascular and 
cerebrovascular events (MACCE), all-cause bleeding, and acute stroke or TIA. It is hypothesised 
that compared to people without a diagnosis of OA, people with OA are more likely to 
experience adverse clinical outcomes following AMI. This is because people with OA are 
generally unhealthier than people without OA and OA is associated with many comorbidities 




2 Chapter 2: Methods 
2.1 Introduction 
The aims of this study were to describe the prevalence of OA in people admitted to secondary 
care for AMI for each year between 2004 and 2015 and to determine the strength and 
direction of the association between OA and invasive managements and outcomes following 
AMI. Secondary care data from the National Inpatient Sample (NIS), the largest inpatient 
electronic health record database in the United States (US), was used in this study. This 
chapter introduces the US healthcare system and describes electronic health record databases 
like the NIS. This chapter also discusses the variables used in this study and describes the 
statistical analysis that was performed. 
2.2 The United States healthcare system 
The United States, unlike many developed nations, does not have a universal healthcare 
system. Instead, Americans receive healthcare through a combination of public programmes 
such as Medicare and Medicaid (each of which having its own eligibility criteria) and private 
programmes paid for independently or by a person’s employer. 
Medicare was enacted in 1965 as part of the Social Security Act. It is paid for via tax revenue 
and provides basic primary and secondary healthcare to Americans over the age of 65 and 
people under 65 who have certain disabilities (Rowland & Lyons, 1996). While providing basic 
coverage, Medicare is not all-inclusive, with many medical conditions and procedures not 
being covered. Additionally, Medicare is not free at the point of contact. Beneficiaries of 
Medicare must pay monthly premiums, annual deductibles, and part of the cost of the health 
services they receive (called coinsurance) (Gornick et al., 1985). 
Medicaid was also enacted in 1965 under the Social Security Act. Also paid for through tax 
revenue, Medicaid is available to specific low-income families and individuals of any age 
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(Rowland & Lyons, 1996). People enrolled in federal welfare payment programmes are 
automatically eligible for Medicaid (Gornick et al., 1985). Medicaid is also available to 
Americans who may end up relying on welfare programmes because of the cost of medical 
bills (Gornick et al., 1985). Additionally, Medicaid is essential in helping cover healthcare costs 
in low income elderly people for which Medicare is not entirely sufficient (Rowland & Lyons, 
1996). 
Americans who are not eligible for Medicare or Medicaid must pay for medical expenses 
through private health insurance plans or by paying of pocket. Because healthcare is not free 
at the point of contact, US hospitals accurately code all services they provide to patients in 
order to be appropriately reimbursed. This routinely collected billing information can be used 
for healthcare research and is the basis of many electronic health record databases, including 
the NIS.  
2.3 Electronic health record data 
Electronic health record (EHR) data is data that is routinely collected by healthcare providers 
or insurers often for billing purposes (Jorm, 2015). In addition to providing clinicians with 
essential information to help make decisions and provide safer care, EHR data may also be 
used to facilitate high quality medical research (Casey et al., 2016). 
The use of EHR in medical research has many benefits. EHR data contains important routinely 
collected patient information including demographics, vital status, diagnoses, symptoms, 
medications, vaccinations, laboratory tests, referral letters, and specialist care information. 
Because EHR data can provide information on entire populations, it can be used as a tool for 
public health surveillance for communicable and chronic illnesses (Calman et al., 2012). The 
inclusion of a large population also facilitates the study of rare diseases or minority groups 
(Jorm, 2015). EHR data can be used for many study designs. If data is pseudo-anonymised 
(each record contains a nonidentifiable code that can be used to retroactively identify 
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participants), then individuals can be tracked over time and EHR data can be used for 
longitudinal designs such as cohort studies. Pseudo-anonymised data can also be linked to 
medical records for a more complete picture of a person’s health status. When data is 
completely anonymised, longitudinal analysis is not possible and other designs (such as cross-
sectional) must be used instead. Additionally, studies using EHR data are cheaper than surveys 
and may limit non-response bias, reporting bias, and attrition (Casey et al., 2016; Jorm, 2015). 
There are also some important limitations when using EHR data in medical research. Firstly, 
coding is a potential source of error through either misclassification or non-random missing 
data (Hemingway et al., 2018). Diseases with well-defined criteria such as AMI are less likely to 
suffer from coding errors. However, diseases with many phenotypes and classifications (such 
as OA) rely more heavily on the judgement of the healthcare provider with respect to the 
accuracy of codes (Hemingway et al., 2018). Additionally, EHR data can be poor for conditions 
that are mild or remittent as people may not always seek medical attention (Casey et al., 
2016). This is the case with OA, as people can live with the disease for many years before 
becoming symptomatic and seeing a primary care physician. These factors may make OA codes 
in EHR data less reliable and more error prone. Finally, EHR data may not capture important 
information that is not routinely collected, including diet, physical activity, employment status, 
socioeconomic status, smoking status, height and weight, and psychosocial factors (Casey et 
al., 2016).  
Primary care EHR databases are commonly used for medical research in the UK. The 
Consultations in Primary Care Archive (CiPCA) is a pseudo-anonymised primary care EHR 
database based in North Staffordshire, and the Clinical Practice Research Datalink (CPRD) is a 
similarly pseudo-anonymised primary care EHR database that spans across the UK. In the 
United states, the technological advancement of the healthcare industry has lagged behind 
nearly every other major industry (Menachemi & Collum, 2011). This prompted the Health 
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Information Technology for Economic and Clinical Health (HITECH) act of 2009, which 
incentivised healthcare providers to adopt EHR systems (Menachemi & Collum, 2011). The 
largest secondary care EHR database in the United States is the National Inpatient Sample 
(NIS), which is the data source for this study. 
2.4 The National Inpatient Sample (NIS) 
2.4.1 Overview 
The NIS is a routinely collected administrative discharge database developed by the Agency for 
Healthcare Research and Quality (AHRQ) and contains data on approximately 7 million hospital 
admissions in the US per year (Healthcare Cost and Utilisation Project, 2019). The NIS is one of 
many databases developed for the Healthcare Cost and Utilisation Project (HCUP), which 
aimed to provide estimates of inpatient outcomes, access, quality, and costs across the United 
States. The NIS is the largest inpatient database in the US and the 2017 weighted sample is 
estimated to be representative to 97% of all discharges from community hospitals regardless 
of payer (including Medicare, Medicaid, private insurance, and uninsured). The AHRQ releases 
the NIS annually, with the dataset encompassing discharges from two years prior to the date 
of release. The 1988 NIS was the first version and the most recent version is the 2017 dataset, 
which includes 7,159,694 unweighted discharges from 4,584 hospitals across 48 states. The 
purchase of consecutive datasets allows for trend analysis across multiple years. 
2.4.2 Data 
The NIS includes both clinical and non-clinical information that comes from discharge 
summaries created by hospitals for billing purposes (Hertzer, 2012). The discharge summaries 
are created by trained coders who analyse inpatient medical records and assign the relevant 
codes to capture a patient’s diagnoses, procedures, and other services that the hospital bills to 
the patient (Hertzer, 2012).  
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The information recorded in the discharge summaries (and subsequently in the NIS) includes 1 
primary diagnosis code, up to 29 secondary diagnosis codes, and up to 15 procedure codes. 
Additional data elements include patient demographics (sex, age, race, and household 
income), length of stay, discharge status, total charges, and hospital characteristics.  
Prior to October 1st, 2015, the NIS was coded using the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM). However, from the 1st October 2015 onwards, 
the codes used by the NIS changed to the newer International Classification of Diseases, Tenth 
Revision, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS).  
2.4.3 Sampling Method and Weights 
The sampling frame of the NIS is every hospital admission in the US per year (approximately 35 
million). Prior to 2012, the NIS was comprised of 100% of discharges from a sample of 20% of 
all eligible hospitals in the US, therefore representing a 20% sample of the population 
(Healthcare Cost and Utilisation Project, 2019). Weights were applied to each record in the 
20% sample to allow for representative national estimates (for example, the 2015 NIS included 
7,153,989 unweighted discharges and 35,769,942 weighted discharges). Weights were 
calculated by dividing the number of expected hospital admissions by the number of sampled 
hospital admissions within a stratum (Healthcare Cost and Utilisation Project, 2017). Strata are 
defined by hospital characteristics including census region (Figure 2.1), urban/rural location, 
bed size, teaching status, and ownership. The expected number of hospital admissions within a 
strata were estimated using the American Hospital Association annual survey. All patients 
admitted to hospitals with the same aforementioned characteristics will therefore have the 





Figure 2.1: The 9 census divisions used in the NIS from 2012 onwards. These divisions make 
up the 4 regions (used prior to 2012) as follows: Region 1 (Northeast) includes Divisions 1 
and 2, Region 2 (Midwest) includes Divisions 3 and 4, Region 3 (South) includes Divisions 5, 6, 




2.4.4 2012 Redesign 
In 2012, the NIS changed name from the “Nationwide Inpatient Sample” to the “National 
Inpatient sample” and underwent a redesign in order to reduce sampling error, improve 
confidentiality, and produce better national estimates (Healthcare Cost and Utilisation Project, 
2014). 
Starting in 2012, the NIS changed its sampling method. Instead of taking 100% of discharges 
from a sample of 20% of all eligible US hospitals, the NIS is now comprised of a 20% sample of 
all discharges from all hospitals in the US. The sample size of the NIS remained 20% of the 
sampling frame. Prior to 2012, the NIS divided the US into 4 census regions, which were 
Northeast, Midwest, South, and West. The new sampling method divides the US into 9 census 
divisions, which are New England, Mid-Atlantic, East North Central, West North Central, South 
Atlantic, East South Central, West South Central, Mountain, and Pacific (Figure 2.1). All 
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discharges within a division were ordered by hospital. Every hospital’s discharges within a 
division were then ordered by diagnosis-related groups (DRG) (every patient is assigned to one 
of over 700 DRGs, with each group having similar illnesses and in-hospital care). The list of 
hospital discharges is also ordered by admission month. This ordered list of hospital discharges 
was then sampled such that every fifth discharge is chosen, thus producing a 20% sample of 
the sampling frame (Figure 2.2). Weights were then calculated for each hospital admission in 
the same way as prior to the redesign (except that census division replaces census region 
when defining a hospital strata). This new sampling method was performed for every hospital 
in all 9 census divisions. Ordering by DRGs and admission month ensured that the sample was 
representative with respect to these two patient factors. Similarly, sampling from all hospitals 
ensured representativeness to hospital level factors including census division, urban/rural 
hospitals, and teaching status. According to the redesign report, this new sampling strategy 
reduced sampling error and decreased confidence intervals for many estimates (Healthcare 
Cost and Utilisation Project, 2014).  
The redesign also removed state and hospital identifiers from the discharges in order to 
enhance confidentiality. The lack of patient identifiers means that there is no way to track 
individual people within the NIS, as one person may contribute to multiple discharges in the 
dataset.  
Additionally, the redesign saw the removal of long-term acute care hospitals from the dataset. 
Long-term acute care (LTAC) hospitals are defined as accredited acute care hospitals with an 
average length of stay greater than 25 days. The NIS removed LTAC hospitals because of a lack 
of uniformly available data across the participating states. The redesign report by HCUP stated 
that the effects of removing LTAC hospitals on estimates were minimal. Rehabilitation facilities 
have been excluded from the NIS since its inception. 
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Overall, this redesign has helped improve the NIS by reducing sampling error, improving 
confidentiality, and producing better national estimates. However this has come at the 
expense of worse hospital-to-hospital estimates, as the NIS no longer samples entire hospitals, 
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2.5 International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) 
The ICD-9-CM is the official diagnosis and procedure classification system for US hospitals and 
is used by the NIS for all datasets prior to the 2016 version (Centers for Disease Control and 
Prevention, 2015). It is based on the World Health Organisations Ninth Revision, International 
Classification of Diseases (ICD-9). Two US government agencies, the National Centre for Health 
Statistics and the Centres for Medicare and Medicaid services, created the ICD-9-CM for use in 
the United States. 
The ICD-9-CM consists of approximately 13,000 codes in 17 chapters (Cartwright, 2013). 
Volume 1 contains a tabular index of all disease codes grouped by body system, volume 2 
contains an alphabetical index of all disease codes, and volume 3 contains codes for surgical, 
diagnostic, and therapeutic procedures. Codes may have a minimum of three and a maximum 
of five characters, in the style “XXX.XX” (Cartwright, 2013). The first three digits represent the 
body system and disease (Centers for Disease Control and Prevention, 2015). The final two 
digits represent the aetiology, anatomical site, and/or manifestation of the disease 
(Cartwright, 2013). Nearly all codes are entirely numeric. The exception are codes for factors 
influencing healthcare, external causes of injury, and the morphology of neoplasms, which 
start with the letters “V”, “E”, and “M”, respectively, followed by a sequence of numbers 
(Cartwright, 2013).  
2.6 Internal validity of EHR studies 
Studies with high internal validity generate valid inferences and accurately measure the 
intended variables (exposures and outcomes) (Grimes & Schulz, 2002). Three ways that a 
study’s internal validity can be negatively affected are through random error, systematic error, 
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and confounding (Tripepi et al., 2010). Random error can only be minimised by increasing the 
sample size of a study. Systematic error (or systematic bias) represents a flaw in a study’s 
methodology and can potentially invalidate the findings. Confounding is a distortion of the 
true relationship between an exposure and an outcome due to a third (confounding) variable 
(Grimes & Schulz, 2002). Two important systematic biases to consider are selection bias and 
information bias (Grimes & Schulz, 2002). 
2.6.1 Selection bias 
Selection bias occurs due to differences between study participants and non-participants in 
variables besides the exposure of interest (Tripepi et al., 2010). Ideally, when comparing the 
cases versus controls and the participants versus non-participants, the groups will be similar in 
all respects except for the exposure of interest.  There are many types of selection bias, some 
of which are not applicable to this study design. Non-response bias, loss to follow up bias, and 
volunteer bias are not applicable because the NIS uses routinely collected data from inpatient 
visits. Confounding by indication is also not applicable because this study’s exposure is not a 
treatment that can be allocated. 
2.6.2 Information bias 
Information bias occurs following inaccurate measurement of the exposure or the outcome. 
Misclassification bias is the inaccurate assignment of either the exposure or the outcome such 
that exposed individuals are classified as non-exposed or diseased individuals are classified as 
non-diseased, or vice versa (Tripepi et al., 2010). There are two types of misclassification bias, 
non-differential and differential. In non-differential misclassification, the degree of 
misclassification of the exposure or the outcome is the same between cases and controls; 
differential misclassification bias is where the misclassification differs between cases and 
controls (Tripepi et al., 2010). Differential misclassification bias tends to skew estimate (odds 
ratios or relative risks) towards the direction of the bias, while non-differential 
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misclassification bias tends to skew estimates towards the null value (Grimes & Schulz, 2002). 
Information bias due to misclassification is inherent to all EHR databases, including the NIS 
(Hertzer, 2012).  
2.6.3 Confounding 
A confounder distorts the relationship between the exposure and the outcome by being 
associated with both variables without being on the causal pathway. Confounders can be 
adjusted for by being included as covariates in multivariable models. Unmeasured confounding 
is the omission of a relevant confounder from the model, while residual confounding is caused 
by measurement error of a confounder in the model (Fewell et al., 2007). Positive confounding 
is when a confounding variable leads to an overestimation of the true effect, resulting in 
adjusted analysis to have a smaller effect size than the unadjusted analysis (Mehio-Sibai et al., 
2005). Negative confounding is when a confounding variable leads to an underestimation of 
the true effect, resulting in adjusted analysis to have a larger effect size than an unadjusted 
analysis. Positive confounders are associated in the same way (direct or inverse) to both the 
exposure and outcome (Szklo & Nieto, 2004). Negative confounders are differently associated 
with the exposure and outcome. For example, if a negative confounder is associated with an 
increased probability of the exposure (direct association), then the negative confounder 
should also be associated with a decreased probability of the outcome (inverse association) 
(Szklo & Nieto, 2004). 
The variables that were considered to confound the relationship between OA and the 
management and outcomes following AMI were considered in the following section. The 
following section also contains a description of how the OA, invasive management, and 





2.7 Definitions of variables in this study 
All variables in this study were derived by searching the NIS 2004 to 2015 data set for the 
relevant ICD-9-CM codes. The codes used for each variable were based on previous studies. A 
table of all codes is found in Appendix 6.1. 
2.7.1 Acute myocardial infarction 
This study’s sample is comprised of people admitted to hospital for AMI between 2004 and 
2015. These patients were identified by searching for ICD-9-CM codes for AMI in the primary 
diagnosis position. The parent ICD-9-CM code for AMI is 410.xx, where each “xx” can take any 
value to represent a daughter code for AMI. The specific codes for ST-elevated myocardial 
infarction include 410.0x for anterolateral, 410.1x for anterior, 410.2x for inferolateral, 410.3x 
for inferoposterior, 410.4x for inferior, 410.5x for lateral, 410.6x for posterior, 410.8x for other 
specified sites, and 410.9x for unspecified site (Bharadwaj et al., 2019). The codes for non ST-
elevated myocardial infarctions were 410.7x (Bharadwaj et al., 2019). These codes were used 
to create a binary AMI variable. 
2.7.2 Independent variable – osteoarthritis 
2.7.2.1 OA 
After selecting for all people with a code for AMI in the primary diagnosis position, people with 
an additional ICD-9-CM code for OA were identified. ICD-9-CM codes 715.0x and 715.8x coded 
for generalised OA; 715.11-4, 715.21-4, 715.31-4, and 715.91-4 for upper limb OA; 715.15-7, 
715.25-7, 715.35-7, and 715.95-7 for lower limb OA; 715.10, 715.18, 715.20, 715.28, 715.30, 
715.38, 715.90, 715.98, and V134 for unspecified OA (Centers for Disease Control and 
Prevention, 2015). People were classified as having OA if an OA code was found in any of the 
29 secondary diagnosis positions, thus creating a binary OA variable.  
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2.7.2.2 Symptomatic OA 
Additionally, a binary “symptomatic OA” variable was created to perform a sensitivity analysis 
of the OA variable. Previous studies have highlighted the underreporting of OA in electronic 
health record databases (Yu et al., 2018). In particular, this study’s definition of OA (ICD-9-CM 
715.xx codes) has been shown to have a low sensitivity (34.6%) and low PPV (33.5%) (Cisternas 
et al., 2016). In order to overcome this, the symptomatic OA variable included the previously 
described OA definition (ICD-9-CM codes 715.xx) plus ICD-9-CM codes for pain in joint (719.4x) 
and effusion of joint (719.0x) in people over 50 years-old (key symptoms for OA) and ICD-9-CM 
codes for joint replacement. The age restriction was used because previous studies have 
suggested that an adequate definition of clinical OA is chronic pain in older adults, and people 
with additional radiographic changes are merely a subset of these patients (Thomas et al., 
2004). The symptomatic OA definition also includes ICD-9-CM codes for joint replacement 
because OA is the most common indication for many joint replacement surgeries including 
total hip replacement (91.7%), total knee replacement (97.4%), and total shoulder 
replacement (92.7%) (National Joint Registry, 2019). Previous studies have identified patients 
undergoing joint replacement as an appropriate way to perform sensitivity analyses on 
definitions of OA (Yu et al., 2018). Joint replacement codes included in the “symptomatic OA” 
definition include total shoulder arthroplasty (81.80), shoulder hemiarthroplasty (81.81), 
reverse total shoulder arthroplasty (81.88), total hip arthroplasty (81.51), total knee 
arthroplasty (81.54), total ankle arthroplasty (81.56), ankle fusion (81.11), ankle arthrodesis 
(81.12), and total elbow arthroplasty (81.84) (Young et al., 2018). In summary, the 
symptomatic OA variable will act as a sensitivity analysis for the OA variable and will examine 





Figure 2.3: Visual representation of the OA and symptomatic OA variables. 
 
 
2.7.3 Dependent variables 
2.7.3.1 Invasive management strategies 
ICD-9-CM codes were used to create binary variables for the following invasive management 
strategies: coronary angiography (88.52, 88.53, 88.54, 88.55, 88.56, 37.22, and 37.23), 
percutaneous coronary intervention (00.66, 36.01, 36.02, 36.06, 36.07, and 36.09), and 
coronary artery bypass grafting (36.1×, 36.20, 36.31, 36.32, and 36.9×) (Bharadwaj et al., 
2019).  
These variables were chosen because they represent explicit management strategies for AMI 
and were likely to be well-coded compared to other conservative management strategies. 
Additionally, the NIS does not have information on pharmacological management, therefore 
interventional and surgical management strategies were the natural choice. Finally, these 
invasive management strategies have been used in previous studies that have examined AMI 











2.7.3.2 Clinical outcomes 
Four binary clinical outcomes were considered: in-hospital mortality, major acute 
cardiovascular and cerebrovascular events (MACCE), all-cause bleeding, and stroke or TIA. 
MACCE is a binary composite score that encompasses in-hospital mortality, cardiac 
complications, and stroke. Cardiac complications were defined as haemopericardium (423.0), 
cardiac tamponade (423.3), pericardiocentesis (37.0), or coronary dissection (414.12) 
(Bharadwaj et al., 2019). A variable representing all-cause bleeding was defined as 
gastrointestinal haemorrhage (578.0, 578.1, and 578.9) or intracranial haemorrhage (430, 431, 
and 432.x). Codes for stroke included 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 
434.11, 434.91, 435.x, and 436 (Bharadwaj et al., 2019). In-hospital mortality, MACCE, all-
cause bleeding, and stroke or TIA all represent hard endpoints that are likely to be well-coded 
in the NIS. These outcomes have also been used in previous studies of AMI in the NIS 
(Bharadwaj et al., 2019; Mohamed et al., 2019).  
2.7.4 Confounding variables 
As outlined above, the following confounding variables were selected because they may be (i) 
associated with osteoarthritis, (ii) associated with management strategies or outcomes and (iii) 
may explain the association between osteoarthritis and management strategies or outcomes 
following AMI. 
2.7.4.1 Demographics 
Patient demographic variables that were included in the NIS dataset are age (continuous), sex 
(binary), income quartile based on ZIP code (categorical), and payer (Medicare, Medicaid, 
private insurance, self-pay, no charge, or other). Hospital demographics include bed size 
(small, medium, and large), hospital region (Figure 2.1), and year of admission. Hospital region 
was used instead of hospital division because hospitals were only assigned divisions in the NIS 
from 2012 onwards. Additionally, a binary smoking history variable was created using ICD-9-
CM codes V15.82 and 305.1 (Mohamed et al., 2019). 
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2.7.4.2 Past Medical history 
A history of cardiovascular disease is associated with OA and an increased risk of recurrent 
cardiovascular events and death, which may confound the relationship between OA and 
outcomes following AMI (Govender et al., 2019; Rahman, Kopec, Cibere, et al., 2013). 
Therefore, previous cardiovascular disease and previous cardiovascular procedures were 
included as confounders. Specifically, binary confounding variables were created for a history 
of ischemic heart disease (IHD) (414.00-07, 414.2-9), previous AMI (412.xx), previous PCI 
(V45.82), previous CABG (V45.81), and previous stroke (V12.54) (Mohamed et al., 2019). 
2.7.4.3 Comorbidities 
The NIS comes with comorbidity data that is developed by the ARHQ and created by searching 
the ICD-9-CM codes and DRG’s of each admission to create a binary variable for each 
comorbidity (Healthcare Cost and Utilisation Project, 2017). The comorbidities include 
acquired immune deficiency syndrome (AIDS), alcoholism, anaemia, rheumatological 
conditions, heart failure, chronic lung disease, coagulopathies, diabetes, depression, substance 
misuse, hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte 
disorders, metastatic cancer, neurological conditions, obesity, paralysis, peripheral vascular 
disease, psychosis, pulmonary circulation disorders, renal failure, solid tumours with no 
metastasis, peptic ulcer disease, valvular heart disease, weight loss, and dementia. Previous 
studies of AMI in the NIS have included all comorbidity variables as covariates in logistic 
regression models (Bharadwaj et al., 2019; Mohamed et al., 2019). This study used all 
comorbidity variables except for “rheumatological conditions” because of potential co-








This study focused on examining the association between binary exposures and outcomes. 
When both the explanatory variable (X) and the response variable (Y) are continuous and 
linearly related, the linear regression model 𝑌 = 𝑎 + 𝐵𝑋 is the simplest method of describing 
their relationship (Bender & Grouven, 1997). However, this model is only valid when Y can take 
any value from negative infinity to positive infinity. In situations where Y is binary, for example 
when measuring vital status (dead or alive) or the receipt of a treatment (0 or 1), the linear 
regression model is invalid. Logistic regression overcomes this by transforming the binary 
outcome Y (from only taking values of 0 or 1) into the logarithm of the odds of the outcome Y, 
which can be any real number. 
Start with the binary outcome Y which can only take the value of 0 or 1. If p is the probability 
of the outcome Y=1, then p can be any real number between 0 and 1. Similarly, the odds of the 
event Y=1, described as the ratio of the probability of the event to the probability of the 
complement, or  
𝑝
1−𝑝




, can hold any value from negative infinity to positive infinity. This logarithm of the odds, 
also known as a logit, overcomes the previously violated assumption of a linear relationship 




= 𝑎 + 𝐵𝑋 (Tu, 1996). If we wish to model the probability of the event using 
multiple explanatory variables, we may add them to the equation as such: ln
𝑝
1−𝑝
= 𝑎 + -
𝐵1𝑋1 + 𝐵2𝑋2 + ⋯ + 𝐵𝑛𝑋𝑛, where n is any positive integer (Bender & Grouven, 1997).  
Using a process called maximum likelihood estimation, logistic regression finds the 
combination of B-coefficients that correspond to the highest likelihood of observing the 
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outcome (Stoltzfus, 2011). This process may involve many iterations to find this optimal 
combination of coefficients.  
Because the logit equation describes the natural logarithm of the odds of an event, it follows 
that the exponent of a single B-coefficient will produce an unadjusted odds ratio (OR). In a 
multivariable model, the exponent of a single B-coefficient produces an OR that is adjusted for 
all the other variables in the model. Furthermore, this adjusted OR represents the effect that 
the exposure variable has on the outcome variable when all other covariates are held 
constant. Odds ratios greater than 1 indicate an increased odds of the outcome Y, while OR’s 
less than 1 indicate a decreased odds. An OR equal to 1 indicates that there is no increased or 
decreased odds of the outcome and is called the null value. 
The interpretation of this OR depends on the scale of measurement of the explanatory variable 
X, which may be continuous or categorical. Consider the example where a logistic regression 
model predicts a binary outcome (Y=0, or Y=1) from one binary (𝑋1) and one continuous (𝑋2) 
explanatory variable. Suppose the exponential of the B-coefficients produced an OR of 4.0 for 
𝑋1 and 2.0 for 𝑋2. Because 𝑋1 is binary, the interpretation of this result is “the odds of 
outcome Y is increased by 4-fold as 𝑋1 “increases” from its reference value to its alternative 
value”. Alternatively, because 𝑋2 is continuous, this may be interpreted as “the odds of 
outcome Y is increased by 2-fold for every single unit increase in 𝑋2”. Furthermore, because 
there are two covariates in the model, the corresponding OR’s are adjusted for each other 
(and any other explanatory variables in the model).  
2.8.2 Considerations 
There are many benefits to logistic regression. Firstly, the ability to examine multiple 
independent covariates at once allows researchers to easily control for confounding variables 
(Stoltzfus, 2011).  
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Another benefit of logistic regression is the ease in which it can be interpreted. Simply taking 
the exponential of a single coefficient will produce an OR that can be easily understood and 
interpreted.  
The next important consideration is deciding which variables to include in the model. 
Covariates should be justified clinically or statistically (Stoltzfus, 2011). Too many variables 
may result in decreased generalisability and overfitting. A general rule is that there should be 
at least 10 cases belonging to  each category of the binary dependent variable Y for every 
covariate in the model (Stoltzfus, 2011). Additionally, it is important to avoid multicollinearity 
by avoiding adjustment for the same variable twice (Stoltzfus, 2011). Multicollinearity results 
in large standard errors for beta coefficients. An example of collinearity is a model that adjusts 
for both weight and body mass index (BMI).  
Model building strategies are the final consideration. There are generally three strategies 
(Stoltzfus, 2011). The first is the direct approach, which involves putting all covariates into the 
model at once with no assumptions about the relative strengths of the covariates. This method 
is best if researchers have no clear predetermined hypothesis. The second strategy is the 
sequential strategy, where you first add the covariate with the strongest association with the 
outcome, and then you continually add other covariates to the model one at a time. The final 
strategy is the stepwise strategy and uses a predefined selection criterion to choose 
covariates. An example of this is backwards elimination, where all covariates are placed into 
the model, and the nonsignificant covariates are removed one at a time until only covariates 






2.9 Statistical Analysis 
2.9.1 Data cleaning 
The NIS data from each year between 2004 and 2015, inclusive, was imported into IBM’s 
Statistical Package for the Social Sciences (SPSS) version 24 (IBM corporation, Armonk, NY). 
Each year’s data was collated into a single dataset. 
All patients were removed except for those with a primary diagnosis code for AMI from 1st 
January 2004 to 30th September 2015. Admissions from the final quarter of 2015 (1st October 
to 31st December) were excluded from the analysis because they were coded using ICD-10-
CM/PCS. All elective admission and patients under the age of 18 years old were also excluded. 
Sampling weights provided by the AHRQ were applied to the data to transform the 20% 
sample of AMI cases into a dataset that is nationally representative to the US. All subsequent 
analyses were of the weighted sample of AMI cases. 
2.9.2 Aim 1: To describe prevalence of AMI and OA in the NIS between 2004 and 2015. 
Basic statistics were used to describe the weighted sample of cases of AMI between 2004 and 
2015. Differences between the OA and non-OA groups were examined with respect to baseline 
demographics, past medical history, and comorbidities. Categorical variables were reported as 
counts and proportions and compared using the Chi-squared test. Continuous variables were 
reported as means (with standard deviations) or medians (with interquartile ranges) and 
compared by the independent samples t-tests.  
In order to investigate the prevalence of AMI over time, the total number of cases of AMI were 
reported for each year between 2004 and 2015. In order to investigate the prevalence of OA in 
people diagnosed with AMI, the proportion of AMI cases that had a concurrent diagnosis of OA 
was reported as a proportion with 95% confidence intervals for each year between 2004 and 
2015. Linear regression, where the dependent variable was OA and the independent variable 
was the year of admission, determined whether there was an overall difference in OA 
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prevalence between 2004 and 2015. In order to account for sex and age differences in OA 
prevalence, these two covariates were included as independent variables in the linear 
regression model. 
2.9.3 Aim 2: To determine the strength and direction of the association between a 
concurrent OA diagnosis and invasive management strategies following a diagnosis of 
AMI. 
Using all cases of AMI in the NIS between 2004 and 2015, the association between OA and the 
following invasive management strategies were investigated: 
• Coronary angiography (CA) 
• Percutaneous coronary intervention (PCI) 
• Coronary artery bypass grafting (CABG) 
Firstly, the number and proportion of patients that have received each invasive management 
strategy following AMI was calculated overall and stratified by sex and age. Sex was 
categorised to male and female. Age was categorised into 5 age bands: less than 50 years, 50 
to 59 years, 60 to 69 years, 70 to 79 years, and more than 80 years. The Chi-squared test 
determined whether there were sex differences in receiving invasive management strategies.  
Next, differences in the proportion of patients receiving each invasive management strategy 
between the OA and non-OA groups was examined using the Chi-squared test. Both groups 
were also stratified by sex and age. The purpose of stratifying the cohort was to identify 
whether either of these variables confound or moderate the relationship between OA and 
each invasive management strategy. 
Thirdly, the strength and direction of the association between OA and each invasive 
management strategy following a diagnosis of AMI was examined by unadjusted binary logistic 
regression. In each logistic regression model OA was the independent variable and each 
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invasive management strategy was the dependent variable. Results were expressed as odds 
ratios (OR) with 95% confidence intervals (95% CI), where the OR represents the odds a person 
with OA had of receiving the invasive management strategy relative to a person without OA. 
Fourthly, adjusted binary logistic regression determined whether OA was significantly 
associated with each invasive management strategy. Models were adjusted for demographics 
(age, sex, smoking status, income, payer, hospital bed size, hospital region, and year), past 
medical history (previous IHD, previous AMI, previous CABG, previous stroke or TIA, previous 
PCI), and comorbidities (AIDS, alcohol abuse, anaemia, heart failure, chronic lung disease, 
coagulopathies, diabetes mellitus, depression, substance misuse, hypertension, hypothyroid, 
liver disease, lymphoma, electrolyte disorders, metastatic cancer, neurological conditions, 
obesity, paralysis, peripheral vascular disease, psychoses, pulmonary circulation disorders, 
renal failure, solid tumour with no metastases, peptic ulcer disease, valvular heart disease, 
weight loss, and dementia). Previous studies of AMI in the NIS have included similar covariates 
in logistic regression models (Bharadwaj et al., 2019; Mohamed et al., 2019).  
Fifthly, adjusted binary logistic regression determined whether OA was significantly associated 
with each invasive management strategy after stratification by sex and age. Sex was 
categorised into males and females. Age was categorised into the same 5 previously 
mentioned age bands. 
Sixthly, adjusted binary logistic regression determined the association between OA and each 
invasive management strategy following AMI for each year between 2004 and 2015. This 
analysis determined whether the association between OA and the receipt of invasive 
management strategies had changed over time. 
Finally, considering the entire NIS from 2004 to 2015, a sensitivity analysis of the OA variable 
was performed using the symptomatic OA variable. Both variables were compared with 
respect to demographics and the receipt of invasive management strategies.  
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2.9.4 Aim 3: To determine the strength and direction of the association between a 
concurrent OA diagnosis and adverse clinical outcomes following a diagnosis of AMI. 
The relationships between OA and the following adverse clinical outcomes were investigated: 
• In-hospital mortality 
• Major acute cardiovascular and cerebrovascular events 
• All-cause bleeding 
• Stroke or TIA 
Similar to aim 2, the number and proportion of patients experiencing each adverse outcome 
following AMI was calculated overall and stratified by sex and age. Sex was categorised into 
males and females and age was categorised into the same 5 previously mentioned age bands. 
The Chi-squared test determined whether there were sex differences in experiencing adverse 
clinical outcomes. 
Secondly, a comparison of the proportion of patients experiencing each adverse clinical 
outcome between the OA and non-OA groups was made using the Chi-squared test. Both 
groups were also stratified by sex and age. 
Thirdly, the strength and direction of the association between OA and each adverse clinical 
outcome following a diagnosis of AMI was examined by unadjusted binary logistic regression. 
In each logistic regression model OA was the independent variable and each adverse clinical 
outcome was the dependent variable. Results are expressed as odds ratios (OR) with 95% 
confidence intervals (95% CI), where the OR represents the odds a person with OA had of 
experiencing the adverse clinical outcome relative to a person without OA. 
Fourthly, adjusted binary logistic regression determined whether OA was significantly 
associated with each adverse clinical outcome. As in aim 2, models were adjusted for 
demographics, past medical history and comorbidities. Additionally, these models were 
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adjusted for the diagnosis codes for cardiac arrest and the procedural codes for the receipt of 
PCI, CABG, and intra-aortic balloon pump or ventricular assist device (IABP) (ICD-9-CM codes 
37.68 and 37.61). These additional covariates were included because they were likely to be 
significantly associated with the four adverse clinical outcomes.  
Fifthly, adjusted binary logistic regression determined whether OA was significantly associated 
with each adverse clinical outcome after stratification by sex and age. Sex was categorised into 
males and females. Age was categorised into the same 5 previously mentioned age bands.  
Sixthly, adjusted binary logistic regression determined the association between OA and each 
adverse clinical outcome following AMI for each year starting from 2004 to 2015. This analysis 
determined whether the association between OA and the experiencing adverse clinical 
outcomes had changed over time. 
Finally, two sensitivity analyses were performed. First, the original OA and symptomatic OA 
variables were compared with respect to the proportion of AMI patients who experienced 
each adverse clinical outcome.  
A second sensitivity analysis was performed to determine the effect of the removal of patient 
identifiers within the NIS, as this means that multiple hospitalisations for AMI may have 
originated from the same patient, potentially biasing the results. This effect was investigated 
by performing adjusted binary logistic regression between OA and each adverse clinical 
outcome after excluding all cases with a previous history of AMI. 
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3 Chapter 3: Results 
3.1 Aim 1: To describe prevalence of AMI and OA in the NIS between 
2004 and 2015. 
3.1.1 AMI cohort demographics 
Between 2004 and 2015, there were 1,464,186 hospital discharges with the primary diagnosis 
code of AMI. Applying discharge weights provided by the AHRQ produced a weighted sample 
of 7,053,475 AMI hospital discharges. All subsequent estimates are based on this weighted 
sample. After the exclusion of elective admissions and people under 18 years old, there were 
6,561,940 cases of AMI (Table 3.1). The mean age was 67.6 years (standard deviation (SD) 14.4 
years), the median age was 68 years (interquartile range 57 to 79), and 39.8% of cases were 
female. Twenty-eight percent were current or ex-smokers. Most patients were White (76.8%), 
followed by Black (10.0%), and Hispanic (7.4%). In terms of cardiovascular disease history, 
76.5% had a history of IHD, 8.7% had a previous AMI, 9.8% had a previous PCI, 6.1% had a 
previous CABG, and 3.1% had a previous stroke or TIA. 
3.1.2 Osteoarthritis 
Of the 6,561,940 patients who had an AMI between 2004 and 2015, 414,072 (6.31%; 95% CI 
6.29%, 6.33%) had a concurrent diagnosis of OA (Table 3.1). Compared to the non-OA group, 
the OA group was older (mean age 75.3, SD 12.3 years-old; versus 67.1, SD 14.4 years-old), had 
more females (56.3% versus 38.7%), fewer smokers (22.7% versus 28.8%), more Whites (81.9% 
versus 76.4%), more payers through Medicare (77.4% versus 56.2%), and fewer payers through 
private insurance (15.6% versus 28.2%) (p<0.001 for all).  
The OA group more frequently experienced a previous AMI (9.3% versus 8.6%) and stroke or 
TIA (4.0% versus 3.0%), however, they were less likely to have had a previous PCI (8.9% versus 
9.8%), previous CABG (5.7% versus 6.2%), or previous history of IHD (74.9% versus 76.6%) 
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(p<0.001 for all) (Table 3.1). Additionally, the OA group had a higher prevalence of 
comorbidities, including heart failure (35.8% versus 31.3%), chronic lung disease (25.5% versus 
20.4%), peripheral vascular disease (13.7% versus 10.8%), obesity (15.8% versus 11.8%), and 














Table 3.1: Baseline demographics of OA cases. 
 
  
Entire AMI cohort No OA OA 
Count 
Column 
N % Mean 
Standard 




N % Mean 
Standard 
Deviation 
Count  6561940 
(100%) 
   
6147868 
(93.7%) 
   
414072 
(6.3%) 
   
Age   68 14   67 14   75 12 
Sex Female 2610000 39.8%   2376838 38.7%   233162 56.3%   
Race White 4221763 76.8%   3931018 76.4%   290745 81.9%   
Black 548050 10.0%   518348 10.1%   29703 8.4%   
Hispanic 407959 7.4%   388022 7.5%   19938 5.6%   








Native American 29200 0.5%   27693 0.5%   1507 0.4%   
Other 168361 3.1%   161152 3.1%   7209 2.0%   
History of 
Smoking 








Medicare 3773955 57.5%   3453446 56.2%   320508 77.4%   
Medicaid 402138 6.1%   388020 6.3%   14118 3.4%   
Private Insurance 1798636 27.4%   1734054 28.2%   64582 15.6%   
Self-pay 374848 5.7%   367581 6.0%   7267 1.8%   
No charge 36935 0.6%   36187 0.6%   748 0.2%   
Other 175428 2.7%   168580 2.7%   6849 1.7%   
Missing 1167248 17.8%   1106676 18.0%   60573 14.6%   
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26th-50th percentile 1463494 22.3%   1364268 22.2%   99225 24.0%   











Small 696162 10.7%   648408 10.6%   47754 11.6%   
Medium 1608785 24.6%   1502044 24.5%   106741 25.9%   
Large 4231664 64.7%   3973614 64.9%   258050 62.6%   
Hospital region Northeast 1289577 19.7%   1221628 19.9%   67949 16.4%   
Midwest 1524853 23.2%   1408491 22.9%   116362 28.1%   
South 2593053 39.5%   2434820 39.6%   158233 38.2%   
West 1154457 17.6%   1082930 17.6%   71527 17.3%   
Previous MI  568827 8.7%   530503 8.6%   38324 9.3%   
History of IHD  5017145 76.5%   4707132 76.6%   310013 74.9%   
Previous PCI  639853 9.8%   603193 9.8%   36661 8.9%   
Previous CABG  403488 6.1%   379718 6.2%   23770 5.7%   
Previous stroke  203267 3.1%   186821 3.0%   16446 4.0%   
Year 2004 596292 9.1%   565290 9.2%   31002 7.5%   
2005 570956 8.7%   541386 8.8%   29570 7.1%   
2006 581741 8.9%   551640 9.0%   30101 7.3%   
2007 534651 8.1%   503507 8.2%   31145 7.5%   
2008 562480 8.6%   529657 8.6%   32823 7.9%   
2009 553088 8.4%   516306 8.4%   36782 8.9%   
2010 523463 8.0%   487912 7.9%   35551 8.6%   
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2011 537733 8.2%   498966 8.1%   38766 9.4%   
2012 557605 8.5%   518120 8.4%   39485 9.5%   
2013 552710 8.4%   513510 8.4%   39200 9.5%   
2014 560890 8.5%   521545 8.5%   39345 9.5%   
2015 430330 6.6%   400030 6.5%   30300 7.3%   
Comorbidities AIDS 8391 0.1%   8212 0.1%   179 0.0%   
Alcoholism 187298 2.9%   180147 2.9%   7150 1.7%   
Anaemia 1036487 15.8%   946156 15.4%   90331 21.8%   
Rheumatic conditions 144455 2.2%   128299 2.1%   16156 3.9%   
Heart failure 2069624 31.5%   1921263 31.3%   148360 35.8%   
Chronic lung disease 1358739 20.7%   1253218 20.4%   105520 25.5%   
Coagulopathies 288569 4.4%   271458 4.4%   17110 4.1%   
Diabetes 2255254 34.4%   2112727 34.4%   142526 34.4%   
Depression 428891 6.5%   379322 6.2%   49569 12.0%   
Drug misuse 137020 2.1%   132559 2.2%   4460 1.1%   
Hypertension 4398845 67.0%   4088085 66.5%   310761 75.0%   
Hypothyroidism 647286 9.9%   579774 9.4%   67512 16.3%   
Liver disease 79833 1.2%   75258 1.2%   4575 1.1%   
Lymphoma 32739 0.5%   30558 0.5%   2181 0.5%   
Fluid and electrolyte 
disorders 1293118 19.7%   1203785 19.6%   89333 21.6%   
Metastatic cancer 58016 0.9%   54902 0.9%   3114 0.8%   
Neurological 
conditions 386469 5.9%   352932 5.7%   33537 8.1%   
Obesity 788554 12.0%   723244 11.8%   65310 15.8%   




disease 718119 10.9%   661370 10.8%   56749 13.7%   
Psychosis 137507 2.1%   126371 2.1%   11135 2.7%   
Pulmonary circulation 
disorders 6531 0.1%   6152 0.1%   379 0.1%   
Renal failure 1111786 16.9%   1028977 16.7%   82810 20.0%   
Solid tumour, no 
metastases 94067 1.4%   87836 1.4%   6232 1.5%   
Peptic ulcer disease 2206 0.0%   1940 0.0%   266 0.1%   
Valvular heart disease 15685 0.2%   14833 0.2%   852 0.2%   
Weight loss 144597 2.2%   134504 2.2%   10092 2.4%   




3.1.3 Temporal Trends 
The total number of AMI’s per year remained similar over time with 596,292 cases in 2004 and 
560,890 in 2014 (Figure 3.1). As previously mentioned, in October 2015 the NIS switched from 
ICD-9-CM to ICD-10-CM/PCS codes. This study only searched for ICD-9-CM codes, therefore 
admissions from the final quarter of 2015 were not captured, resulting in an approximately 
25% decline in the number of AMI cases in 2015. 
Figure 3.1: Crude number of AMI cases per year. 
 
The crude number of OA cases among the AMI cohort increased from 31,002 cases in 2004 to 
39,345 cases in 2014 (Figure 3.2). There was a decrease in the crude number of OA cases 
between 2014 and 2015 due to the change to ICD-10-CM/PCS. The prevalence of OA among 
AMI patients rose significantly from 5.20% (95% CI 5.14 to 5.26) in 2004 to 7.04% (6.96 to 7.12) 
in 2015 (Figure 3.3). Most of this increase occurred between 2006 and 2011 where the 
prevalence of OA increased significantly from 2006 to 2007 (5.17% (5.12 to 5.23) to 5.82% 
(5.76 to 5.89)) and in each consecutive year from 2008 to 2011 (5.84% (5.77 to 5.90), 6.65% 
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(6.58 to 6.71), 6.79% (6.72 to 6.86), and 7.21% (7.14, 7.28), respectively). The prevalence 
remained relatively stable between 2004 and 2006 and 2011 and 2015. When considering the 
entire study period, linear regression identified a significant difference in the prevalence of OA 
cases among AMI patients (p<0.001) in both unadjusted and adjusted models. 
Compared to OA cases in 2004 to 2006, cases in 2011 to 2015 had fewer females, fewer 
Whites, more people paying with Medicare or Medicaid, fewer people paying out of pocket or 
with private insurance, more smokers, a lower average income based on ZIP code, and were 
younger (Table 3.2).  
Table 3.2: Comparing the OA cohort between 2004 to 2006 and 2011 to 2015. 




Count  90,674 187,097 
Age  75.6 (SD 12.4) 74.9 (SD 12.0) 
Sex Male 41.3% 45.8% 
Female 58.7% 54.2% 
Race White 84.4% 80.6% 
Black 6.5% 9.3% 
Hispanic 5.6% 5.9% 
Asian or Pacific Islander 1.3% 1.7% 
Native American 0.2% 0.4% 
Other 2.0% 2.0% 
Payer Medicare 77.5% 77.9% 
Medicaid 2.9% 4.0% 
Private Insurance 16.2% 14.6% 
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Self-pay 1.6% 1.7% 
No charge 0.2% 0.2% 
Other 1.5% 1.7% 
Smoking history  19.6% 24.8% 
Days in hospital  4.6 (SD 3.8) 4.6 (SD 4.3) 
Income quartile by ZIP 
code 
0-25th 27.1% 31.2% 
26th-50th 28.0% 27.4% 
51st-75th 24.4% 23.7% 
















Figure 3.2: Crude number of OA cases per year. 
 

































3.2 Aim 2: To determine the strength and direction of the association 
between a concurrent OA diagnosis and invasive management 
strategies following a diagnosis of AMI. 
3.2.1 Proportion receiving invasive management strategies 
Of all cases of AMI, 64.6% received CA, 42.9% received PCI, and 8.4% received CABG (Table 
3.3). Stratification by sex showed that men were more likely to receive CA (69.8% versus 
56.6%), PCI (48.6% versus 34.2%), and CABG (10.0% versus 6.0%). Stratification by age showed 
that advanced age was associated with a decreased likelihood of receiving CA and PCI. The 
oldest age band (80 years and older) had the lowest likelihood of receiving CA and PCI (36.6% 
and 21.7% respectively). Each subsequently younger age band was more likely to receive CA 
and PCI, with the highest prevalence of both management strategies seen in people under 50 
years old (81.5% had CA and 60.2% had PCI). Age also affected the likelihood of receiving 
CABG, where the 60 to 69-year-old age band was most likely to receive CABG (11.4%) and the 
oldest (3.7%) and youngest (6.9%) age bands were least likely to receive CABG.  
3.2.2 Proportion receiving invasive management strategies by OA status 
Compared to non-OA cases, OA cases were less likely to receive invasive management 
strategies including CA (55.1% versus 65.2%), PCI (33.1% versus 43.5%), and CABG (7.4% versus 
8.5%) following AMI (Table 3.3 and Figure 3.4). Both men and women with OA were less likely 
than their non-OA counterparts to receive CA (63.3% versus 70.1% and 48.8% versus 57.4%, 
respectively) and PCI (40.0% versus 49.0% and 27.8% versus 34.9%, respectively). However, 
women with OA were less likely to receive CABG (5.0% versus 6.1%) than women without OA 
and men with OA were more likely to receive CABG (10.5% versus 10.0%) than men without 
OA. Stratification by age showed that people with OA were less likely to receive invasive 
management strategies except for the following differences. For people aged less than 50 and 
50 to 59 years old, people with OA were more likely to receive CABG (8.6% versus 6.8% and 
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11.9% versus 9.9%, respectively) than people without OA. People aged 60 to 69 with OA had a 
similar likelihood of having CA (74.2% versus 74.0%) and CABG (12.0% versus 11.4%) compared 
to people without OA. People aged 70 to 79 with OA also had a similar likelihood of receiving 
CA (64.6% versus 63.7%) compared to people without OA. 
Table 3.3: The receipt of invasive management strategies between OA and non-OA cases 
overall and stratified by sex and age. 
Entire cohort: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 4236305 64.6% 4008011 65.2% 228295 55.1% 
PCI 2812655 42.9% 2675574 43.5% 137081 33.1% 
CABG 553254 8.4% 522641 8.5% 30613 7.4% 
 
Men: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 2758377 69.8% 2643885 70.1% 114493 63.3% 
PCI 1919056 48.6% 1846763 49.0% 72293 40.0% 
CABG 396409 10.0% 377485 10.0% 18924 10.5% 
 
Women: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 1477928 56.6% 1364126 57.4% 113802 48.8% 
PCI 893598 34.2% 828811 34.9% 64788 27.8% 
CABG 156845 6.0% 145156 6.1% 11689 5.0% 
 
Under 50 years old: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 612216 81.5% 603683 81.5% 8533 80.0% 
PCI 452006 60.2% 446252 60.3% 5754 53.9% 
CABG 51562 6.9% 50649 6.8% 913 8.6% 
 
50 to 59 years old: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 1019776 79.8% 987734 79.8% 32042 79.1% 
PCI 736619 57.6% 715429 57.8% 21190 52.3% 




60 to 69 years old: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 1103900 74.0% 1047005 74.0% 56895 74.2% 
PCI 730700 49.0% 695426 49.1% 35274 46.0% 
CABG 170514 11.4% 161302 11.4% 9212 12.0% 
 
70 to 79 years old: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 910088 63.8% 840715 63.7% 69373 64.6% 
PCI 542635 38.0% 503400 38.1% 39235 36.5% 
CABG 144639 10.1% 134180 10.2% 10459 9.7% 
 
Over 80 years old: 
 All AMI No OA OA 
 Count Column N% Count Column N % Count Column N % 
CA 590325 36.6% 528872 36.9% 61452 34.4% 
PCI 350695 21.7% 315067 22.0% 35628 19.9% 
CABG 59118 3.7% 53920 3.8% 5198 2.9% 
 





















3.2.3 Association between OA and invasive management strategies 
Unadjusted binary logistic regression showed that people with OA were associated with a 
decreased odds of receiving CA (odds ratio 0.656; 95% confidence interval 0.652, 0.660), PCI 
(0.642; 0.638, 0.647) and CABG (0.859; 0.849, 0.870). After adjustment for confounders, OA 
remained significantly associated with a decreased odds of receiving CA (0.909; 0.903, 0.916), 
PCI (0.873; 0.866, 0.879), and CABG (0.983; 0.971, 0.996). The extent of co-occurrence 
between the OA variable and the other rheumatological conditions (which was not included in 
the binary logistic regression models) is presented in Table 3.4. This table shows that of all 
people with an ICD-9-CM diagnosis code for OA (n=414,071), only 3.9% (n=16,156) were 
considered to have another rheumatological condition. This suggests there to be minimal co-
occurrence between the two variables. This also suggests that one or both variables may not 
be completely valid because one would expect there to be at least as many individuals with a 
rheumatological condition as there were an OA diagnosis because rheumatological conditions 
encompass OA as well as many other conditions (including RA, PsA, etc). 
Table 3.4: The co-occurrence between the OA and other rheumatological conditions. 
 ICD-9-CM coded OA variable 
Yes No  
Rheumatological 
conditions 





















3.2.4 Association between OA and invasive management strategies – stratified by sex 
After stratifying by sex, adjusted binary logistic regression showed both men and women with 
OA to be associated with a decreased odds of CA (0.929; 0.918, 0.940; and 0.910; 0.901, 0.919) 
and PCI (0.877; 0.868, 0.887; and 0.866; 0.857, 0.876) relative to men and women without OA, 
respectively (Table 3.5). However, the association with CABG differed by sex, as men with OA 
were associated with an increased odds of CABG (1.039; 1.022, 1.056) compared to men 
without OA and women with OA had a decreased odds of CABG (0.941; 0.922, 0.960) 
compared to women without OA. 
3.2.5 Association between OA and invasive management strategies – stratified by age 
Similar to the unstratified results, people with OA were associated with a decreased odds of CA 
and PCI compared to people without OA in every age band (Table 3.5). The age band that was 
most strongly associated with a decreased odds of CA was the oldest age band (0.913; 0.902, 
0.924) and the age band that was most strongly associated with a decreased odds of PCI was 
the youngest age band (0.801; 0.768, 0.836). The effect of OA on receiving CABG changed with 
age. OA was significantly associated with an increased odds of CABG In the youngest three age 
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3.2.6 Annual association between OA and invasive management strategies – 2004 to 2015 
The overall association between OA and CA and PCI following AMI remained relatively 
constant from 2004 to 2015 (Table 3.6). However, the odds of receiving CABG appeared to 
increase over time from 2004 to 2015, changing from a decreased odds before 2009 to an 
increased odds after 2010. 
Table 3.6: The adjusted odds of receiving invasive management strategies among OA cases 
relative to non-OA cases stratified by year. 
Adjusted odds of invasive management strategies for people with OA stratified by year 
Year 
Number of 
AMI cases CA PCI CABG 
2004-
2015 
6561940 0.909 (0.903, 0.916) 0.873 (0.866, 0.879) 0.983 (0.971, 0.996) 
2004 596292 0.893 (0.869, 0.918) 0.868 (0.843, 0.893) 0.926 (0.885, 0.969) 
2005 570956 0.847 (0.823, 0.871) 0.832 (0.808, 0.856) 0.846 (0.806, 0.889) 
2006 580129 0.842 (0.819, 0.866) 0.822 (0.799, 0.846) 0.923 (0.881, 0.967) 
2007 533970 0.926 (0.900, 0.952) 0.829 (0.806, 0.853) 0.944 (0.901, 0.990) 
2008 561863 0.922 (0.898, 0.948) 0.891 (0.867, 0.916) 0.889 (0.849, 0.932) 
2009 543755 0.964 (0.939, 0.989) 0.899 (0.867, 0.912) 1.103 (1.059, 1.148) 
2010 517049 0.895 (0.872, 0.919) 0.870 (0.848, 0.893) 0.921 (0.880, 0.964) 
2011 531064 0.942 (0.919, 0.966) 0.941 (0.918, 0.965) 1.013 (0.970, 1.058) 
2012 557605 0.913 (0.890, 0.936) 0.854 (0.834, 0.875) 1.090 (1.046, 1.136) 
2013 552710 0.940 (0.917, 0.964) 0.883 (0.862, 0.904) 1.031 (0.990, 1.075) 
2014 560890 0.930 (0.907, 0.953) 0.878 (0.858, 0.899) 1.021 (0.980, 1.064) 
2015 430330 0.944 (0.918, 0.972) 0.863 (0.841, 0.887) 1.143 (1.092, 1.195) 
 
3.2.7 Sensitivity analysis of the OA variable using symptomatic OA 
A comparison of both definitions of OA showed them to be similar in most regards. The 
proportion of AMI patients with symptomatic OA was 6.77% (95% CI 6.75%, 6.79%) 
(n=444,217) compared to 6.31% using the original definition of OA (Table 3.7). The mean age 
of the symptomatic OA group was 75.1 years (SD 12.3) which was similar to the original OA 
group (75.3 years, SD 12.3). The symptomatic OA group had slightly fewer females (55.7% 
versus 56.3%) and slightly more smokers (22.9% versus 22.7%) than the original OA definition. 
There was a similar proportion of people in the symptomatic OA group and the original OA 
group who experienced a previous AMI (9.267% versus 9.255%), previous IHD (74.86% versus 
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74.87%), previous PCI (8.8% versus 8.9%), previous CABG (5.8% versus 5.7%), and previous 
stroke or TIA (3.95% versus 3.97%) (Table 3.7). The symptomatic OA and original OA groups 
also had similar proportions of comorbidities including heart failure (35.6% versus 35.8%), 
chronic lung disease (25.3% versus 25.5%), peripheral vascular disease (13.6% versus 13.7%), 
obesity (15.7% versus 15.8%), and hypertension (74.9% versus 75.0%). 
The symptomatic and original OA groups received a similar proportion of invasive 
management strategies including CA (55.3% versus 55.1%), PCI (33.3% versus 33.1%), and 
CABG (7.35% versus 7.39%) (Table 3.7). 
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Table 3.7: The baseline demographics of the OA and symptomatic OA variables. 
  
OA Symptomatic OA 
Count Column N % Mean 
Standard 
Deviation Count Column N % Mean Standard Deviation 
Count and % of 
AMI cohort 
  414072 6.3%     444217 6.8%     
Age     75.3 12.3     75.1 12.3 
Sex Male 180909 43.7%     196770 44.3%     
Female 233162 56.3%     247447 55.7%     
Race White 290745 81.9%     310927 81.6%     
Black 29703 8.4%     32441 8.5%     
Hispanic 19938 5.6%     21668 5.7%     
Asian or Pacific 
Islander 
5816 1.6%     6377 1.7%     
Native American 1507 0.4%     1627 0.4%     
Other 7209 2.0%     7966 2.1%     
Smoking history   94087 22.7%     101734 22.9%     
Payer Medicare 320508 77.4%     340756 76.7%     
Medicaid 14118 3.4%     15848 3.6%     
Private insurance 64582 15.6%     70771 15.9%     
Self-pay 7267 1.8%     8444 1.9%     
No charge 748 0.2%     824 0.2%     
Other 6849 1.7%     7574 1.7%     
Income quartile 
(by ZIP code) 
Unknown 60573 14.6%     63345 14.3%     
0-25th percentile 
(lowest income) 
106077 25.6%     113970 25.7%     
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26th to 50th 
percentile 
99225 24.0%     107158 24.1%     
51st to 75th 
percentile 
83204 20.1%     89763 20.2%     
76th to 100th 
percentile (highest 
income) 
64992 15.7%     69982 15.8%     
Hospital bedsize Small 47754 11.6%     51309 11.6%     
Medium 106741 25.9%     114261 25.8%     
Large 258050 62.6%     277007 62.6%     
Hospital region Northeast 67949 16.4%     72273 16.3%     
Midwest 116362 28.1%     124564 28.0%     
South 158233 38.2%     169710 38.2%     
West 71527 17.3%     77671 17.5%     
Previous AMI   38324 9.3%     41168 9.3%     
History of IHD   310013 74.9%     332581 74.9%     
Previous PCI   36661 8.9%     39241 8.8%     
Previous CABG   23770 5.7%     25551 5.8%     
Previous 
stroke/TIA 
  16446 4.0%     17566 4.0%     
Year 2004 31002 7.5%     32461 7.3%     
2005 29570 7.1%     30884 7.0%     
2006 30101 7.3%     31738 7.1%     
2007 31145 7.5%     32831 7.4%     
2008 32823 7.9%     34981 7.9%     
2009 36782 8.9%     39222 8.8%     
2010 35551 8.6%     37947 8.5%     
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2011 38766 9.4%     41884 9.4%     
2012 39485 9.5%     42745 9.6%     
2013 39200 9.5%     42790 9.6%     
2014 39345 9.5%     43395 9.8%     
2015 30300 7.3%     33340 7.5%     
AIDS   179 0.0%     203 0.0%     
Alcoholism   7150 1.7%     8197 1.8%     
Anemia   90331 21.8%     97164 21.9%     
Rheumatological 
conditions 
  16156 3.9%     16987 3.8%     
Heart failure   148360 35.8%     158091 35.6%     
Chronic lung 
disease 
  105520 25.5%     112328 25.3%     
Coagulopathies   17110 4.1%     18652 4.2%     
Diabetes mellitus   142526 34.4%     153594 34.6%     
Depression   49569 12.0%     52576 11.8%     
Drug misuse   4460 1.1%     5111 1.2%     
Hypertension   310761 75.0%     332927 74.9%     
Hypothyroidism   67512 16.3%     71344 16.1%     
Liver disease   4575 1.1%     5059 1.1%     
Lymphoma   2181 0.5%     2387 0.5%     
Electrolyte or fluid 
disorders 
  89333 21.6%     96937 21.8%     
Metastatic cancer   3114 0.8%     3410 0.8%     
Neurological 
conditions 
  33537 8.1%     35934 8.1%     
103 
 
Obesity   65310 15.8%     69553 15.7%     
Paralysis   7116 1.7%     7764 1.7%     
Peripheral 
vascular disease 
  56749 13.7%     60553 13.6%     




  379 0.1%     422 0.1%     




  6232 1.5%     6671 1.5%     
Peptic ulcer 
disease 
  266 0.1%     271 0.1%     
Valvular heart 
disease 
  852 0.2%     946 0.2%     
Weight loss   10092 2.4%     11076 2.5%     
Dementia   12533 3.0%     13386 3.0%     
          
CA  228295 55.1%   245815 55.3%   
PCI  137081 33.1%   147930 33.3%   
CABG  30613 7.4%   32656 7.4%   

























3.3 Aim 3: To determine the strength and direction of the association 
between a concurrent OA diagnosis and adverse clinical outcomes 
following a diagnosis of AMI. 
3.3.1 Proportion of cases experiencing adverse clinical outcomes 
Of all cases of AMI, 5.8% died in-hospital, 7.1% suffered from MACCE, 3.2% suffered from 
bleeding, and 1.5% suffered from stroke or TIA (Table 3.8). Stratification by sex showed that 
women were more likely to suffer from mortality (6.9% versus 5.1%), MACCE (8.6% versus 
6.1%), all-cause bleeding (3.4% versus 3.0%), and stroke or TIA (2.0% versus 1.2%). 
Stratification by age showed that advanced age was associated with an increased likelihood of 
experiencing each adverse clinical outcome. The oldest age band had the highest proportion of 
in-hospital mortality (11.1%), MACCE (13.0%), all-cause bleeding (4.2%), and stroke or TIA 
(2.3%) and the lowest age band had the lowest proportion of each adverse clinical outcome 
(1.7%, 2.3%, 1.7%, and 0.6%, respectively). 
3.3.2 The proportion of cases receiving adverse clinical outcomes by OA status 
Compared to non-OA cases, the proportion of patients with OA who suffered a stroke or TIA 
was similar (1.50% versus 1.51%) and a lower proportion of OA cases experienced in-hospital 
mortality (4.8% versus 5.9%), MACCE (6.1% versus 7.2%), and all-cause bleeding (2.5% versus 
3.2%) following AMI (Table 3.8 and Figure 3.5). Similar to the unstratified sample, both men 
and women with OA were less likely to experience in-hospital mortality (4.0% versus 5.1% and 
5.4% versus 7.0%, respectively), MACCE (5.0% versus 6.2% and 7.0% versus 8.7%, respectively), 
and all-cause bleeding (2.3% versus 3.1% and 2.6% versus 3.4%, respectively) than their non-
OA counterparts. Both men and women with OA had a similar likelihood of experiencing stroke 
or TIA compared to their non-OA counterparts (1.1% versus 1.2% and 1.8% versus 2.0%, 
respectively). Stratification by age showed that people with OA were less likely to suffer from 
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in-hospital mortality, MACCE, all-cause bleeding, and stroke or TIA than people without OA in 
every age band.  
Table 3.8: The proportion of cases experiencing adverse clinical outcomes between OA and 
non-OA cases overall and stratified by sex and age. 
 
Entire cohort: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 381400 5.8% 361638 5.9% 19763 4.8% 
MACCE 466766 7.1% 441368 7.2% 25398 6.1% 
All-cause bleeding 207713 3.2% 197489 3.2% 10224 2.5% 
Stroke/TIA 99038 1.5% 92811 1.51% 6227 1.50% 
 
Men: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 201419 5.1% 194130 5.1% 7288 4.0% 
MACCE 242497 6.1% 233402 6.2% 9095 5.0% 
All-cause bleeding 120050 3.0% 115843 3.1% 4207 2.3% 
Stroke/TIA 47047 1.2% 45058 1.2% 1989 1.1% 
 
Women: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 179982 6.9% 167507 7.0% 12475 5.4% 
MACCE 224269 8.6% 207966 8.7% 16303 7.0% 
All-cause bleeding 87663 3.4% 81646 3.4% 6017 2.6% 
Stroke/TIA 51990 2.0% 47753 2.0% 4237 1.8% 
 
Under 50 years old: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 13102 1.7% 13013 1.8% 89 0.8% 
MACCE 17029 2.3% 16902 2.3% 128 1.2% 
All-cause bleeding 12711 1.7% 12584 1.7% 127 1.2% 
Stroke/TIA 4277 0.6% 4238 0.6% 39 0.4% 
 
50 to 59 years old: 




Count  Column 
N% Count Column N % Count Column N % 
In-hospital mortality 33124 2.6% 32627 2.6% 497 1.2% 
MACCE 43187 3.4% 42474 3.4% 712 1.8% 
All-cause bleeding 26056 2.0% 25431 2.1% 625 1.5% 
Stroke/TIA 11146 0.9% 10921 0.9% 225 0.6% 
 
60 to 69 years old: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 61542 4.1% 59968 4.2% 1573 2.1% 
MACCE 79499 5.3% 77210 5.5% 2289 3.0% 
All-cause bleeding 43507 2.9% 42107 3.0% 1399 1.8% 
Stroke/TIA 19985 1.3% 19211 1.4% 775 1.0% 
 
70 to 79 years old: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 95050 6.7% 91314 6.9% 3736 3.5% 
MACCE 118209 8.3% 113016 8.6% 5194 4.8% 
All-cause bleeding 58054 4.1% 55152 4.2% 2902 2.7% 
Stroke/TIA 26901 1.9% 25352 1.9% 1548 1.4% 
 
Over 80 years old: 
 All AMI No OA OA 
 
Count Column 
N% Count Column N % Count Column N % 
In-hospital mortality 178582 11.1% 164715 11.5% 13867 7.8% 
MACCE 208841 13.0% 191766 13.4% 17075 9.5% 
All-cause bleeding 67385 4.2% 62215 4.3% 5171 2.9% 
Stroke/TIA 36729 2.3% 33089 2.3% 3639 2.0% 
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3.3.3 Association between OA and adverse clinical outcomes 
In unadjusted models, there was no association between OA and stroke or TIA (0.996; 0.971, 
1.022), however, OA was significantly associated with decreased odds of mortality (0.802; 
0.790, 0.814), MACCE (0.845; 0.834, 0.856), and all-cause bleeding (0.763; 0.748, 0.778) (Table 
3.9). After adjustment for confounders, the association between OA and better outcomes 
increased (in-hospital mortality: 0.680; 0.670, 0.691; MACCE: 0.709; 0.699, 0.719; all-cause 
bleeding: 0.757; 0.741, 0.772; stroke/TIA: 0.844; 0.822, 0.868).  
3.3.4 Association between OA and adverse clinical outcomes – stratified by sex 
Similar to the unstratified sample, stratification by sex showed that both men and women with 
OA were associated with a decreased odds of experiencing adverse clinical outcomes 
compared to people without OA (Table 3.9). In adjusted analysis, men with OA were less likely 
to suffer from adverse clinical outcomes compared to their non-OA counterparts than women 
were. Negative confounding was seen in both sexes for every outcome except for all-cause 





















3.3.5 Association between OA and adverse clinical outcomes – stratified by age 
In adjusted analysis, OA was associated with a decreased odds of adverse clinical outcomes in 
each age band (Table 3.9). However, there appeared to be a trend where OA was most 
strongly associated with a decreased odds of experiencing adverse clinical outcomes in the 
younger age bands and OA was least strongly associated with experiencing adverse clinical 




Table 3.9: The association between OA and adverse clinical outcomes overall and stratified by sex and age. 
Independent variable: Dependent variables: 
Osteoarthritis In-hospital mortality MACCE All-cause bleeding Stroke or TIA 













































































































































































3.3.6 Annual association between OA and Adverse clinical outcomes – 2004 to 2015 
The annual association between OA and in-hospital mortality, MACCE, and stroke or TIA was 
constant over time, however the relationship between OA and all-cause bleeding appeared to 
change (Table 3.10). The relatively strong association between OA and a decreased odds of 
decreased bleeding seen in 2004 to 2006 tended to diminish towards the end of the study 
period (2011 onwards). 
Table 3.10: The adjusted odds of adverse clinical outcomes among OA cases relative to non-



































































































































3.3.7 Sensitivity analysis of the OA variable using symptomatic OA 
Differences in the baseline demographics between the OA variables was discussed in section 
3.2.7. Compared to the original OA group, the symptomatic OA group experienced similar 
likelihoods of adverse clinical outcomes including in-hospital mortality (4.7% versus 4.8%), 
MACCE (6.1% versus 6.1%), all-cause bleeding (2.5% versus 2.5%), and stroke or TIA (1.5% 
versus 1.5%) (Table 3.7).  
3.3.8 Sensitivity analysis of the effect of reinfarction 
After excluding patients with a previous AMI, 5,993,113 remained. Binary logistic regression 
showed the association between OA and each adverse clinical outcome to be nearly identical 
to analysis of the entire cohort (which included cases with a previous AMI) in both unadjusted 
and adjusted analysis (Table 3.X). This provides evidence that patients experiencing multiple 
hospitalisations due to reinfarction did not bias this study’s results.  
Table 3.11: The association between OA and adverse clinical outcome after excluding 
patients with a previous AMI. 
 Not excluding previous AMI Excluding previous AMI                   
  
Unadjusted OA Adjusted OR 












































4 Chapter 4: Discussion 
4.1 Summary of results and link to previous literature 
While OA has been associated with overall CVD, reports of the association between OA and 
AMI are conflicting. Furthermore, the effects of OA on treatments and outcomes following 
AMI have not been previously studied. This had guided the three aims of this study, which 
were to describe the prevalence of OA among AMI patients in the NIS between 2004 and 2015, 
to describe the association between OA and invasive management strategies following AMI, 
and to describe the association between OA and adverse clinical outcomes following AMI. 
4.1.1 Aim 1 
4.1.1.1 Prevalence of AMI 
There were between 500,000 and 600,000 weighted individual admissions per year with a 
primary diagnosis code of AMI between 2004 and 2014 (2015 had approximately 25% fewer 
admissions because of the switch to ICD-10-CM/PCS starting 1st October 2015) (Figure 3.1). 
There were 6,651,940 cases of AMI during the study period. The annual number of people with 
AMI that presented to secondary care appeared stable over time and there was no apparent 
trend when comparing across multiple years.  
The 2019 report from the American Heart Association (AHA) estimated the annual incidence of 
MI in 2019 to be approximately 805,000 and decreasing significantly each year (Benjamin et 
al., 2019). Differences between the number of AMI cases in this study and the AHA incidence 
estimate may be attributed to the exclusion of elective admissions. Additionally, because the 
NIS is an inpatient discharge database, fatal, pre-hospital AMI’s were not captured, potentially 
highlighting a selection bias against severe cases of AMI. A study in New Zealand concluded 
that 24-25% of major ischemic heart disease events are fatal, of which the majority occur in 
the pre-hospital setting (Grey et al., 2017). Another study from Sweden with a similar sex and 
age distribution to this study (34.9% versus 39.8% women and mean age 70.5 versus 67.6 
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years) found that among 384,597 cases of AMI, 28.9% died pre-hospital (Dudas et al., 2011). 
Therefore, it can be reasonably assumed that 25% of AMI’s in the United States are fatal in the 
pre-hospital setting and are not captured by the NIS, thus accounting for the fewer number of 
AMI cases in this study compared to the AHA annual incidence estimates. However, the 
exclusion of severe AMI cases means that this study’s AMI cohort may have better clinical 
outcomes compared to the total population of AMI patients between 2004 and 2015 in the US, 
highlighting a lack of representativeness that may affect external validity. Despite this, 
accurate comparisons between this study’s AMI group and the population of AMI patients who 
reach hospital in the United States can be made, as both groups do not include fatal pre-
hospital AMI’s. 
Furthermore, this study’s estimate of 6,651,940 AMI hospitalisations between 2004 and 2015 
is similar to other studies that have used the NIS (6,968,777 AMI hospitalisations between 
2004 and 2014 (Mohamed et al., 2019) and 6,563,255 AMI hospitalisations between 2004 and 
2014 (Bharadwaj et al., 2019)). This, combined with AHRQ estimates of the weighted NIS being 
representative to 97% of all hospitalisations in the US, provides evidence that this study’s 
sample of AMI admissions is representative to the US population. 
4.1.1.2 Prevalence of OA among AMI cases 
This study identified the overall prevalence of OA, as recorded by professional coders who 
analyse inpatient discharge summaries, to be 6.3% in the AMI group between 2004 and 2015.  
This study’s overall prevalence of OA among AMI patients was much lower than the estimated 
prevalence of OA in the general population. Among US adults over 60 years old, approximately 
10% of men and 13% of women suffer from symptomatic OA (Y. Zhang & Jordan, 2010). 
Additionally, data from the Framingham Study estimated the prevalence of symptomatic OA to 
be 9.5% in patients 63-94 years-old (O’Neill et al., 2018). The mean age in this study was 67.6 
years old which is similar to the aforementioned studies. 
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This study’s low prevalence of OA was unexpected because previous studies have identified an 
increased prevalence of MI, heart failure, angina, and stroke in people with OA compared to 
people without OA (Ong et al., 2013), and a systematic review of the association between OA 
and CVD has shown them to be significantly linked (Hall et al., 2016). While the prevalence of 
OA within the general population has been extensively examined, no previous studies have 
identified the prevalence of OA among patients diagnosed with AMI. Given the association 
between OA and CVD, it is reasonable to hypothesise the prevalence of OA among AMI 
patients to be higher than the prevalence of OA in the general population, not lower. 
Two possible explanations for the low prevalence of OA are as follows. Firstly, the exclusion of 
severe cases of AMI (fatal in the pre-hospital setting) may have affected this study OA 
prevalence estimates. One study found that of all patients suffering from a fatal pre-hospital 
AMI, 57% were 80 years-old or older (Grey et al., 2017). Because these patients do not make it 
to hospital, the NIS is potentially younger than the true population. Furthermore, age is the 
strongest risk factor for OA. Therefore, the NIS is likely to exclude older patients, many of 
whom will have OA. This selection bias is a possible explanation as to why the prevalence of 
OA was low within the AMI cohort. Secondly, previous studies have suggested that the 
prevalence of OA in EHR data may be low because of the underreporting of OA and other 
comorbidities in routinely collected data (Quan et al., 2002; Yu et al., 2018). Poor coding 
practices for OA in the NIS was evidenced in this study through the creation of a new non-
binary OA variable based on anatomical location called OA sites (Appendix 6.2). Of the 5 
categories of OA sites (no OA, upper limb OA, lower limb OA, generalised OA, or OA of 
unspecified location), the majority of people had a code for unspecified OA (81.5%). This 
implies OA was poorly coded in the NIS, and this may have been responsible for the low 
prevalence of OA among AMI cases. 
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This study also found that certain comorbidities were less common in people with OA 
compared to people without OA (Table 3.1). Particularly, people with OA tended to smoke less, 
were less likely to have had a previous PCI, CABG, or history of IHD, and had shorter hospital 
stays (4.63 (4.62, 4.65) days versus 4.86 (4.86, 4.87) days). Despite other baseline 
demographics that showed the OA group to have worse health than the non-OA group (they 
were older, and more likely to have suffered from obesity, hypertension, heart failure, and 
chronic lung disease), OA being associated with a better cardiovascular history and a shorter 
hospital stay is still unexpected given the previously mentioned associations between OA and 
CVD (Hall et al., 2016). Therefore, it is possible that there is a bias in the methodology of the 
NIS, particularly, in the coding practices of OA. The effect of these practices on the validity of 
OA prevalence estimates and associations between OA and clinical outcomes within the NIS is 
discussed further in section 4.2. 
4.1.1.3 Temporal trends of OA among AMI cases 
This study found that the prevalence of OA among the AMI cohort increased from 5.20% in 
2004 to 7.04% in 2015 (Figure 3.3). This trend is in keeping with reports of an increasing 
prevalence of OA due to the ageing population and the increasing prevalence of obesity, two 
strong risk factors for OA (Hunter et al., 2014; Murray et al., 2012). However, most of this 
increase in prevalence occurred between 2006 and 2011 and the prevalence remained 
constant in the beginning and end of the study period (Figure 3.3). It is possible that the quality 
of the data has improved over time causing the prevalence to increase towards approximately 
10% to 13% which is recognised to be an accurate estimate of the prevalence of symptomatic 
OA (Y. Zhang & Jordan, 2010). It is also possible that incentives encouraging the better coding 
of comorbidities such as OA may have been implemented in the years prior to 2006 which 
caused the steady increase of OA prevalence. Additionally, the NIS underwent a redesign in 
2011 that was meant to reduce sampling error. This may have impacted the apparent 
increasing trend of OA prevalence prior to the redesign. 
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4.1.2 Aim 2 
4.1.2.1 Association between OA and invasive management strategies 
This study also identified that among AMI patients, those with OA were less likely to receive 
invasive management strategies such as CA, PCI, and CABG, even after adjustment for 
confounders (Table 3.5). Stratification by sex showed that it may moderate the relationship 
between OA and the receipt of CABG. Specifically, men with OA were more likely to receive 
CABG than men without OA, and women with OA were less likely to receive CABG than women 
without OA. Stratification by age showed that younger people with OA were more likely to 
undergo CABG than younger people without OA, and older people with OA were less likely to 
undergo CABG than older people without OA.  
Previous studies have identified women, minority populations, lower socioeconomic status, 
and multiple comorbidities to be associated with a decreased likelihood of receiving invasive 
management strategies following AMI (Haglund et al., 2004; Pathak & Strom, 2008). A study 
using the NIS to investigate the effect of RA on outcomes following AMI found that RA patients 
were 39% more like to receive medical management instead of PCI or CABG (OR 1.39, 95% CI 
1.30 to 1.49) (Francis et al., 2010). Other comorbidities associated with a decreased odds of 
receiving PCI include COPD (OR 0.5; 95% CI 0.4, 0.6) due to the inability to lay supine without 
coughing, end-stage renal disease (0.4; 0.3, 0.5) possibly due to the risk of contrast-induced 
nephropathy, diabetes mellitus (0.8; 0.7, 0.9) and alcohol abuse (0.6; 0.3, 1.0) (Pathak & Strom, 
2008). A study of 961 patients diagnosed with STEMI similarly found that patients were less 
likely to receive PCI if they had a concurrent diagnosis of either heart failure, stroke, chronic 
kidney disease, anaemia, atrial fibrillation, COPD, or diabetes mellitus (Tisminetzky et al., 
2015). Another study of 8831 STEMI patients found dementia to be associated with a 
decreased odds of CA, PCI, and CABG; the same study also found that among all patients 
undergoing CA, those with a diagnosis of diabetes mellitus, stroke, chronic kidney disease, 
heart failure, or COPD were at a decreased odds of receiving PCI (Chanti-Ketterl et al., 2014). 
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There do not appear to be any previous studies investigating whether the odds of receiving 
invasive management following AMI is affected by a diagnosis of OA. One proposed 
explanation for this study’s result is that people with severe OA were less able to lay supine for 
long enough to undergo CA or PCI. Another possible explanation is that people with OA were 
perceived to be frail, and this perceived frailty may have biased healthcare providers away 
from invasive management strategies such as CA, PCI, or CABG. Overall, this study’s result of 
OA being associated with a decreased odds of receiving CA, PCI, and CABG is congruent with 
the previous literature which says that comorbidities decrease a person’s odds of invasive 
management strategies following AMI. 
4.1.2.2 Annual association between OA and invasive management strategies – 2004 to 2015 
The odds of people with OA receiving CA and PCI remained similar over the study period (Table 
3.6). However, the odds of people with OA receiving CABG appeared to change from a 
decreased odds (2004 to 2009) to an increased odds (2011 to 2015).  
Compared to CABG, PCI is less invasive and has been shown to have similar short-term (less 
than 5 years) outcomes including survival and rates of stroke and reinfarction (Stone et al., 
2019). Studies of long-term outcomes have shown CABG to be superior to PCI with respect to 
survival and reintervention rates, however, CABG carries greater peri-operative risks (Habib et 
al., 2015). The EuroSCORE 2 is a risk assessment tool for estimating the risk of mortality after 
cardiac surgery (Nashef et al., 2012). The risk of mortality (calculated as a percent) is used by 
many clinicians to help decide if the benefits of cardiac surgery outweigh the risks. The 
EuroSCORE 2 model considers many factors that increase peri-procedural mortality including 
musculoskeletal dysfunction, previous AMI, previous cardiac surgery, and angina, all of which 
may be more prevalent in people with OA than people without OA (Nashef et al., 2012; Ong et 
al., 2013). Therefore, OA being associated with a decreased odds of CABG fits with the 
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previous literature, however, this does not explain why OA was associated with an increased 
odds of CABG in the second half of the study period. 
4.1.2.3 Sensitivity analysis of the OA variable using symptomatic OA 
Expanding this study’s definition of OA to include people who suffered from joint pain, joint 
effusion, or previous joint replacement surgery significantly increased the prevalence of OA 
among AMI cases from 6.3% to 6.8% (Table 3.7). However, there were no differences between 
the demographics, past medical history, or the receipt of invasive management strategies 
between the two OA groups. Similar to the prevalence of the original OA definition, the 
prevalence of symptomatic OA among AMI cases was lower than the prevalence of OA in the 
general population. As previously discussed, it is reasonable to expect the prevalence of OA to 
be higher in a group of AMI patients than in the general population. This unexpected result 
may once again be attributed to the poor coding practices of OA in the NIS. 
4.1.3 Aim 3 
4.1.3.1 Association between OA and adverse clinical outcomes 
This study found that AMI patients with OA had significantly better clinical outcomes than their 
non-OA counterparts. The results of the logistic regression modelling were that patients with 
OA had a decreased odds of experiencing in-hospital mortality, MACCE, bleeding, and stroke or 
TIA. These results persisted after adjusting for confounding variables and stratification by sex 
and age (Table 3.9). Negative confounding was observed in the relationship between OA and 
each adverse clinical outcome; the implications of this are discussed in section 4.3.3.2. 
These findings directly contrast the findings of previous studies. Firstly, people with OA may be 
at an increased risk of all-cause and cardiovascular specific mortality (Cleveland & Callahan, 
2017; Wilkie et al., 2019). Despite a lack of consensus on whether OA does predict mortality, it 
seems unlikely for OA to be associated with better outcomes compared to patients without 
OA. Secondly, people with OA are more likely to be taking NSAIDs for the relief of pain and 
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inflammation. Observational studies have identified NSAIDs to be associated with coronary 
artery disease and gastrointestinal bleeding (Farkouh et al., 2007). A limitation of the NIS is its 
lack of pharmacological data, meaning unmeasured confounding from medications may have 
significantly affected this study’s result. However, unmeasured confounding through the use of 
NSAIDs would have increased the risk of adverse clinical outcomes such as bleeding in people 
with OA compared to people without OA. This further provides evidence against the validity of 
this study’s result that OA was associated with better clinical outcomes. Finally, people with 
poorly managed OA are likely to avoid physical activities that may cause pain. This may lead to 
a decreased fitness and an increased risk of CVD and mortality (Hawker et al., 2014), further 
questioning this study’s reported association between OA and better clinical outcomes 
following AMI.  
A cross-sectional study published in 2010 using the NIS to investigate the effect of RA on 
outcomes following AMI had findings similar to this study. The researchers found that patients 
with RA experienced better in-hospital survival following AMI in both crude (OR 0.76, 95% CI 
0.68 to 0.86) and adjusted models (AdjOR 0.66, 95% CI 0.59 to 0.74), and like this study, 
negative confounding was observed (Francis et al., 2010). The authors were unable to fully 
reconcile this finding. They suggest that RA’s protective effect on mortality following AMI may 
be due to the RA group being 60% less likely to have heart failure compared to the non-RA 
controls. In contrast, a cohort study examining the effect of RA after AMI found the RA group 
to experience significantly higher rates of mortality (HR 1.47, 95% CI 1.04 to 2.08) and 
recurrent ischemia (HR 1.51, 95% CI 1.04 to 2.18) (McCoy et al., 2013). Therefore, it is likely 
that the apparent protective effect of RA against mortality after AMI in the Francis et al paper 
is attributed to a methodological bias. Specifically, it is possible that errors in the coding of OA 




4.1.3.2 Annual association between OA and adverse clinical outcomes – 2004 to 2015 
This study found the odds of in-hospital mortality, MACCE, and stroke or TIA in people with OA 
to remain similar throughout the study period (Table 3.10). While OA remained associated 
with a decreased odds of bleeding in each year of the study period, the association was 
stronger in the first half of the study period compared to the second half. As previously 
discussed, the use of NSAIDs has been associated with gastrointestinal bleeding. The relatively 
higher odds of bleeding in the second half of the study period may be attributed to changes in 
NSAID prescription habits by primary care physicians.   
4.1.3.3 Sensitivity analysis of the OA variable using symptomatic OA 
Similar to the analysis of invasive management strategies, expanding this study’s definition of 
OA to include symptomatic OA and previous joint replacement made no significant difference 
in the association between OA and adverse clinical outcomes (Table 3.7). A proposed 
mechanism explaining how misclassification bias can lead to these results can be found in the 
next section. 
4.2 The effect of information bias in the NIS 
Information bias is one explanation for some of the unexpected results in this study. The 
following sections discuss the potential for this with regard to the variables included in the 
analysis. 
4.2.1 Validity of AMI codes 
The validity of AMI codes are generally good; a study of 5,151 discharges from the Veterans 
Health Administration found the positive predictive value (PPV) of AMI codes in the primary 
diagnosis position to be 96.9% when using chart-abstracted data as the reference standard 
(Petersen et al., 1999). A similar study comparing an administrative database with chart data 
found that ICD-9-CM diagnosis codes for AMI had a PPV of 92.0% and a negative predictive 
value (NPV) of 93.1% (Quan et al., 2002). A more recent systematic review of the validity of MI 
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codes in EHR databases (mostly consisting of ICD-9-CM codes) found that in most studies, both 
the sensitivity and specificity were greater than 86% and the PPV greater than 93% 
(McCormick et al., 2014). The validity of ICD-9-CM codes corresponding to major illnesses 
(such as AMI) is high, and one can confidently infer there to be minimal information bias in this 
study’s AMI codes. 
4.2.2 Validity of invasive management codes 
The validity of ICD-9-CM codes for CA, PCI, and CABG are also generally good. A comparison of 
discharge data versus chart data in 1200 randomly selected inpatients found similar 
proportions of CA (0.9% and 0.8% respectively), with a PPV of 50% and an NPV of 99.5% (Quan 
et al., 2004). A similar study found high sensitivities and specificities for both PCI (90.3% and 
99.7%, respectively) and CABG (95.7% and 100%, respectively) (Petersen et al., 1999). Another 
study analysing Medicare claim data found that ICD-9-CM codes for CABG carried a specificity 
of 96% and PPV of 100% (Fisher et al., 1992). These results align with the existing literature in 
providing evidence that codes for major procedures (occurring in operating theatres) have a 
higher validity than codes for minor procedures performed on the ward or in radiology 
departments (Quan et al., 2004).  
4.2.3 Validity of OA codes 
While AMI and cardiac procedure codes tend to be highly valid, previous studies have found 
that OA is generally underreported in administrative databases (Yu et al., 2018). This is likely 
because OA lacks precise definitions, has a variety of phenotypes, and varies by the affected 
joint. All of these factors decrease the reliability of these codes and increase the likelihood of 
misclassification bias. As previously mentioned, the prevalence of OA is expected to increase 
due to the ageing population and increasing prevalence of obesity, two strong risk factors for 
OA (Hunter et al., 2014; Murray et al., 2012). While the prevalence of OA in this study 
increased over time, there was still an overall underreporting of OA, a trend that has been 
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observed in other studies examining OA in administrative databases. One study identified an 
increasing trend of the underreporting of OA in a UK primary care database, using total knee 
and hip replacement patients as the reference population for people with OA (Yu et al., 2018). 
A systematic review of the diagnostic accuracy of OA diagnoses in administrative data similarly 
found that OA was generally underreported, with sensitivities ranging from 29% to 83% and 
specificities ranging from 60% to 100% (Shrestha et al., 2016). A Massachusetts study in 2000 
used a combination of medical records and an outpatient administrative database to 
determine the PPV and NPV of ICD-9-CM OA codes to be 62% and 78% respectively (Harrold et 
al., 2000). A more recent study found that a “strict” definition of OA (only using ICD-9-CM 
codes for osteoarthrosis, 715.xx) had a sensitivity and specificity of 34.6% and 97.5%, 
respectively (Cisternas et al., 2016). To increase validity, the authors also used an “expanded” 
definition of OA (ICD-9-CM codes 715.xx for osteoarthrosis, 716.xx for other and unspecified 
arthropathies, and 719.xx for other unspecified joint disorders) which increased the sensitivity 
(73.8%) at the cost of a slightly lower specificity (90.5%). However, the PPV of both definitions 
remained similar (33.5% for “strict” and 26.3% for “expanded”). The results of this “expanded 
OA” variable were similar to this study’s symptomatic OA variable in that both definitions 
could not adequately encompass OA in EHR data despite including additional codes for allied 
disorders and symptoms. The problems associated with OA coding may be compounded in the 
NIS because the main incentive for accurate diagnosis coding is though reimbursement, and a 
diagnosis of OA is likely to be of little reimbursement value to hospitals (Khera & Krumholz, 
2017).  
4.2.4 Validity of comorbidity codes 
Osteoarthritis is not the only chronic comorbidity described to be underreported in EHR data. 
A study comparing an ICD-9-CM coded administrative database to hospital chart data in a 
random sample of 1200 patients found that there was a general underreporting of Charlson 
comorbidities in the administrative database (Quan et al., 2002). The Charlson comorbidities 
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that were most significantly underreported included rheumatological disease, cerebrovascular 
disease, dementia, diabetes with chronic complications, peptic ulcer disease, and peripheral 
vascular disease. A similar study comparing the coding accuracy of Charlson comorbidities 
found there to be a low correlation (kappa = 0.47) between the comorbidities documented in 
administrative data and chart data (Kieszak et al., 1999). 
4.2.5 Further decline in comorbidity code validity in unwell patients 
The problem of comorbidities being underreported in administrative data tends to worsen 
when patients are unwell or die in-hospital. In a cohort of 817 patients undergoing PCI, 
concordance between chart data and administrative data was poor for chronic comorbidities 
including diabetes (17.6% versus 14.7%), hyperlipidaemia (40.5% versus 14.9%), and 
hypertension (41.1% versus 27.5%) (Humphries et al., 2000). The authors also noted that 
asymptomatic conditions generally had the lowest level of agreement. Another study 
examined 162,790 discharges in California in 1988 to investigate the effect of secondary 
diagnoses on death among a group of elderly patients hospitalised for stroke, pneumonia, 
AMI, or heart failure (Iezzoni et al., 1992). The study found that AMI patients were associated 
with better in-hospital survival if they had a concurrent diagnosis of hypertension (relative risk 
0.57, p<0.0001), previous AMI (0.84, p<0.01), angina pectoris (0.41, p<0.0001), COPD (0.89, 
p<0.05), or ventricular premature beats (0.49, p<0.0001). It is unlikely that there is a biological 
mechanism causing these comorbidities to confer better in-hospital survival. The authors 
attributed this result to a coding bias, where the patients who died were less likely to have 
codes for chronic comorbidities because they were replaced by codes for acute complications 
relating to death, such as cardiac arrest or respiratory failure. Additionally, the authors 
referenced ICD-9-CM coding guidelines that suggested that diagnoses that have no bearing on 
the current hospital stay should be excluded.  
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The previously mentioned study did not examine the association of OA on in-hospital 
mortality, however, a very similar study found that in patients over 65 years-old diagnosed 
with AMI, those with a concurrent diagnoses of OA (and many other chronic comorbidities) 
experienced significantly lower rates of short and long term mortality (Jencks et al., 1988). The 
conditions with the strongest associations to lower short-term in-hospital mortality were 
obesity (odds ratio 0.33, p<0.0001), OA (0.33, p<0.0001), benign prostatic hyperplasia (BPH) 
(0.35, p<0.0001), diverticulosis (0.39, p<0.01), and hypertension (0.48, p<0.0001). The authors 
argued that this relationship is clinically highly unlikely and may be attributed to the 
underreporting of chronic conditions in unwell patients (such as those diagnosed with AMI). 
They hypothesised that this underreporting of comorbidities occurs because ICD-9-CM codes 
associated with death (such as cardiac arrest) took precedence over codes for chronic 
comorbidities (such as OA). They provided evidence for this by arguing that the chronic 
conditions with the lowest likelihood of affecting mortality (OA and BPH) should not have had 
the strongest associations with better survival.  
Although the previous two studies were published many years ago, they were the only studies 
found to investigate the prognostic effect of comorbidities (such as OA) on the outcomes 
following AMI. It is possible that the bias identified in these studies had similar effects on the 
results of this study.  
4.2.6 Systematic differential misclassification bias 
This study has suggested that OA was underreported among AMI patients in the NIS, as only 
6.8% of the cohort was identified using the “symptomatic” definition of OA. This result aligns 
with the previously reported hypothesis that there is a significant underreporting of 
comorbidities (including OA) among unwell patients (such as those suffering from AMI) in EHR 
data. This hypothesis is further supported by the results of this study’s binary logistic 
regression, which implied that people with OA experienced better clinical outcomes than 
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people without OA. A biological mechanism explaining this result is highly unlikely because 
previous studies have associated OA with an increased risk of CVD. A chronic condition like OA 
is likely to increase one’s risk profile (or at the minimum exert no effect) and should not be 
“protective” against adverse clinical outcomes. Therefore, the most likely explanation for OA 
being associated with better clinical outcomes is a systematic, differential misclassification 
bias, where OA patients who experienced adverse clinical outcomes (i.e. are “unwell”) were 
less likely to receive a code for OA. This misclassification occurred because codes associated 
with serious illness and death took precedence over OA codes. Because the unwell OA patients 
were potentially removed from the true OA cohort and were misclassified as not having OA, 
this study’s OA group may have been “healthier” than the non-OA group. This makes it 
reasonable to expect the OA group to have better clinical outcomes than the non-OA group, 
and implies that OA is adequately reported in well patients but underreported in those that 
are unwell. This is evidenced in Table 3.1 which showed that people with OA tended to smoke 
less, were less likely to have had a previous PCI, CABG, or history of IHD, and had shorter 
hospital stays (4.63 (4.62, 4.65) days versus 4.86 (4.86, 4.87) days). However, Table 3.1 also 
showed the OA group to have characteristics that are normally associated with worse clinical 
outcomes, including advanced age (mean age 75.3, SD 12.3; versus 67.1, SD 14.4 years-old) 
and the higher prevalence of certain comorbidities (including hypertension and chronic lung 
disease). Despite these characteristics generally conferring worse clinical outcomes following 
AMI, it is hypothesised that the effect of misclassifying the subset of OA cases that were very 
unwell as not having OA was great enough to confer better outcomes in the OA group. 
Therefore, the cases that remained in the OA group had better clinical outcomes because of 
the removal of the severe cases from the cohort, despite the OA group also being older and 




4.3 Strengths and limitations 
4.3.1 The NIS 
There are many benefits to using the NIS. Firstly, it is the largest publicly available all-payer 
database in the United States, recording over 7 million unweighted hospital admissions per 
year, with each admission including up to 30 diagnosis and 15 procedure codes (Healthcare 
Cost and Utilisation Project, 2019). The large number of admissions within the NIS allows for 
precise estimates and the study of rare diseases that are difficult to study using small datasets. 
Additionally, according to HCUP, the number of annual peer-reviewed articles studying the NIS 
has sharply increased from 100 in 2006 to 550 in 2016 (Khera & Krumholz, 2017). Secondly, as 
previously discussed, the NIS has good quality information on AMI and invasive procedures 
such as CA, PCI, and CABG, allowing for accurate analyses of these variables. Finally, weights 
may be applied to the NIS’s 20% sample to produce estimates that are representative to the 
entire inpatient population of the United States (Healthcare Cost and Utilisation Project, 2019). 
The NIS’s sampling method ensures that it is representative to the US population with respect 
to diagnosis-related groups (DRG), admission month, and hospital level factors including 
location, size, and teaching status (Healthcare Cost and Utilisation Project, 2014). All these 
factors contribute towards good external validity when studying the NIS. 
The NIS inherently comes with several limitations. Firstly, as previously mentioned, a 
consequence of the 2012 redesign was the removal of patient identifiers in order to enhance 
patient confidentiality. This means that multiple hospital discharges within the dataset may be 
attributed to the same individual (Khera & Krumholz, 2017). This design change was significant 
for patients with conditions causing recurrent hospital visits (for example chronic lower 
respiratory diseases) because of the inability to track multiple admissions from the same 
patient. Despite AMI not being a relapsing and remitting condition, a significant proportion of 
patients suffer from reinfarction. One study found that after a person’s first AMI, there was a 
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6% reinfarction rate over one year (Kornowski et al., 1993), while another study found 
reinfarction rates for PCI managed and medically managed AMIs to be 9.4% and 8.0%, 
respectively, over 7 years (White et al., 2012). Therefore, recurrent admissions from patients 
suffering from reinfarction had the potential to introduce bias into this thesis’ results. 
However, the analysis performed in section 3.3.8 provided evidence that the effect of people 
being admitted multiple times due to reinfarction was unlikely to have biased this study’s 
results. Secondly, the NIS does not contain information on the severity of AMI, which may 
have differed by OA status. Thirdly, the AHRQ estimated that the NIS redesign caused a 4% 
decrease in the total number of discharges in 2012 compared to 2011, potentially leading to 
inaccuracies when analysing temporal trends (Healthcare Cost and Utilisation Project, 2019). 
This one time decrease in the total number of discharges did not appear to affect this study’s 
analysis, as the number of AMI patients remained similar throughout the study period. 
Fourthly, the NIS only contains routinely collected data encompassing a patient’s 
hospitalisation and does not contain information about the patient’s follow-up appointments 
or outpatient visits. The final drawback is the lack of medication data stored within the NIS, 
which is discussed in section 4.3.3.1. 
4.3.2 Study design 
This thesis was limited to a cross-sectional study design due to the lack of follow-up data on 
each hospitalisation record. Diagnosis codes were generated upon discharge from hospital, 
thus making it impossible to know with certainty whether a diagnosis code is referring to a 
pre-existing comorbidity or a complication that developed during the hospital stay (Bharadwaj 
et al., 2019). We therefore cannot comment on whether OA caused better or worse outcomes 
in patients following AMI, we may only comment on associations. Further cohort studies are 
required to make assertions about temporality in the relationship between OA and treatments 




4.3.3.1 Unmeasured confounding 
Unmeasured confounding, defined as the omission of a relevant confounder from a model 
(Fewell et al., 2007), may have affected this study’s results. The NIS does not contain 
medication data, and because this could not be adjusted for in logistic regression modelling, 
medication data is a potential source of unmeasured confounding. This may be particularly 
problematic when studying the association between OA and CVD because the use of oral 
NSAIDs confounds their relationship. Oral NSAIDs are commonly taken by people with OA 
because they are effective in relieving joint pain and inflammation. However, oral NSAIDs have 
serious side effects including gastrointestinal tract ulcers, reductions in glomerular filtration 
rate, and cardiovascular risks including hypertension, myocardial infarction, and stroke (Varga 
et al., 2017). Therefore, the regular use of NSAIDs is likely to place people with OA at an 
increased risk of adverse clinical outcomes (including stroke, MACCE, and bleeding). However, 
the opposite association was observed in this study, providing further evidence of a systematic 
differential misclassification bias being responsible for the observed protective effect of OA. 
Another potential unmeasured confounder is frailty. This study found OA to be associated with 
a decreased odds of receiving invasive management including CA, PCI, and CABG. A possible 
explanation for this association is that people with OA appear to be frail, and this perceived 
frailty may make healthcare providers more hesitant in offering invasive managements. The 
effect of other unidentified unmeasured confounders may also have biased this study’s results. 
4.3.3.2 Negative confounding 
Negative confounding was seen in the regression analyses between OA and each adverse 
clinical outcome (Table 3.9). In order to determine the source of the negative confounding, the 
adjusted binary logistic regression models were built by adding one covariate at a time. This 
identified most of the negative confounding to be attributed to demographic factors, 
particularly age. As an example, consider the relationship between OA and in-hospital 
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mortality. The crude OR of the association between OA and in-hospital mortality was 0.802 
and the adjusted OR was 0.680. When only OA and age were included as independent 
variables in the model, the OR was 0.567. This implies that in this study age was a negative 
confounder and thus differently associated (either direct or inverse) with OA (the “exposure”) 
and in-hospital mortality (the “outcome”). However, common knowledge and previous studies 
have shown age to be strongly positively associated with OA and with mortality following AMI 
(Mehta et al., 2001; Vina & Kwoh, 2018; Y. Zhang & Jordan, 2010). Additionally, this study 
showed that OA patients were older (75.3 (SD 12.3) versus 67.1 (14.4) years-old) than people 
without OA, and people who died were older than people who survived (76.0 (12.7) versus 
67.1 (14.3) years-old), providing further evidence that age is positively associated with OA and 
with mortality.  
It remains unclear why age-adjusted estimates tended further from the null than crude 
estimates when considering the relationship between OA and in-hospital mortality. This may 
be due to age exerting a different effect on OA and mortality depending on the age that is 
considered. Interestingly, further model building strategies found age to have a similar 
relationship between OA and the remaining adverse clinical outcomes, including MACCE 
(crude OR: 0.845; age-adjusted OR: 0.608), all-cause bleeding (crude OR: 0.763; age-adjusted 
OR: 0.643), and stroke or TIA (crude OR: 0.996; age-adjusted OR: 0.795). 
4.4 Implications 
4.4.1 Future research 
The most important implication of this work is its critique of the validity of comorbidity codes 
in large administrative databases. The findings from this study suggest the validity of 
comorbidity codes is lower than primary diagnosis codes in the NIS. The validity of codes for 
comorbidities with imprecise definitions like OA are even poorer, as are codes for patients who 
are acutely unwell because more serious codes take precedent. These considerations are 
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relevant to not only the NIS but all EHR databases, as this bias has been reported in previous 
studies of OA and acute illness in large administrative databases (Jencks et al., 1988; Yu et al., 
2018). However, this bias is likely to be worse in secondary care versus primary care EHR 
databases because patients presenting to primary care with acute illnesses are often 
transferred immediately to secondary care. Therefore, it is important to exercise caution when 
analysing secondary care comorbidity data, especially in unwell patients. Researchers must 
also ensure the validity of OA coding practices within their database in order to avoid potential 
information biases and to facilitate better research.  
No previous studies have examined the association between OA and outcomes other than 
death (such as MACCE, bleeding, stroke, or the receipt of invasive management strategies) 
following AMI. Therefore, this study presents novel findings of the association between OA 
and treatment and outcomes following AMI. However, there is still a need for further research 
into this topic because of the bias that is likely to have obscured this study’s results. Previous 
studies using EHR data have similarly observed misclassification bias when analysing 
comorbidity data in acutely unwell patients (Iezzoni et al., 1992; Jencks et al., 1988). These 
difficulties are likely inherent to all EHR databases as there is always a degree of 
misclassification. An alternative way to investigate this research question may be through a 
cohort study design that uses questionnaires that are linked to medical records. However, this 
comes with its own difficulties because patients may not be able to accurately recall the details 
of hospital visits. Future research may also focus on very similar questions in order to elucidate 
the precise reason for the bias. For example, would the misclassification bias observed with 
this study’s OA codes remain if a less serious illness such as angina pectoris was studied 
instead of AMI? Alternatively, future studies can investigate whether other chronic 
comorbidities (such as hypertension or BPH) experience the same misclassification bias as OA 
following AMI. Additionally, it has been shown that comorbidities more serious than OA such 
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as RA are also likely to be subject to information bias when being associated with mortality 
following AMI (Francis et al., 2010). 
4.4.2 Clinical practice 
This study found that people with OA were less likely to receive invasive management 
strategies and less likely to experience adverse clinical outcomes following AMI compared to 
people without OA. People with OA are already a target group for health promotion strategies 
because of the association of OA with comorbidities. Clinicians should also be aware of the 
potential inequality that people with OA have with respect to the availability of invasive 
management strategies following AMI. A possible explanation for people with OA being less 
likely to receive invasive management is that people with severe OA are less able to lay supine 
for long enough to undergo CA or PCI. An awareness of the barriers to invasive management 
strategies may improve outcomes following AMI for people with OA. 
Additionally, women were identified to be more likely to suffer from adverse clinical outcomes 
than men. In order to address this inequality in care, clinicians should consider why this is may 
occur. Women are more likely to present with atypical AMI symptoms such as neck pain, back 
pain, jaw pain, and nausea, and are less likely to present with chest pain and diaphoresis 
(Goldberg et al., 1998). These atypical symptoms may cause delays in diagnosis and potentially 
cause women to experience worse outcomes following AMI compared to men. 
Finally, this study found that both men and women with OA were associated with better 
clinical outcomes compared to people without OA. However, because of the misclassification 
bias hypothesised to be affecting this study, clinical practice should not be changed to reflect 
this finding. Previous studies have shown OA to be associated with poorer health related 
outcomes, therefore, more research into the effect of OA on outcomes following AMI must be 





There is an association between OA and overall CVD, however, the association between OA 
and AMI is less clear. This study identified that people with OA were less likely to receive 
invasive management strategies and were, unexpectedly, more likely to have better outcomes 
following AMI compared to people that did not have OA. This unexpected result is likely to be 
partially attributable to a systematic differential misclassification bias where people with OA 
were classified as not having OA because precedence was given to diagnosis codes for acute 
illness. Future research into the association between OA and AMI using secondary care EHR 







Agha, M., & Agha, R. (2017). The rising prevalence of obesity. International Journal of Surgery 
Oncology, 2(7), e17. https://doi.org/10.1097/ij9.0000000000000017 
Anderson, J. L., & Morrow, D. A. (2017). Acute Myocardial Infarction. New England Journal of 
Medicine, 376(21), 2053–2064. https://doi.org/10.1056/NEJMra1606915 
Anderson, S., & Loeser, R. F. (2010). Why is osteoarthritis an age-related disease? Best Practice 
& Research Clinical Rheumatology, 24(1), 15–26. 
https://doi.org/10.1016/j.berh.2009.08.006 
Arden, N. K., Cro, S., Sheard, S., Doré, C. J., Bara, A., Tebbs, S. A., Hunter, D. J., James, S., 
Cooper, C., O’Neill, T. W., Macgregor, A., Birrell, F., & Keen, R. (2016). The effect of 
vitamin D supplementation on knee osteoarthritis, the VIDEO study: A randomised 
controlled trial. Osteoarthritis and Cartilage, 24(11), 1858–1866. 
https://doi.org/10.1016/j.joca.2016.05.020 
Atiquzzaman, M., Karim, M. E., Kopec, J., Wong, H., & Anis, A. H. (2019). Role of Nonsteroidal 
Antiinflammatory Drugs in the Association Between Osteoarthritis and Cardiovascular 
Diseases: A Longitudinal Study. Arthritis & Rheumatology, 71(11), 1835–1843. 
https://doi.org/10.1002/art.41027 
Bender, R., & Grouven, U. (1997). Ordinal logistic regression in medical research. Journal of the 
Royal College of Physicians of London, 31(5), 546–551. 
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., 
Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, 
M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C., Khan, S. S., Kissela, B. M., Knutson, 
K. L., … Virani, S. S. (2019). Heart Disease and Stroke Statistics-2019 Update: A Report 




Bennell, K. L., Hunter, D. J., & Hinman, R. S. (2012). Management of osteoarthritis of the knee. 
BMJ, 345. https://doi.org/10.1136/bmj.e4934 
Berenbaum, F. (2013). Osteoarthritis as an inflammatory disease (osteoarthritis is not 
osteoarthrosis!). Osteoarthritis and Cartilage, 21(1), 16–21. 
https://doi.org/10.1016/j.joca.2012.11.012 
Berenbaum, F. (2019). Deep phenotyping of osteoarthritis: A step forward. Annals of the 
Rheumatic Diseases, 78(1), 3–5. https://doi.org/10.1136/annrheumdis-2018-213864 
Berg, A. H., & Scherer, P. E. (2005). Adipose tissue, inflammation, and cardiovascular disease. 
Circulation Research, 96(9), 939–949. 
https://doi.org/10.1161/01.RES.0000163635.62927.34 
Bergholm, R., Leirisalo-Repo, M., Vehkavaara, S., Mäkimattila, S., Taskinen, M. R., & Yki-
Järvinen, H. (2002). Impaired responsiveness to NO in newly diagnosed patients with 
rheumatoid arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(10), 1637–
1641. https://doi.org/10.1161/01.ATV.0000033516.73864.4E 
Bharadwaj, A., Potts, J., Mohamed, M. O., Parwani, P., Swamy, P., Lopez-Mattei, J. C., Rashid, 
M., Kwok, C. S., Fischman, D. L., Vassiliou, V. S., Freeman, P., Michos, E. D., & Mamas, 
M. A. (2019). Acute myocardial infarction treatments and outcomes in 6.5 million 
patients with a current or historical diagnosis of cancer in the USA. European Heart 
Journal. https://doi.org/10.1093/eurheartj/ehz851 
Bijlsma, J. W. J., Berenbaum, F., & Lafeber, F. P. J. G. (2011). Osteoarthritis: An update with 
relevance for clinical practice. Lancet (London, England), 377(9783), 2115–2126. 
https://doi.org/10.1016/S0140-6736(11)60243-2 
Biondi-Zoccai, G., Lotrionte, M., Landoni, G., & Modena, M. G. (2011). The rough guide to 
systematic reviews and meta-analyses. HSR Proceedings in Intensive Care & 
Cardiovascular Anesthesia, 3(3), 161–173. 
135 
 
Blagojevic, M., Jinks, C., Jeffery, A., & Jordan, K. P. (2010). Risk factors for onset of 
osteoarthritis of the knee in older adults: A systematic review and meta-analysis. 
Osteoarthritis and Cartilage, 18(1), 24–33. https://doi.org/10.1016/j.joca.2009.08.010 
Boden, W. E., O’Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, 
M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., 
Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., … Weintraub, 
W. S. (2007). Optimal Medical Therapy with or without PCI for Stable Coronary 
Disease. New England Journal of Medicine, 356(15), 1503–1516. 
https://doi.org/10.1056/NEJMoa070829 
Boersma, E., Mercado, N., Poldermans, D., Gardien, M., Vos, J., & Simoons, M. L. (2003). Acute 
myocardial infarction. Lancet, 361(9360), 847–858. https://doi.org/10.1016/S0140-
6736(03)12712-2 
Brouwer, R. W., Huizinga, M. R., Duivenvoorden, T., Raaij, T. M. van, Verhagen, A. P., Bierma‐
Zeinstra, S. M., & Verhaar, J. A. (2014). Osteotomy for treating knee osteoarthritis. 
Cochrane Database of Systematic Reviews, 12. 
https://doi.org/10.1002/14651858.CD004019.pub4 
Brown, T. D., Johnston, R. C., Saltzman, C. L., Marsh, J. L., & Buckwalter, J. A. (2006). 
Posttraumatic Osteoarthritis: A First Estimate of Incidence, Prevalence, and Burden of 
Disease. Journal of Orthopaedic Trauma, 20(10), 739–744. 
https://doi.org/10.1097/01.bot.0000246468.80635.ef 
Calman, N., Hauser, D., Lurio, J., Wu, W. Y., & Pichardo, M. (2012). Strengthening Public Health 
and Primary Care Collaboration Through Electronic Health Records. American Journal 
of Public Health, 102(11), e13–e18. https://doi.org/10.2105/AJPH.2012.301000 
Cartwright, D. J. (2013). ICD-9-CM to ICD-10-CM Codes: What? Why? How? Advances in 
Wound Care, 2(10), 588–592. https://doi.org/10.1089/wound.2013.0478 
136 
 
Casey, J. A., Schwartz, B. S., Stewart, W. F., & Adler, N. E. (2016). Using Electronic Health 
Records for Population Health Research: A Review of Methods and Applications. 
Annual Review of Public Health, 37(1), 61–81. https://doi.org/10.1146/annurev-
publhealth-032315-021353 
Castañeda, S., Roman-Blas, J. A., Largo, R., & Herrero-Beaumont, G. (2014). Osteoarthritis: A 
progressive disease with changing phenotypes | Rheumatology | Oxford Academic. 
Rheumatology, 53(1), 1–3. 
Centers for Disease Control and Prevention. (2015). ICD - ICD-9-CM - International 
Classification of Diseases, Ninth Revision, Clinical Modification. 
https://www.cdc.gov/nchs/icd/icd9cm.htm 
Chanti-Ketterl, M., Pathak, E. B., Andel, R., & Mortimer, J. A. (2014). Dementia: A barrier to 
receiving percutaneous coronary intervention for elderly patients with ST-elevated 
myocardial infarction. International Journal of Geriatric Psychiatry, 29(9), 906–914. 
https://doi.org/10.1002/gps.4078 
Cibere, J. (2006). Do we need radiographs to diagnose osteoarthritis? Best Practice & Research 
Clinical Rheumatology, 20(1), 27–38. https://doi.org/10.1016/j.berh.2005.08.001 
Cisternas, M. G., Murphy, L., Sacks, J. J., Solomon, D. H., Pasta, D. J., & Helmick, C. G. (2016). 
Alternative Methods for Defining Osteoarthritis and the Impact on Estimating 
Prevalence in a US Population-Based Survey. Arthritis Care & Research, 68(5), 574–580. 
https://doi.org/10.1002/acr.22721 
Cleveland, R. J., & Callahan, L. F. (2017). Can Osteoarthritis Predict Mortality? North Carolina 
Medical Journal, 78(5), 322–325. https://doi.org/10.18043/ncm.78.5.322 
Crema, M. D., Guermazi, A., Sayre, E. C., Roemer, F. W., Wong, H., Thorne, A., Singer, J., 
Esdaile, J. M., Marra, M. D., Kopec, J. A., Nicolaou, S., & Cibere, J. (2011). The 
association of magnetic resonance imaging (MRI)-detected structural pathology of the 
knee with crepitus in a population-based cohort with knee pain: The MoDEKO study. 
137 
 
Osteoarthritis and Cartilage, 19(12), 1429–1432. 
https://doi.org/10.1016/j.joca.2011.09.003 
Daga, L. C., Kaul, U., & Mansoor, A. (2011). Approach to STEMI and NSTEMI. Journal of 
Association of Physicians of India, 59(12 SPEC. ISSUE), 19–25. 
Dahlöf, B. (2010). Cardiovascular Disease Risk Factors: Epidemiology and Risk Assessment. 
American Journal of Cardiology, 105(1 Supplement), 3A-9A. 
https://doi.org/10.1016/j.amjcard.2009.10.007 
Del Rincón, I., Williams, K., Stern, M. P., Freeman, G. L., & Escalante, A. (2001). High incidence 
of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional 
cardiac risk factors. Arthritis and Rheumatism, 44(12), 2737–2745. 
https://doi.org/10.1002/1529-0131(200112)44:12<2737::aid-art460>3.0.co;2-%23 
Dell’Isola, A., Allan, R., Smith, S. L., Marreiros, S. S. P., & Steultjens, M. (2016). Identification of 
clinical phenotypes in knee osteoarthritis: A systematic review of the literature. BMC 
Musculoskeletal Disorders, 17(1), 1–12. https://doi.org/10.1186/s12891-016-1286-2 
Dillon, C. F., Rasch, E. K., Gu, Q., & Hirsch, R. (2006). Prevalence of knee osteoarthritis in the 
United States: Arthritis data from the Third National Health and Nutrition Examination 
Survey 1991-94. The Journal of Rheumatology, 33(11), 2271–2279. 
Dudas, K., Lappas, G., Stewart, S., & Rosengren, A. (2011). Trends in out-of-hospital deaths due 
to coronary heart disease in Sweden (1991 to 2006). Circulation, 123(1), 46–52. 
https://doi.org/10.1161/CIRCULATIONAHA.110.964999 
Englund, M., Guermazi, A., Gale, D., Hunter, D. J., Aliabadi, P., Clancy, M., & Felson, D. T. 
(2008). Incidental meniscal findings on knee MRI in middle-aged and elderly persons. 
New England Journal of Medicine, 359(11), 1108–1115. 
https://doi.org/10.1056/NEJMoa0800777 
Farkouh, M. E., Greenberg, J. D., Jeger, R. V., Ramanathan, K., Verheugt, F. W. A., Chesebro, J. 
H., Kirshner, H., Hochman, J. S., Lay, C. L., Ruland, S., Mellein, B., Matchaba, P. T., 
138 
 
Fuster, V., & Abramson, S. B. (2007). Cardiovascular outcomes in high risk patients with 
osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Annals of the 
Rheumatic Diseases, 66(6), 764–770. https://doi.org/10.1136/ard.2006.066001 
Felce, D., & Perry, J. (1995). Quality of life: Its definition and measurement. Research in 
Developmental Disabilities, 16(1), 51–74. https://doi.org/10.1016/0891-
4222(94)00028-8 
Felson, D. T. (2010). Identifying different osteoarthritis phenotypes through epidemiology. 
Osteoarthritis and Cartilage, 18(5), 601–604. 
https://doi.org/10.1016/j.joca.2010.01.007 
Felson, David T., Zhang, Y., Anthony, J. M., Naimark, A., & Anderson, J. J. (1992). Weight loss 
reduces the risk for symptomatic knee osteoarthritis in women: The framingham 
study. Annals of Internal Medicine, 116(7), 535–539. https://doi.org/10.7326/0003-
4819-116-7-535 
Ferguson, R. J., Prieto‐Alhambra, D., Walker, C., Yu, D., Valderas, J. M., Judge, A., Griffiths, J., 
Jordan, K. P., Peat, G., Glyn‐Jones, S., & Silman, A. J. (2019). Validation of hip 
osteoarthritis diagnosis recording in the UK Clinical Practice Research Datalink. 
Pharmacoepidemiology and Drug Safety, 28(2), 187–193. 
https://doi.org/10.1002/pds.4673 
Ferrucci, L., & Fabbri, E. (2018). Inflammageing: Chronic inflammation in ageing, cardiovascular 
disease, and frailty. Nature Reviews. Cardiology, 15(9), 505–522. 
https://doi.org/10.1038/s41569-018-0064-2 
Fewell, Z., Smith, G. D., & Sterne, J. A. C. (2007). The impact of residual and unmeasured 
confounding in epidemiologic studies: A simulation study. American Journal of 
Epidemiology, 166(6), 646–655. https://doi.org/10.1093/aje/kwm165 
Fisher, E. S., Whaley, F. S., Krushat, W. M., Malenka, D. J., Fleming, C., Baron, J. A., & Hsia, D. C. 
(1992). The accuracy of Medicare’s hospital claims data: Progress has been made, but 
139 
 
problems remain. American Journal of Public Health, 82(2), 243–248. 
https://doi.org/10.2105/AJPH.82.2.243 
Forouhi, N. G., & Sattar, N. (2006). CVD risk factors and ethnicity—A homogeneous 
relationship? Atherosclerosis Supplements, 7(1 SPEC. ISS.), 11–19. 
https://doi.org/10.1016/j.atherosclerosissup.2006.01.003 
Francis, M. L., Varghese, J. J., Mathew, J. M., Koneru, S., Scaife, S. L., & Zahnd, W. E. (2010). 
Outcomes in patients with rheumatoid arthritis and myocardial infarction. The 
American Journal of Medicine, 123(10), 922–928. 
https://doi.org/10.1016/j.amjmed.2010.05.017 
Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., & Carr, A. J. 
(2015). Osteoarthritis. The Lancet, 386(9991), 376–387. 
https://doi.org/10.1016/S0140-6736(14)60802-3 
Goldberg, R. J., O’Donnell, C., Yarzebski, J., Bigelow, C., Savageau, J., & Gore, J. M. (1998). Sex 
differences in symptom presentation associated with acute myocardial infarction: A 
population-based perspective. American Heart Journal, 136(2), 189–195. 
https://doi.org/10.1053/hj.1998.v136.88874 
Gornick, M., Greenberg, J. N., Eggers, P. W., & Dobson, A. (1985). Twenty years of Medicare 
and Medicaid: Covered populations, use of benefits, and program expenditures. 
Health Care Financing Review, 1985(Suppl), 13–59. 
Govender, R. D., Al-Shamsi, S., Soteriades, E. S., & Regmi, D. (2019). Incidence and risk factors 
for recurrent cardiovascular disease in middle-eastern adults: A retrospective study. 
BMC Cardiovascular Disorders, 19. https://doi.org/10.1186/s12872-019-1231-z 
Grey, C., Jackson, R., Schmidt, M., Ezzati, M., Asaria, P., Exeter, D. J., & Kerr, A. J. (2017). One in 
four major ischaemic heart disease events are fatal and 60% are pre-hospital deaths: A 




Grimes, D. A., & Schulz, K. F. (2002). Bias and causal associations in observational research. In 
Lancet (Vol. 359, Issue 9302, pp. 248–252). Elsevier Limited. 
https://doi.org/10.1016/S0140-6736(02)07451-2 
Gustafson, B. (2010). Adipose tissue, inflammation and atherosclerosis. Journal of 
Atherosclerosis and Thrombosis, 17(4), 332–341. https://doi.org/10.5551/jat.3939 
Habib, R. H., Dimitrova, K. R., Badour, S. A., Yammine, M. B., El-Hage-Sleiman, A.-K. M., 
Hoffman, D. M., Geller, C. M., Schwann, T. A., & Tranbaugh, R. F. (2015). CABG Versus 
PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting. 
Journal of the American College of Cardiology, 66(13), 1417–1427. 
https://doi.org/10.1016/j.jacc.2015.07.060 
Haglund, B., Köster, M., Nilsson, T., & Rosén, M. (2004). Inequality in access to coronary 
revascularization in Sweden. Scandinavian Cardiovascular Journal, 38(6), 334–339. 
https://doi.org/10.1080/14017430410021516 
Hall, A. J., Stubbs, B., Mamas, M. A., Myint, P. K., & Smith, T. O. (2016). Association between 
osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. 
European Journal of Preventive Cardiology, 23(9), 938–946. 
https://doi.org/10.1177/2047487315610663 
Harrold, L. R., Yood, R. A., Andrade, S. E., Reed, J. I., Cernieux, J., Straus, W., Weeks, M., Lewis, 
B., & Gurwitz, J. H. (2000). Evaluating the predictive value of osteoarthritis diagnoses in 
an administrative database. Arthritis and Rheumatism, 43(8), 1881–1885. 
https://doi.org/10.1002/1529-0131(200008)43:8<1881::aid-anr26>3.0.co;2-%23 
Hawker, G. A., Croxford, R., Bierman, A. S., Harvey, P. J., Ravi, B., Stanaitis, I., & Lipscombe, L. L. 
(2014). All-cause mortality and serious cardiovascular events in people with hip and 




Healthcare Cost and Utilisation Project. (2014). Nationwide Inpatient Sample (NIS) Redesign 
Final Report. http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp.HCUP 
Healthcare Cost and Utilisation Project. (2017). Introduction to the HCUP National Inpatient 
Sample (NIS) 2015. NIS Database Documentation Archive. https://www.hcup-
us.ahrq.gov/db/nation/nis/nisarchive.jsp 
Healthcare Cost and Utilisation Project. (2019). NIS Overview. https://www.hcup-
us.ahrq.gov/nisoverview.jsp 
Heidari, B. (2011). Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part 
I. Caspian Journal of Internal Medicine, 2(2), 205–212. 
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A., van 
Thiel, G. J. M., Cronin, M., Brobert, G., Vardas, P., Anker, S. D., Grobbee, D. E., Denaxas, 
S., & Innovative Medicines Initiative 2nd programme, Big Data for Better Outcomes, 
BigData@Heart Consortium of 20 academic and industry partners including ESC. 
(2018). Big data from electronic health records for early and late translational 
cardiovascular research: Challenges and potential. European Heart Journal, 39(16), 
1481–1495. https://doi.org/10.1093/eurheartj/ehx487 
Hertzer, N. R. (2012). The Nationwide Inpatient Sample may contain inaccurate data for carotid 
endarterectomy and carotid stenting. Journal of Vascular Surgery, 55(1), 263–266. 
https://doi.org/10.1016/j.jvs.2011.08.059 
Humphries, K. H., Rankin, J. M., Carere, R. G., Buller, C. E., Kiely, F. M., & Spinelli, J. J. (2000). 
Co-morbidity data in outcomes research: Are clinical data derived from administrative 
databases a reliable alternative to chart review? Journal of Clinical Epidemiology, 
53(4), 343–349. https://doi.org/10.1016/S0895-4356(99)00188-2 




Hunter, D. J., Schofield, D., & Callander, E. (2014). The individual and socioeconomic impact of 
osteoarthritis. Nature Reviews. Rheumatology, 10(7), 437–441. 
https://doi.org/10.1038/nrrheum.2014.44 
Iezzoni, L. I., Foley, S. M., Daley, J., Hughes, J., Fisher, E. S., & Heeren, T. (1992). Comorbidities, 
Complications, and Coding Bias: Does the Number of Diagnosis Codes Matter in 
Predicting In-Hospital Mortality? JAMA: The Journal of the American Medical 
Association, 267(16), 2197–2203. 
https://doi.org/10.1001/jama.1992.03480160055034 
Jalali, S., & Wohlin, C. (2012). Systematic literature studies: Database searches vs. Backward 
snowballing. International Symposium on Empirical Software Engineering and 
Measurement, 29–38. https://doi.org/10.1145/2372251.2372257 
Jatwani, S., Jatwani, K., Tiwari, P., Wadhwa, N., & Chugh, K. (2020). Trends in hospitalisations 
and inpatient mortality from acute myocardial infarction among patients with psoriatic 
arthritis: An analysis of nationwide inpatient sample 2004-2014. Clinical and 
Experimental Rheumatology. 
Jencks, S. F., Williams, D. K., & Kay, T. L. (1988). Assessing Hospital-Associated Deaths From 
Discharge Data: The Role of Length of Stay and Comorbidities. JAMA: The Journal of 
the American Medical Association, 260(15), 2240–2246. 
https://doi.org/10.1001/jama.1988.03410150088036 
Jiang, L., Xie, X., Wang, Y., Wang, Y., Lu, Y., Tian, T., Chu, M., & Shen, Y. (2016). Body mass 
index and hand osteoarthritis susceptibility: An updated meta-analysis. International 
Journal of Rheumatic Diseases, 19(12), 1244–1254. https://doi.org/10.1111/1756-
185X.12895 
Johnson, V. L., & Hunter, D. J. (2014). The epidemiology of osteoarthritis. Best Practice & 




Jorm, L. (2015). Routinely collected data as a strategic resource for research: Priorities for 
methods and workforce. Public Health Research & Practice, 25(4), e2541540. 
https://doi.org/10.17061/phrp2541540 
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011). Role of 
proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews. 
Rheumatology, 7(1), 33–42. https://doi.org/10.1038/nrrheum.2010.196 
Katz, J. N., Earp, B. E., & Gomoll, A. H. (2010). Surgical management of osteoarthritis. Arthritis 
Care & Research, 62(9), 1220–1228. https://doi.org/10.1002/acr.20231 
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous 
thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 
randomised trials. Lancet, 361(9351), 13–20. https://doi.org/10.1016/S0140-
6736(03)12113-7 
Khera, R., & Krumholz, H. M. (2017). With Great Power Comes Great Responsibility: Big Data 
Research from the National Inpatient Sample. Circulation: Cardiovascular Quality and 
Outcomes, 10(7). https://doi.org/10.1161/CIRCOUTCOMES.117.003846 
Kieszak, S. M., Flanders, W. D., Kosinski, A. S., Shipp, C. C., & Karp, H. (1999). A comparison of 
the Charlson Comorbidity Index derived from medical record data and administrative 
billing data. Journal of Clinical Epidemiology, 52(2), 137–142. 
https://doi.org/10.1016/S0895-4356(98)00154-1 
Kirkley, A., Birmingham, T. B., Litchfield, R. B., Giffin, J. R., Willits, K. R., Wong, C. J., Feagan, B. 
G., Donner, A., Griffin, S. H., D’Ascanio, L. M., Pope, J. E., & Fowler, P. J. (2008). A 
randomized trial of arthroscopic surgery for osteoarthritis of the knee.[Erratum 
appears in N Engl J Med. 2009 Nov 12;361(20):2004]. New England Journal of 
Medicine, 359(11), 1097–1107. https://dx.doi.org/10.1056/NEJMoa0708333 
Kluzek, S., Sanchez-Santos, M. T., Leyland, K. M., Judge, A., Spector, T. D., Hart, D., Cooper, C., 
Newton, J., & Arden, N. K. (2016). Painful knee but not hand osteoarthritis is an 
144 
 
independent predictor of mortality over 23 years follow-up of a population-based 
cohort of middle-aged women. Annals of the Rheumatic Diseases, 75(10), 1749–1756. 
https://doi.org/10.1136/annrheumdis-2015-208056 
Knoop, J., Leeden, M. van der, Thorstensson, C. A., Roorda, L. D., Lems, W. F., Knol, D. L., 
Steultjens, M. P. M., & Dekker, J. (2011). Identification of phenotypes with different 
clinical outcomes in knee osteoarthritis: Data from the osteoarthritis initiative. 
Arthritis Care & Research, 63(11), 1535–1542. https://doi.org/10.1002/acr.20571 
Kornowski, R., Goldbourt, U., Zion, M., Mandelzweig, L., Kaplinsky, E., Levo, Y., & Behar, S. 
(1993). Predictors and long-term prognostic significance of recurrent infarction in the 
year after a first myocardial infarction. The American Journal of Cardiology, 72(12), 
883–888. https://doi.org/10.1016/0002-9149(93)91100-V 
Martel-Pelletier, J. (1999). Pathophysiology of osteoarthritis. Osteoarthritis and Cartilage, 7(4), 
371–373. https://doi.org/10.1053/joca.1998.0214 
Mcalindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, 
S. M., Hawker, G. A., Yyzz, Y. H., Hunter, D. J., Kawaguchi, H., Kwoh, K., Lohmander ##, 
S., Rannou, F., Zzz, E. M. R., & Underwood, M. (2014). OARSI guidelines for the non-
surgical management of knee osteoarthritis. Osteoarthritis and Cartilage, 22, 363–388. 
https://doi.org/10.1016/j.joca.2014.01.003 
McAlindon, T. E., Wilson, P. W. F., Aliabadi, P., Weissman, B., & Felson, D. T. (1999). Level of 
physical activity and the risk of radiographic and symptomatic knee osteoarthritis in 
the elderly: The Framingham study. American Journal of Medicine, 106(2), 151–157. 
https://doi.org/10.1016/S0002-9343(98)00413-6 
McCormick, N., Lacaille, D., Bhole, V., & Avina-Zubieta, J. A. (2014). Validity of Myocardial 




McCoy, S. S., Crowson, C. S., Maradit-Kremers, H., Therneau, T. M., Roger, V. L., Matteson, E. 
L., & Gabriel, S. E. (2013). Longterm outcomes and treatment after myocardial 
infarction in patients with rheumatoid arthritis. The Journal of Rheumatology, 40(5), 
605–610. https://doi.org/10.3899/jrheum.120941 
MEDLINE®. (2019). Description of the Database [FAQs, Help Files, Pocket Cards]. U.S. National 
Library of Medicine. https://www.nlm.nih.gov/bsd/medline.html 
Mehio-Sibai, A., Feinleib, M., Sibai, T. A., & Armenian, H. K. (2005). A Positive or a Negative 
Confounding Variable? A Simple Teaching Aid for Clinicians and Students. Annals of 
Epidemiology, 15(6), 421–423. https://doi.org/10.1016/j.annepidem.2004.10.004 
Mehta, R. H., Rathore, S. S., Radford, M. J., Wang, Y., Wang, Y., & Krumholz, H. M. (2001). 
Acute myocardial infarction in the elderly: Differences by age. Journal of the American 
College of Cardiology, 38(3), 736–741. https://doi.org/10.1016/S0735-1097(01)01432-
2 
Menachemi, N., & Collum, T. H. (2011). Benefits and drawbacks of electronic health record 
systems. Risk Management and Healthcare Policy, 4, 47–55. 
https://doi.org/10.2147/RMHP.S12985 
Messier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, 
W. H., Pahor, M., & Williamson, J. D. (2004). Exercise and Dietary Weight Loss in 
Overweight and Obese Older Adults with Knee Osteoarthritis: The Arthritis, Diet, and 
Activity Promotion Trial. Arthritis and Rheumatism, 50(5), 1501–1510. 
https://doi.org/10.1002/art.20256 
Mobasheri, A., & Batt, M. (2016). An update on the pathophysiology of osteoarthritis. Annals 
of Physical and Rehabilitation Medicine, 59(5–6), 333–339. 
https://doi.org/10.1016/j.rehab.2016.07.004 
Mohamed, M. O., Rashid, M., Farooq, S., Siddiqui, N., Parwani, P., Shiers, D., Thamman, R., 
Gulati, M., Shoaib, A., Chew-Graham, C., & Mamas, M. A. (2019). Acute Myocardial 
146 
 
Infarction in Severe Mental Illness: Prevalence, Clinical Outcomes, and Process of Care 
in U.S. Hospitalizations. Canadian Journal of Cardiology, 35(7), 821–830. 
https://doi.org/10.1016/j.cjca.2019.04.021 
Moseley, B. J., O’Malley, K., Petersen, N. J., Menke, T. J., Brody, B. A., Kuykendall, D. H., 
Hollingsworth, J. C., Ashton, C. M., & Wray, N. P. (2002). A controlled trial of 
arthroscopic surgery for osteoarthritis of the knee. New England Journal of Medicine, 
347(2), 81–88. https://doi.org/10.1056/NEJMoa013259 
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., 
Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., 
Aggarwal, R., Ahn, S. Y., Ali, M. K., AlMazroa, M. A., Alvarado, M., Anderson, H. R., … 
Lopez, A. D. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries 
in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 
2010. The Lancet, 380(9859), 2197–2223. https://doi.org/10.1016/S0140-
6736(12)61689-4 
Nashef, S. A. M., Roques, F., Sharples, L. D., Nilsson, J., Smith, C., Goldstone, A. R., & 
Lockowandt, U. (2012). EuroSCORE II. European Journal of Cardio-Thoracic Surgery, 
41(4), 734–745. https://doi.org/10.1093/ejcts/ezs043 
National Institute for Health and Care Excellence. (2014). Osteoarthritis: Care and 
management. National Institute for Health and Care Excellence. 
National Joint Registry. (2019). 16th Annual Report. 
https://reports.njrcentre.org.uk/downloads 
Nelson, A. E., Braga, L., Renner, J. B., Atashili, J., Woodard, J., Hochberg, M. C., Helmick, C. G., 
& Jordan, J. M. (2010). Characterization of individual radiographic features of hip 
osteoarthritis in African American and white women and men: The Johnston County 




Nevitt, M. C., Felson, D. T., Williams, E. N., & Grady, D. (2001). The effect of estrogen plus 
progestin on knee symptoms and related disability in postmenopausal women: The 
Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, 
placebo-controlled trial. Arthritis and Rheumatism, 44(4), 811–818. 
https://doi.org/10.1002/1529-0131(200104)44:4<811::AID-ANR137>3.0.CO;2-F 
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013). Low-dose colchicine 
for secondary prevention of cardiovascular disease. Journal of the American College of 
Cardiology, 61(4), 404–410. https://doi.org/10.1016/j.jacc.2012.10.027 
O’Neill, T. W., McCabe, P. S., & McBeth, J. (2018). Update on the epidemiology, risk factors and 
disease outcomes of osteoarthritis. Best Practice & Research. Clinical Rheumatology, 
32(2), 312–326. https://doi.org/10.1016/j.berh.2018.10.007 
Ong, K. L., Wu, B. J., Cheung, B. M. Y., Barter, P. J., & Rye, K. A. (2013). Arthritis: Its prevalence, 
Risk factors, And association with cardiovascular diseases in the United States, 1999 to 
2008. Annals of Epidemiology, 23(2), 80–86. 
https://doi.org/10.1016/j.annepidem.2012.11.008 
Pathak, E. B., & Strom, J. A. (2008). Disparities in Use of Same-Day Percutaneous Coronary 
Intervention for Patients With ST-Elevation Myocardial Infarction in Florida, 2001-
2005. American Journal of Cardiology, 102(7), 802–808. 
https://doi.org/10.1016/j.amjcard.2008.05.023 
Petersen, L. A., Wright, S., Normand, S. L. T., & Daley, J. (1999). Positive predictive value of the 
diagnosis of acute myocardial infarction in an administrative database. Journal of 
General Internal Medicine, 14(9), 555–558. https://doi.org/10.1046/j.1525-
1497.1999.10198.x 
Quan, H., Parsons, G. A., & Ghali, W. A. (2002). Validity of information on comorbidity derived 




Quan, H., Parsons, G. A., & Ghali, W. A. (2004). Validity of procedure codes in international 
classification of diseases, 9th revision, clinical modification administrative data. 
Medical Care, 42(8), 801–809. https://doi.org/10.1097/01.mlr.0000132391.59713.0d 
Rahman, M. M., Kopec, J. A., Anis, A. H., Cibere, J., & Goldsmith, C. H. (2013). Risk of 
Cardiovascular Disease in Patients With Osteoarthritis: A Prospective Longitudinal 
Study. Arthritis Care & Research, 65(12), 1951–1958. 
https://doi.org/10.1002/acr.22092 
Rahman, M. M., Kopec, J. A., Cibere, J., Goldsmith, C. H., & Anis, A. H. (2013). The relationship 
between osteoarthritis and cardiovascular disease in a population health survey: A 
cross-sectional study. BMJ Open, 3(5). https://doi.org/10.1136/bmjopen-2013-002624 
Roberts, D., Brown, J., Medley, N., & Dalziel, S. R. (2017). Antenatal corticosteroids for 
accelerating fetal lung maturation for women at risk of preterm birth. The Cochrane 
Database of Systematic Reviews, 3, CD004454. 
https://doi.org/10.1002/14651858.CD004454.pub3 
Rocha, V. Z., & Libby, P. (2009). Obesity, inflammation, and atherosclerosis. Nature Reviews 
Cardiology, 6(6), 399–409. https://doi.org/10.1038/nrcardio.2009.55 
Rowland, D., & Lyons, B. (1996). Medicare, Medicaid, and the Elderly Poor. Health Care 
Financing Review, 18(2), 61–85. 
Rumona, D. (2014). Systematic reviews. In Achieving Evidence-Based Practice E-Book: A 
Handbook for Practitioners (2nd ed., p. 43). 
Sakakura, K., Nakano, M., Otsuka, F., Ladich, E., Kolodgie, F. D., & Virmani, R. (2013). 
Pathophysiology of atherosclerosis plaque progression. Heart, Lung & Circulation, 
22(6), 399–411. https://doi.org/10.1016/j.hlc.2013.03.001 
Sanchis-Gomar, F., Perez-Quilis, C., Leischik, R., & Lucia, A. (2016). Epidemiology of coronary 




Santos-Gallego, C. G., Picatoste, B., & Badimón, J. J. (2014). Pathophysiology of acute coronary 
syndrome. Current Atherosclerosis Reports, 16(4), 401. 
https://doi.org/10.1007/s11883-014-0401-9 
Santulli, G. (2013). Epidemiology of Cardiovascular Disease in the 21st Century: Updated 
Numbers and Updated Facts. J Cardiovasc Dis, 1(1), 1–2. 
Sassi, F. (2006). Calculating QALYs, comparing QALY and DALY calculations. Health Policy and 
Planning, 21(5), 402–408. https://doi.org/10.1093/heapol/czl018 
Schieir, O., Tosevski, C., Glazier, R. H., Hogg-Johnson, S., & Badley, E. M. (2017). Incident 
myocardial infarction associated with major types of arthritis in the general 
population: A systematic review and meta-analysis. Annals of the Rheumatic Diseases, 
76(8), 1396–1404. https://doi.org/10.1136/annrheumdis-2016-210275 
Sellam, J., & Berenbaum, F. (2010). The role of synovitis in pathophysiology and clinical 
symptoms of osteoarthritis. Nature Reviews. Rheumatology, 6(11), 625–635. 
https://doi.org/10.1038/nrrheum.2010.159 
Sharma, A. R., Jagga, S., Lee, S.-S., & Nam, J.-S. (2013). Interplay between Cartilage and 
Subchondral Bone Contributing to Pathogenesis of Osteoarthritis. International Journal 
of Molecular Sciences, 14(10), 19805–19830. https://doi.org/10.3390/ijms141019805 
Sharma, L., Song, J., Dunlop, D., Felson, D., Lewis, C. E., Segal, N., Torner, J., Cooke, T. D. V., 
Hietpas, J., Lynch, J., & Nevitt, M. (2010). Varus and valgus alignment and incident and 
progressive knee osteoarthritis. Annals of the Rheumatic Diseases, 69(11), 1940–1945. 
https://doi.org/10.1136/ard.2010.129742 
Shrestha, S., Dave, A. J., Losina, E., & Katz, J. N. (2016). Diagnostic accuracy of administrative 
data algorithms in the diagnosis of osteoarthritis: A systematic review. BMC Medical 
Informatics and Decision Making, 16. https://doi.org/10.1186/s12911-016-0319-y 
Silverwood, V., Blagojevic-Bucknall, M., Jinks, C., Jordan, J. L., Protheroe, J., & Jordan, K. P. 
(2015). Current evidence on risk factors for knee osteoarthritis in older adults: A 
150 
 
systematic review and meta-analysis. Osteoarthritis and Cartilage, 23(4), 507–515. 
https://doi.org/10.1016/j.joca.2014.11.019 
Singh, J. (2013). Critical appraisal skills programme. Journal of Pharmacology and 
Pharmacotherapeutics, 4(1), 76. https://doi.org/10.4103/0976-500X.107697 
Sowers, M. R., & Karvonen-Gutierrez, C. A. (2010). The evolving role of obesity in knee 
osteoarthritis. Current Opinion in Rheumatology, 22(5), 533–537. 
https://doi.org/10.1097/BOR.0b013e32833b4682 
Srikanth, V. K., Fryer, J. L., Zhai, G., Winzenberg, T. M., Hosmer, D., & Jones, G. (2005). A meta-
analysis of sex differences prevalence, incidence and severity of osteoarthritis. 
Osteoarthritis and Cartilage, 13(9), 769–781. 
https://doi.org/10.1016/j.joca.2005.04.014 
Stewart, G. (2010). Meta-analysis in applied ecology. Biology Letters, 6(1), 78–81. 
https://doi.org/10.1098/rsbl.2009.0546 
Steyers, C. M., & Miller, F. J. (2014). Endothelial dysfunction in chronic inflammatory diseases. 
International Journal of Molecular Sciences, 15(7), 11324–11349. 
https://doi.org/10.3390/ijms150711324 
Stoltzfus, J. C. (2011). Logistic Regression: A Brief Primer. Academic Emergency Medicine, 
18(10), 1099–1104. https://doi.org/10.1111/j.1553-2712.2011.01185.x 
Stone, G. W., Kappetein, A. P., Sabik, J. F., Pocock, S. J., Morice, M.-C., Puskas, J., Kandzari, D. 
E., Karmpaliotis, D., Brown, W. M., Lembo, N. J., Banning, A., Merkely, B., Horkay, F., 
Boonstra, P. W., van Boven, A. J., Ungi, I., Bogáts, G., Mansour, S., Noiseux, N., … EXCEL 
Trial Investigators. (2019). Five-Year Outcomes after PCI or CABG for Left Main 
Coronary Disease. The New England Journal of Medicine, 381(19), 1820–1830. 
https://doi.org/10.1056/NEJMoa1909406 
Suter, L. G., Smith, S. R., Katz, J. N., Englund, M., Hunter, D. J., Frobell, R., & Losina, E. (2017). 
Projecting Lifetime Risk of Symptomatic Knee Osteoarthritis and Total Knee 
151 
 
Replacement in Individuals Sustaining a Complete Anterior Cruciate Ligament Tear in 
Early Adulthood. Arthritis Care and Research, 69(2), 201–208. 
https://doi.org/10.1002/acr.22940 
Swain, S., Sarmanova, A., Coupland, C., Doherty, M., & Zhang, W. (2019). Comorbidities in 
Osteoarthritis: A systematic review and meta-analysis of observational studies. 
Arthritis Care & Research. https://doi.org/10.1002/acr.24008 
Symmons, D. P. M., & Gabriel, S. E. (2011). Epidemiology of CVD in rheumatic disease, with a 
focus on RA and SLE. Nature Reviews. Rheumatology, 7(7), 399–408. 
https://doi.org/10.1038/nrrheum.2011.75 
Szklo, M., & Nieto, F. J. (2004). Identifying Noncausal Associaitons: Confounding. In 
Epidemiology: Beyond the Basics (p. 203). Jones and Bartlett Publishers, Inc. 
Thomas, E., Wilkie, R., Peat, G., Hill, S., Dziedzic, K., & Croft, P. (2004). The North Staffordshire 
Osteoarthritis Project—NorStOP: Prospective, 3-year study of the epidemiology and 
management of clinical osteoarthritis in a general population of older adults. BMC 
Musculoskeletal Disorders, 5, 1–7. https://doi.org/10.1186/1471-2474-5-2 
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., 
Mickley, H., Crea, F., Werf, F. V. D., Bucciarelli-Ducci, C., Katus, H. A., Pinto, F. J., 
Antman, E. M., Hamm, C. W., Caterina, R. D., Januzzi, J. L., Apple, F. S., Garcia, M. A. A., 
… Windecker, S. (2019). Fourth universal definition of myocardial infarction (2018). 
European Heart Journal, 40(3), 237–269. https://doi.org/10.1093/eurheartj/ehy462 
Tisminetzky, M., Erskine, N., Chen, H. Y., Gore, J., Gurwitz, J., Yarzebski, J., Joffe, S., Shaw, P., & 
Goldberg, R. (2015). Changing trends in, and characteristics associated with, not 
undergoing cardiac catheterization in elderly adults hospitalized with St-segment 




Tripepi, G., Jager, K. J., Dekker, F. W., & Zoccali, C. (2010). Selection Bias and Information Bias 
in Clinical Research. Nephron Clinical Practice, 115(2), c94–c99. 
https://doi.org/10.1159/000312871 
Tu, J. V. (1996). Advantages and disadvantages of using artificial neural networks versus logistic 
regression for predicting medical outcomes. Journal of Clinical Epidemiology, 49(11), 
1225–1231. https://doi.org/10.1016/S0895-4356(96)00002-9 
Uman, L. S. (2011). Systematic Reviews and Meta-Analyses Information Management for the 
Busy Practitioner. In J Can Acad Child Adolesc Psychiatry (Vol. 20, Issue 1, p. 57). 
www.cochrane.org 
Van der Esch, M., Knoop, J., van der Leeden, M., Roorda, L. D., Lems, W. F., Knol, D. L., & 
Dekker, J. (2015). Clinical phenotypes in patients with knee osteoarthritis: A study in 
the Amsterdam osteoarthritis cohort. Osteoarthritis and Cartilage, 23(4), 544–549. 
https://doi.org/10.1016/j.joca.2015.01.006 
Varga, Z., Sabzwari, S. rafay ali, & Vargova, V. (2017). Cardiovascular Risk of Nonsteroidal Anti-
Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus, 9(4), e1144. 
https://doi.org/10.7759/cureus.1144 
Varghese, J. J., Koneru, S., Scaife, S. L., Zahnd, W. E., & Francis, M. L. (2010). Mortality after 
coronary artery revascularization of patients with rheumatoid arthritis. The Journal of 
Thoracic and Cardiovascular Surgery, 140(1), 91–96. 
https://doi.org/10.1016/j.jtcvs.2009.09.036 
Vina, E. R., & Kwoh, C. K. (2018). Epidemiology of Osteoarthritis: Literature Update. Current 
Opinion in Rheumatology, 30(2), 160–167. 
https://doi.org/10.1097/BOR.0000000000000479 
Warner, S. C., & Valdes, A. M. (2017). Genetic association studies in osteoarthritis: Is it 




White, H. D., & Chew, D. P. (2008). Acute myocardial infarction. The Lancet, 372(9638), 570–
584. https://doi.org/10.1016/S0140-6736(08)61237-4 
White, H. D., Reynolds, H. R., Carvalho, A. C., Pearte, C. A., Liu, L., Martin, C. E., Knatterud, G. L., 
Džavík, V., Kruk, M., Steg, P. G., Cantor, W. J., Menon, V., Lamas, G. A., & Hochman, J. 
S. (2012). Reinfarction after percutaneous coronary intervention or medical 
management using the universal definition in patients with total occlusion after 
myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial 
(OAT) cohort. American Heart Journal, 163(4), 563–571. 
https://doi.org/10.1016/j.ahj.2012.01.016 
Wilkie, R., Parmar, S. S., Blagojevic-Bucknall, M., Smith, D., Thomas, M. J., Seale, B. J., Mansell, 
G., & Peat, G. (2019). Reasons why osteoarthritis predicts mortality: Path analysis 
within a Cox proportional hazards model. RMD Open, 5(2). 
https://doi.org/10.1136/rmdopen-2019-001048 
Wluka, A. E., Cicuttini, F. M., & Spector, T. D. (2000). Menopause, oestrogens and arthritis. 
Maturitas, 35(3), 183–199. https://doi.org/10.1016/s0378-5122(00)00118-3 
World Health Organisation. (2007). International classification of functioning, disability and 
health—Children & youth version. World Health Organization. 
https://www.cabdirect.org/cabdirect/abstract/20083120892 
World Health Organisation. (2020). About cardiovascular diseases. WHO; World Health 
Organization. https://www.who.int/cardiovascular_diseases/about_cvd/en/ 
Wright, R. W., Brand, R. A., Dunn, W., & Spindler, K. P. (2007). How to write a systematic 
review. Clinical Orthopaedics and Related Research, 455(455), 23–29. 
https://doi.org/10.1097/BLO.0b013e31802c9098 
Young, B. L., Watson, S. L., Perez, J. L., McGwin, G., Singh, J. A., & Ponce, B. A. (2018). Trends in 
joint replacement surgery in patients with rheumatoid arthritis. Journal of 
Rheumatology, 45(2), 158–164. https://doi.org/10.3899/jrheum.170001 
154 
 
Yu, D., Jordan, K. P., & Peat, G. (2018). Underrecording of osteoarthritis in united kingdom 
primary care electronic health record data. Clinical Epidemiology, 10, 1195–1201. 
https://doi.org/10.2147/CLEP.S160059 
Zhang, W., Doherty, M., Peat, G., Bierma-Zeinstra, S. M. A., Arden, N. K., Bresnihan, B., 
Herrero-Beaumont, G., Kirschner, S., Leeb, B. F., Lohmander, L. S., Mazières, B., 
Pavelka, K., Punzi, L., So, A. K., Tuncer, T., Watt, I., & Bijlsma, J. W. (2010). EULAR 
evidence-based recommendations for the diagnosis of knee osteoarthritis. Annals of 
the Rheumatic Diseases, 69(3), 483–489. https://doi.org/10.1136/ard.2009.113100 
Zhang, Y., & Jordan, J. M. (2010). Epidemiology of osteoarthritis. Clinics in Geriatric Medicine, 








6.1 ICD-9-CM codes used in this study 
 
Table 6.1: Table of ICD-9-CM codes. 
Acute myocardial infarction 
(410.xx) 
  
 Anterolateral 410.0x 
 Anterior 410.1x 
 Inferolateral 410.2x 
 inferoposterior 410.3x 
 Inferior 410.4x 
 Lateral 410.5x 
 Posterior 410.6x 
 Non-ST elevated MI 410.7x 
 Other specified sites 410.8x 
 Unspecified site 410.9x 
   
Osteoarthritis (715.xx)   
 Generalised OA 715.0x, 715.8x 
 Upper limb OA 715.11-4, 715.21-4, 715.31-4, 715.91-4 
 Lower limb OA 715.15-7, 715.25-7, 715.35-7, 715.95-7 
 Unspecified 715.10, 715.18, 715.20, 715.28, 715.30, 
715.38, 715.90, 715.98, V134 
   
Pain in joint  719.4x 
Effusion of joint  719.0x 
   
Joint replacement   






 Reverse total shoulder 
arthroplasty 
81.88 
 Total hip arthroplasty 81.51 





 Total ankle 
arthroplasty 
81.56 
 Ankle fusion 81.11 
 Ankle arthrodesis 81.12 
 Total elbow 
arthroplasty 
81.84 








00.66, 36.01, 36.02, 36.06, 36.07, 36.09 
 Coronary artery 
bypass grafting 
36.1x, 36.20, 36.31, 36.32, 36.9x 
   
Adverse clinical outcomes   
 In-hospital mortality Recorded in the NIS 




Haemopericardium (423.0), cardiac 
tamponade (423.3), pericardiocentesis 
(37.0), coronary dissection (414.12) 
 All-cause bleeding Gastrointestinal haemorrhage (578.0, 
578.1, and 578.9), intracranial 
haemorrhage (430, 431, and 432.x) 
 Stroke and TIA 433.01, 433.11, 433.21, 433.31, 433.81, 
433.91, 434.01, 434.11, 434.91, 435.x, 
436 
   
Past cardiovascular history   
 Previous AMI 412.xx 
 Previous PCI V45.82 
 Previous CABG V45.81 
 Previous stroke V12.54 
 History of IHD 414.00-07, 414.2-9 









6.2 OA sites 
A categorical variable called “OA sites” was created based on the anatomical site of OA. The 
ICD-9-CM 715.xx codes from Appendix 1 were used to stratify the AMI cohort into the five 
anatomical OA subtypes, no-OA, upper limb OA, lower limb OA, generalised OA, and 
unspecified OA. Cases that had codes for two different OA sites were excluded from this 
variable, leaving cases that only have OA in a single site. 
Of all AMI cases, 414,072 (6.3%) cases of OA were identified. After excluding people with 
multiple subtypes of OA (n=3,063), 411,009 (6.3%) cases of OA remained to be analysed by 
site. Of these remaining cases, 10,057 (2.4%) had upper limb OA, 46,132 (11.2%) had lower 
limb OA, 19,820 (4.8%) had generalised OA, and 335,000 (81.5%) had OA of unspecified 
location and type. 
